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Abstract 
 
Human immunodeficiency virus type 1 (HIV-1) is responsible for the acquired 
immunodeficiency syndrome (AIDS), a leading cause of death worldwide infecting 
millions of people each year. Despite intensive research in vaccine development, therapies 
against HIV-1 infection are not curative and the huge genetic variability of HIV-1 
challenges drug development. Current animal models for HIV-1 research present important 
limitations, impairing the progress of in vivo approaches. Macaques require CD8+ 
depletion or large portions of the genome to be replaced by sequences derived from simian 
immunodeficiency viruses to progress to AIDS, and the maintenance cost is high. Mice are 
a cheaper alternative, but need to be 'humanized' and breeding is not possible and knockout 
experiments are difficult.  
 
The development of an HIV-1 clone able to replicate in mice is a challenging proposal. 
The lack of human co-factors in mice impedes function of the HIV-1 accessory proteins 
Tat and Rev, hampering HIV-1 replication. The Tat and Rev function can be replaced by 
constitutive/chimeric promoters, codon-optimized genes and the constitutive transport 
element (CTE), generating a novel HIV-1 clone able to replicate in mice without 
disrupting the amino acid sequence of the virus. By minimally manipulating the genomic 
'identity' of the virus, we propose the generation of an HIV-1 clone able to replicate in 
mice to assist in antiviral drug development. My results have determined that murine NIH 
3T3 cells are able to generate pseudotyped HIV-1 particles, but they are not infectious. 
Codon-optimized HIV-1 constructs are efficiently made in human HEK-293T cells in a Tat 
and Rev independent manner and capable of packaging a competent genome in trans. 
CSGW (an HIV-1 vector genome) efficiently generates infectious particles in the absence 
of Tat and Rev in human cells when 4 copies of the CTE are placed preceding the 3’LTR. 
HIV-1 replication competent genomes lacking tat expression and encoding different 
promoters are functional during the first cycle of replication when Tat is added in trans. 
Finally, we developed a replication competent HIV-1 clone lacking tat and rev genes and 
encoding 4CTEs that could be a future candidate for HIV research.  
 
My results shown that the development of an HIV-1 Tat-Rev independent clone could 
become a candidate for HIV research in a near future, but further investigations are 
necessary before proposing our model as an alternative yet.  
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   NFAT  nuclear factor of activated T-cells 
   NIS  nuclear inhibitory signal 
   NLS  nuclear localization signal 
   NNRTI  non-nucleoside transcriptase inhibitor 
   NRTI  nucleoside analog reverse-transcriptase inhibitor 
   NtART  nucleotide analog reverse-transcriptase inhibitor 
   NPC  nuclear pore complex 
   Nt  nucleotide 
   Nup  nucleophorin 
   ORF  open reading frame 
   P-TEFb  human transcription elongation factor 
   PBS  primer binding site/ phosphate buffered saline 
   PCR  polymerase chain reaction 
   PEI  polyethylenimine 
   PIC  pre-integration complex 
   Pol  polymerase 
   PPT  polypurine track 
   PR  protease 
   qPCR  quantitative PCR 
   R  R region 
   RCF  relative centrifuge force (g) 
   RCL  replication competent lentivirus 
   Rev  regulator of the expression of the viral proteins 
   RFP  red fluorescent protein 
   RH  ribonuclease H 
   RNA   ribonucleic acid 
   Rpm  revolutions per minute 
   RPMI  Roswell Park Memorial Institute 
   RSV  Rous sarcoma virus 
   RT  reverse transcriptase 
   RTI  reverse transcriptase inhibitor 
   SCID  severe combined immune deficiency  
   SD  splice donor 
   SDS  sodium dodecyl sulphate 
 XVII 
	
	
	
	
	
      
   SFFV  spleen focus-forming virus 
   SFV  simian foamy virus 
   SHIV  SIV/HIV chimera 
   SIN  self-inactivating vector 
   SIV  simian immunodeficiency virus 
   ssRNA  single stranded RNA 
   SU  surface protein 
   TAE  tris-acetic acid-EDTA 
   TAR  trans-activator response element 
   Tat  trans-activator protein 
   TCR  T-cell receptor 
   TM  trans membrane protein 
   TRIM5α  tripartite motif-containing protein 5  
   tRNA  transfer RNA 
   U3  unique to the 3’ region 
   U5  unique to the 5’ region 
   vif  viral infectivity factor 
   VLP  viral-like particle 
   Vpr  viral protein R 
   Vpu  viral protein U 
   Vpx   viral protein x 
   VSV  vesicular stomatitis virus 
   VSV-G  vesicular stomatitis virus G protein 
   WDSV  Walleye dermal sarcoma virus 
   WPRE  post-transcriptional regulatory element of Woodchuck Hepatitis virus 
   Wt  wild type 
   ψ  packaging signal 
 XVIII 
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1. Introduction 
 
1.1 Retroviruses 
  
1.1.1 Classification 
 
The family Retroviridae comprises a diverse family of enveloped RNA viruses divided 
into seven genera: Alpharetrovirus, Betaretrovirus, Gammaretrovirus, Deltaretrovirus, 
Epsilonretrovirus, Lentivirus and Spumavirus (Table 1.1), which possess the ability to 
reverse transcribe a single stranded RNA (ssRNA) genome through a reverse transcription 
mechanism to generate double stranded DNA (dsDNA), which subsequently integrates into 
the host cell genome becoming a proviral DNA (Dahlberg 1988).  The enzyme capable of 
reverse transcription is called reverse transcriptase (RT), and was discovered by David 
Baltimore (Baltimore 1970) and Howard M. Temin, awarded with the Nobel prize jointly 
with and Renato Dulbecco (which demonstrated that the infection of normal cells with 
some types of viruses (oncoviruses) were able to incorporate virus-derived genes into the 
host-cell genome, generating tumoral phenotypes in infected cells) in 1975 for	 their 
discoveries concerning the interaction between tumour viruses and the genetic material of 
the cell. The discovery of reverse transcriptase is one of the most important of the medicin 
discipline, which contributed to the generation of novel techniques in molecular biology. 
 
Retroviruses can be divided into two different groups:  
 
(i) Endogenous retroviruses (ERVs) are transmitted vertically through the germ line of the 
host, and comprise about 5%-8% of the human genome (Belshaw et al. 2004). A possible 
explanation for the origin of ERVs could be a result of exogenous retroviruses infecting 
the germ line cells at some point in the past, where ERVs can later become fixed in the 
gene pool of the host population and inherited by its offspring as a novel allele (vertical 
transmission). Analysis of sequenced genomes has revealed that between four and ten per 
cent of vertebrate DNA is made up of retroviral remnants (Stoye et al. 2012). The human 
ERVs (HERV) integration could severely affect the function of nearby genes, where the 
transcriptional orientation in relation to the host gene can act as a promoter or repressor of 
neighbouring genes (Jern et al. 2008), and HERVs that have been integrated within introns 
provide an alternative transcription initiation or termination sites, generating truncated host 
mRNA transcripts (Cohen et al. 2009). Several reports have described that CpG DNA  
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methylation participates in the transcriptional silencing of HERVs, and can also reverse the 
silencing of ERVs long terminal repeats (LTRs) (Isbel et al. 2012).  
 
(ii) Exogenous retroviruses whose genetic information is sufficient for the generation of 
replication competent viruses capable of transmitting from one individual to another from 
the same specie (horizontal transmission). These retroviruses need to propagate through 
several individuals in order to survive and evolve along episodes of infection in novel 
infected hosts. The success of the infection of exogenous retroviruses is closely related to 
the virulence and pathogenicity within the host to complete the cycle of replication and 
spread in the infected host. One example of an exogenous retrovirus that can cause severe 
disease is the Human Immunodeficiency Virus 1 (HIV-1), the causative agent of Acquired 
Immunodeficiency Syndrome (AIDS). 
 
Therefore, retrovirus research has led to the discovery of oncogenes and, among other 
things, has also enhanced our understanding of eukaryotic gene expression and cancer 
genetics (Vogt 2012). For example, the mouse mammary tumor virus (MMTV) was 
identified as the causative agent of mammary carcinoma in mice following milk 
transmission from mother to suckling offspring (Spiegelman et al. 1972). Retroviruses are 
valuable research tools in molecular biology, and they have been used successfully in gene 
delivery systems. 
 
Table 1.1 Classification of Retroviruses  
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1.1.2 Genera 
 
1.1.2.1 Lentiviruses 
Lentiviruses are classified into five groups according to the vertebrate hosts they infect. 
Lentiviruses are retroviruses with additional accessory and regulatory proteins, that differ 
in morphology and genetic composition: feline immunodeficiency virus (FIV) encodes 6 
genes, and the human immunodeficiency virus 1 (HIV-1) genome encodes 9 genes in total. 
Several lentiviruses such as HIV-1 can deliver large amounts of genetic information into 
the DNA of host cells and replicate in non-dividing cells, causing slowly progressing 
diseases (Sakuma et al. 2012). This feature (infecting nondividing cells) converts the 
lentiviruses into a useful tool for gene therapy, but integrating the lentiviral DNA into the 
host cell genome can disturb the function of host cell genes by leading to the repression or 
overexpression of such genes and insertional mutagenesis (Bokhoven et al. 2009). In 
addition, some patients treated with retroviral vectors to cure their diseases subsequently 
developed vector-related leukemia diseases in a significant number of patients, 
demonstrating that the future success of these vectors requires more research to understand 
their biology in depth (Escors et al. 2011). Thus, MLV-based vectors employed in cancer 
therapies have been related to DNA replication instability and DNA damage in severe 
combined immune deficiency (SCID) patients (Bester et al. 2013) 
 
 
 
 
 
 
 
Figure 1-1. HIV-1 particles budding and released at the host plasma membrane. B) EM 
representative sections depicting normal mature virions released from wild-type HIV-1.Some 
aberrant HIV-1 particles are observed in image B (right). Photos taken from Bartonova, V. y col. 
(2008) J. Biol. Chem. 283:32024-33033 
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Other approaches in gene therapy are related to adeno-associated virus 2 (AAV-2), 
developed to stablish long-term gene expression. The replication cycle of AAV-2 involves 
a transformation of single stranded DNA genome into a double stranded DNA suitable for 
gene expression (Fisher et al. 1996). Thus, the serotype tropism comprises a clinical 
problem that impedes AAV-2 vectors to infect target cells, which are not susceptible to 
infection. There are several limitations in AAV-2 gene therapy such as the low expression 
of cellular receptors and co-receptors in non-permissive cells and the intracellular 
trafficking process after infection, but these inconvenients have been approached with 
current recombinant AAV vectors (rAAV) (based on AAV-2 vectors) and increasing 
genome capacity and gene expression (Fisher et al. 1997). Moreover, the AAV-2 vectors 
integration occurs at low frequency meanwhile lentiviral vectors integration can integrate 
at many sites along the human genome contributing to the generation of mutagenesis in 
patients, but the limitations of AAV-2 serotypes and genomic capacity represent relevant 
disadvantages that lentiviral vectors can overcome. 
The AAV vectors have demonstrated the greatest clinical success in vivo given the 
existence of many serotypes and capsid variants developed that target a wide variety of 
cells, but the limitations to carry large amounts of genetic material need to be developed to 
increase the potential in gene therapy using AAV-2 vectors. 
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1.2 Genome organization and virion characteristics 
 
Retroviruses are a large and diverse family of infectious agents classified by virion 
morphogenesis and replication cycle. However, all intact retroviruses share three genes: 
gag, pol and env (Coffin 1979), which are precursors of different viral proteins. In the 
HIV-1 genome, the capsid (CA/p24), matrix (MA/p17), nucleocapsid proteins (NC/p7), p2, 
p1 and p6 are encoded in gag; protease (PR), reverse transcriptase (RT), ribonuclease H 
(RH) and integrase (IN) are encoded in pol; and transmembrane (gp41) and surface 
proteins (gp120) are encoded in env. The CA and NC proteins compose the viral core, and 
the MA lines the inner surface of viral envelope; the PR, RT, RH and IN proteins are 
involved in viral gene expression and integration, and the envelope proteins determine the 
tropism of the virus. The PR is essential for the cleavage of Gag polyprotein to separate 
matrix, capsid and nucleocapsid proteins, and the RT enzyme synthesizes a dsDNA from 
the viral RNA genome (through a reverse transcription mechanism), which will be 
subsequently integrated into the host genome. 
 
The HIV-1 virion possess a similar structure: enveloped particles about 100nm in diameter, 
containing two molecules of single-stranded RNA about 7 to 10 kilobases in length, linked 
by their 5′ end to form a dimeric RNA structure (Greatorex 2004). The viral envelope 
requires conformational changes required for the process of attachment and fusion with the 
host membrane (Riedel et al. 2017). Thus, HIV-1 matrix is composed of amino terminal 
myristyl acids creating the isometric structure of the particles, which are also associated 
with the viral envelope (Conte et al. 1998; Sun et al. 2014). The viral capsid is composed 
of Gag proteins, which associate with the viral membrane. There are several elements that 
are located inside the capsid in HIV-1 virion: two RNA molecules associated with the 
nucleocapsid proteins (Zuber et al. 2000). (Figure 1-2).  
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Figure 1. HIV-1 assembly, budding, and maturation. (A) Schematic illustration showing the different stages of
HIV-1 assembly, budding, and maturation. (B) Domain structure of the HIV-1 Gag protein; arrows denote the
five sites that are cleaved by the viral PR during maturation. (C) Structural model of the HIV-1 Gag protein,
created by combining structures of the isolated MA-CANTD (2GOL), CACTD (1BAJ), and NC (1MFS) proteins,
with a helical model for SP1. (D) Schematic model showing the organization of the immature HIV-1 virion. (E)
Schematic model showing the organization of the mature HIV-1 virion. (F) Central section from a cryo-EM
tomographic reconstruction of an immature HIV-1 virion. (G) Central section from a tomographic reconstruc-
tion of a mature HIV-1 virion. (H ) Structure of HIV-1 protease (PR, 3D3T). The two subunits in the dimer are
shown in different shades of purple, the “flap” and dimerization interfaces are labeled, positions of the active site
Asp25 residues are shown in red, and a bound peptide corresponding to the SP2-p6 cleavage site is shown as a
stick model, with oxygen atoms in red and nitrogen atoms in blue.
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Figure 1-2. A) HIV-1 virion composition. B) Schematic representation of the structure of mature 
and immature HIV-1 virions (upper panel) and their corresponding tomographic reconstructions 
(bottom panel). C) Genome organization of a standard retrovirus. Diagrams taken from Swiss 
Institue of Bioinformatics (2015); https://viralzone.expasy.org/7?outline=all_by_species and 
Karlsson Hedestam, G. B., Fouchier, R. A. M., Phogat, S., Burton, D. R., Sodroski, J., & Wyatt, R. 
T. (2008). The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. 
Nature Reviews Microbiology, 6, 143. Taken from http://dx.doi.org/10.1038/nrmicro1819. 
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1.3 HIV-1 replication cycle 
 
1.3.1 Attachment and uncoating 
The HIV-1 replication cycle starts with the attachment of HIV-1 via the gp120 envelope 
protein to the CD4 receptor and co-receptors CCR5 or CXCR4, depending of the tropism 
of the virus (Feng et al. 1996; Clapham et al. 2001).  Despite all HIV-1 strains recognizing 
the CD4 receptor, viral entry requires coreceptors (usually CXCR4 and/or CCR5) in order 
to undergo fusion and entry into the host cell (Clapham et al. 1991; Dittmar et al. 1997). 
Both CXCR4 and CCR5 are chemokine receptors involved in the migration of several 
leukocytes to inflammation sites and also specific niches in lymphoid organs (Mackay, 
1996). Nowadays, CCR5 is recognized as the major co-receptor for the virus and R5 
tropism appears to be more prevalent than CXCR4. Approximately 50% of infected 
patients undergo the switch from R5 virus (the majority in primary infections) to R5X4 
tropism, which is associated with a progressive decline in the CD4+ cell count and rapid 
disease progression. The HIV-1 tropism swift is determined by the highly variable and 
flexible V3 loop region of the viral gp120 Env protein (Briggs et al. 2000), specifically the 
amino acids between Cys263 and Cys296. The interaction between gp120 and 
CCR5/CXCR4 suggests that the accumulation of amino acid replacements within the V3 
loop is responsible for the eventual switch in co-receptor affinity (Masso et al. 2010). 
However, the ‘gatekeeper’ mechanism that restrict HIV-1 transmission could be related 
with superimposition of multiple imperfect gatekeepers (Margolis et al. 2006). Thus, the 
CCR5 inhibitors employed in clinical trials represent a powerful tool to provide new 
insights about HIV-1 envelope tropism (Hemelaar et al. 2006).  
The envelope HIV-1 glycoprotein (Env) is synthesized as a gp160 precursor of 850 amino 
acids. After the cleavage of gp120 precursor, the gp120 and gp41 proteins are generated, 
following folding and glycosylation within the endoplasmic reticulum (Wyatt et al. 1998). 
The gp160 precursor is cleaved by host furin-like proteases to produce the gp120 and gp41 
subunits (Mao et al. 2012). This cleavage requires several arginine and lysine residues in 
the consensus amino-acid sequence Arg-X-Lys/Arg-Arg located at the cleavage site 
(McCune et al. 1988; Hallenberger et al. 1992). The Env glycoprotein consists of a trimer 
of heterodimers containing three gp41 and three gp120 molecules (each trimer), where the 
gp41 subunit remains hidden within the viral envelope by non-covalent interactions 
between gp120 and gp41 subunits (Mao et al. 2012).  
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When the viral envelope binds the cellular CD4 receptor and co-receptor, CCR5/CXCR4 
conformational changes are triggered in envelope the proteins (gp120 and gp41), exposing 
the fusion peptide within the gp41 subunit that drives the fusion of the viral and cell 
membranes (Kong et al. 2016). Following penetration of the host-cell, the process termed 
‘uncoating’ occurs.  The HIV-1 uncoating mechanism is a highly controversial area and 
still uncertain. Several reports suggest that uncoating of the viral capsid occurs within the 
cell cytoplasm, releasing the viral genome, which will be reverse transcribed within the 
reverse transcription complex to generate dsDNA (Iordanskyi et al. 2007).  However, there 
are multiple lines of evidence suggesting that the HIV-1 capsid remains intact (or partially 
intact) as it traverses the cytoplasm during the early stages of infection. The intact viral 
capsid is required to engage the nuclear envelope, and assembled capsid proteins interact 
with the nuclear pore complex (Jacques et al. 2016; Ambrose et al. 2014). The uncoating 
may occurs within the nucleus, and reverse transcription could take place within the HIV-1 
virion during cytoplasmic transit before it reaches the host nuclear membrane. Moreover, 
mutations that alter the CA stability severely reduce reverse transcription (Rihn et al. 
2013). 
 
 
 
 
 
Figure 1-3. HIV-1 fusion process. Both gp120 and gp41 are required during this process. The gp41 
subunit is shown in green and gp120 in blue. Diagram taken from Jan Münch, Ludger Ständker, 
Wolf-Georg Forssmann & Frank Kirchhoff (2014). Discovery of modulators of HIV-1 infection 
from the human peptidome. Nature Reviews Microbiology 12, 715–722 (2014) 
doi:10.1038/nrmicro3312 
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Figure 1-4. HIV-1 uncoating mechanism linked to rerverse transcription requires nuclear import and host
cell factors. A) Capsid core opening. B) Premature uncoating. C) Uncoating acceleration by host viral
inhibitors such as TRIM5a, that causes a reduction in reverse transcription levels and nuclear importo of
viral DNA. Diagram taken from Zandrea Ambrose and Christopher Aiken (2014). HIV-1 Uncoating:
Connection to Nuclear Entry and Regulation by Host Proteins. Virology. 2014 April ; 0: 371–379.
doi:10.1016/j.virol.2014.02.004.
 
 
 
 
 
 
 
 
Figure 1-4. I -1 uncoating mechanism linked to rerverse transcription requires nuclear import 
and host cell factors. A) Capsid core opening. B) Premature uncoating. C) Uncoating acceleration 
by host viral inhibitors such as TRIM5α, that causes a reduction in reverse transcription levels and 
nuclear importo of viral DNA. Diagram taken from Zandrea Ambrose and Christopher Aiken 
(2014). HIV-1 Uncoating: Connection to Nuclear Entry and Regulation by Host Proteins. 
Virology. 2014 April ; 0: 371–379. doi:10.1016/j.virol.2014.02.004.  
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1.3.2 Reverse transcription  
The place where reverse transcription takes place in the cell is still controversial. There are 
reports suggesting that reverse transcription occurs immediately after the viral genome is 
released from the viral capsid into the target cell cytoplasm (Mamede et al. 2017). 
However, more recent studies suggest that reverse transcription may occur within the viral 
capsid during cytoplasmic transit and inhibiting reverse transcription may delay uncoating 
(Figure 1-4) (Hulme et al. 2011). 
The HIV-1 genome is composed of two identical molecules of ssRNA (positive sense) that 
act as a template for reverse transcription (Canard et al. 1997). Reverse transcription is a 
complicated process involving several strand transfer events required to generate the 
complete LTRs in the DNA provirus, which are not present in the viral RNA (O’Neil et al. 
2002). The viral enzymes RNase H and reverse transcriptase (RT) are essential for reverse 
transcription, which generates dsDNA in the host cell cytoplasm that will be trafficked to 
the nucleus and will subsequently become integrated into the host genome (Figure 1-5). 
The steps involved in reverse transcription are the following: 
1. Minus DNA strand synthesis starts at the 3'-OH of a cellular tRNA acting as a 
primer that binds the PBS in the virus RNA.  
2. The first strand DNA is synthesized until the RT enzyme reaches the terminus of 
the 5' end, generating a small ssDNA fragment around 100-150 bases (this 
termination is termed ‘strong-stop DNA’). 
3. Viral RNase H degrades the RNA fragment used as template and the ssDNA 
(which includes the reverse transcribed R region) 'jumps' and attaches to the R 
region in the 3' end of the viral RNA.  
4. Next, this intermediate DNA is extended towards the 5' end of the viral RNA 
genome (terminating at the PBS), and the RNA strand used as template is now 
degraded by the RNAse H except the polypurine tract (PPT), which is resistant to 
RNase H activity.  
5. This RNA fragment containing the PPT acts as a primer for the generation of the 
+DNA strand synthesis, which is generated until it reaches the 3'-end of the -DNA 
strand.  
6. Now RNAseH degrades all viral RNA remaining, exposing complementary 
sequences near the 3'-end of the +DNA strand. 
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7. The +DNA strand is transferred to the 5'-end of the -DNA strand, annealing to the 
complementary PBS at the 5' end. 
8. Finally, the synthesis of both DNA strands is completed, with each strand serving 
as template for the other strand. Once the dsDNA is synthesized, the provirus will 
be transferred into the nucleus to be integrated into the host genomic DNA. 
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Figure 1-5. Reverse transcription mechanism. Diagram adapted from Virology: Principles and 
Applications, John Carter, Venetia Saunders. 
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1.3.3 Nuclear import and integration 
Following reverse transcription, the pre-integration complex traverses the nuclear envelope 
and subsequently the viral dsDNA is integrated into the host cell genome (Endsley et al. 
2014). The dsDNA remains associated with viral (CA, MA and Vpr) and cellular proteins 
at the pre-intregration complex (PIC) within the cytoplasm (Figure 1-6). The PIC is 
translocated to the host nucleus through nuclear pore complexes (NPCs) prior to 
integration into the host genome (Bukrinsky et al. 1998). There are several host proteins 
involved in the traslocation of the PIC into the host nucleus, such as importins (Imp) and 
nucleophorins (NUPs). The viral integrase recruits importin α and β to import the viral 
dsDNA into the nucleus, and Nup153 is also involved in nuclear import (Woodward et al. 
2009). Thus, the viral CA from the PIC could be an essential factor for HIV-1 nuclear 
import because a reduction in CA levels within the PIC results in a reduction of viral 
replication in cell cycle arrested cells (Yamashita et al. 2004). 
Interestingly, another study showed that Impα dependent nuclear localization of Vpr does 
not require Impβ, and Vpr also interacts with several Nups and localizes to the nuclear 
envelope (Nitahara-Kasahara et al. 2007). However, the MA protein located in the PIC is 
also required for nuclear import via an IN interaction. Therefore, the viral DNA is also 
involved in nuclear integration of the PIC. The polypurine tract from HIV-1 cDNA (cPPT) 
forms a triple stranded DNA structure called the DNA flap that seems to be involved in 
nuclear import, and mutations in the DNA flap may contribute to retain the cDNA within 
the viral coat (Arhel et al. 2007). 
Following the PIC formation, the viral dsDNA integrates in the chromatin of mitotic and 
non-mitotic target cells overcoming the nuclear membrane barrier, and allowing HIV-1 to 
successfully replicate in dividing and non-dividing cells (Gallay et al. 1997). HIV 
integration location is influenced by DNA structure and host factors such as the lens 
epithelium-derived growth factor (LEDGF/p75), a chromatin binding protein that interacts 
with HIV-1 integrase though specific binding domains and targets HIV-1 to 
transcriptionally active regions of the host chromosome (Marshall et al. 2007). Recent 
studies shown that knockout experiments for LEDGF severely reduce HIV infectivity and 
replication, suggesting that the HIV IN-LEDGF interaction could be a potential candidate 
for antiviral therapy (Llano et al. 2006). 
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During integration, IN cleaves specific phosphodiester bonds near the viral DNA end, and 
then uses the resulting DNA 3′-OH groups during strand transfer to cut chromosomal 
target DNA (Cherepanov et al. 2014). However, the integration site location of HIV-1 
DNA is still controversial (Woodward et al. 2009; Gonçalves et al. 2016), but recent 
evidence suggests that specific integration sites are related to cell cycle control and 
proliferation of HIV-1 infected cells (Sunshine et al. 2016; Maldarelli et al. 2014). 
The viral integration into host DNA occurs at preferred sites that are associated with active 
transcription (Lewinski et al. 2006), where the HIV integrase associates with the cellular 
chromatin factor LEDGF/p75. This interaction represents an antiviral target to develop 
drugs that counteract this interaction, leading to the development of an integrase inhibitor 
called raltegravir that was approved for clinical use in 2007 for the treatment of HIV-AIDS 
by allosteric inhibition of the strand transfer reaction of the viral integrase (Summa et al. 
2008). However, the raltegravir resistance evolves rapidly in clinic even in the presence of 
highly active antiretroviral therapy (HAART). Thus, the drugs targeting the LDGF/p75-IN 
interaction are small molecule inhibitors (LEDGINs) binding to this dimer to inhibit viral 
replication with a dual mechanism of action: the inhibition of LEDGF/p75-IN interaction 
and modifying the multimerization state of IN by allosteric inhibition within the catalytic 
activity. For example, the LEDGF/p75 binding to the pocket in the dimer interface of HIV-
IN catalytic core domain can be inhibited by D77, a potential drug that interacts with 
LEDGF/p75 biding pocket (Du et al.2008). 
 
1.3.4 Transcription, translation and splicing  
 
There are two gene expression phases in the HIV- 1 life cycle: early and late expression. 
HIV-1 gene expression is highly regulated by splicing to generate the different viral 
proteins encoded by the genome. At early expression phases, HIV-1 uses three different 
reading frames, which overlap each other, allowing the control of gene expression in 
multiple pathways (Locker et al. 2011). Transcription from the viral genome is initiated 
when cellular transcription factors bind to the proviral LTR promoter located at the 5' 
region of the viral genome (Kutky et al. 2017). Then, viral transcripts are polyadenylated at 
the R–U5 junction within the 3' LTR. Most of these nascent RNAs are spliced in early 
infection, transported and translated in the cytoplasm generating Tat, Rev and Nef proteins 
(Strebel 2003). The regulatory proteins Tat and Rev are essential for the viability of HIV-1 
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and are translated in the cytoplasm following integration and these proteins traffic to the 
nucleus, where they exert their functions (Sawaya et al. 2000). However, Nef remains in 
the cytoplasm and is myristoylated close to the N-terminus (Mishra et al. 2011; Love et al. 
1998; Bentham et al. 2006) causing it to associate with cellular membranes. 
Most of the regulatory mechanisms of HIV gene expression are controlled by splicing, 
which seems to be independent of Tat (Leblanc et al. 2013; Debaisieux et al. 2012). In 
addition, spliced viral RNAs are transported to the cytoplasm during early stages of 
infection in a Rev independent manner (Dayton 2004). However, the export of full length 
viral RNAs are Rev dependent. Rev protein interacts with the Rev Response Element 
(RRE) located in the env gene RNA (Sherpa et al. 2015). The formation of the Rev-RRE 
complex is essential for unspliced viral RNA export to the cytoplasm to permit translation 
of viral proteins (Fernandes et al. 2012) and provide full length RNA-genomes to be 
packaged into nascent virions. Cellular co-factors are also required in this step such as the 
chromosomal maintenance 1 (CRM1) (Sherer et al. 2011).  
 
1.3.5 Packaging, assembly and release 
 
The assembly for viral particles production requires two copies of the viral RNA genome, 
a cellular tRNALys,3, Gag and Env proteins and the viral enzymes RT, PR and IN. The viral 
packaging and assembly occurs at the plasma membrane, where Gag proteins form 
multimeric complexes and bind to multiple molecules including the viral genome 
(Nikolaitchik et al. 2017). The polyprotein precursors Gag and Gag-Pol regulate the events 
for viral assembly: Gag assembly leads to the generation of immature particles, and Gag 
molecules are extended radially in the immature virions, with their N-terminal MA 
domains bound to the inner membrane. HIV-1 assembly and budding appears to occur 
predominantly at the plasma membrane. However, several parameters of HIV-1 assembly 
are challenging to determine, and some have been controversial (Jouvenet et al. 2011) 
 
The NC and MA proteins are essential for the generation of immature virions, and the 
maturation of HIV virions ocurrs when the PR cleaves Gag and Gag-pol polyproteins 
generating MA, CA, NC, p6, PR, RT, and IN proteins during budding process (Scarlata et 
al. 2003). The viral protease cleaves Gag and Gag-pol polyproteins generating MA, CA, 
NC, p6, PR, RT, and IN proteins during the budding process to generate immature viral 
particles that will be released and subsequently rearranged into the mature infectious form.  
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This cleavage triggers the dimeric formation of the viral RNA genome and the NC protein, 
which contains basic residues with zinc fingers that bind a dimeric, unspliced HIV-1 RNA 
called the packaging signal (ψ) (Dannull et al. 1994). Approximately 95% of the 
translating ribosomes produce Gag, while 5% produce a Gag-Pol fusion protein originating 
from a ribosomal frameshift sequence located at the end of gag, which allows the 
expression of the Pol viral polyprotein (Hung et al. 1998; Biswas et al. 2004). In the case 
of gagpol, the GagPol polyprotein is translated when a ribosome frameshift occurs due to 
the slippery sequence U UUU UUA located at the end of gag (Mathew et al. 2015). 
Finally, the envelope gp160 proteins are synthesized, glycosylated and cleaved by host 
furin-like proteases to produce the gp120 and gp41 subunits (Sharma et al. 2015). The 
Rev-dependent full-length HIV-1 genome dimerizes via base pairing between 
complementary sequences at the 5' end of each RNA strand, stabilized by the kissing-loop 
complex (Checkley et al. 2011).  
The rest of viral proteins translocate to the cell surface to assemble into new immature 
virus particles that are released by the ESCRT (endosomal sorting complexes required for 
transport) machinery (Morita et al. 2007). Capsid proteins bind the host protein cyclophilin 
A and Gag C-terminal p6 domain bind to Vpr (Zhu et al. 2004). Vif could be packaged into 
virions as a component of the viral nucleoprotein complex (Khan et al. 2001), but there are 
other data suggesting that Vif packaging is irrelevant and is required for sustained HIV-1 
infection to counteract antiviral factors within infected cells (Salter et al. 2014).  
The cellular intrinsic immunity family of cytidine deaminases APOBEC3G (A3G) are 
involved in antiviral mechanisms of mRNA modification by deamination of the cytidines 
(cytidine to urinine) of the target viral RNA to impair viral replication within the infected 
cell (Sheehy et al. 2002). Once the viral RNA is released into the cytoplasm the A3G 
proteins edit the viral genome sequence to inhibit viral infection, reducing the 
accumulation of nascent HIV-1 reverse transcripts in newly challenged cells. These effects 
have been described for early and late reverse transcription intermediates, and it appears 
that the magnitude of the defects increases as later cDNA products are measured 
(Anderson et al. 2008). The A3G proteins are encapsidated by viral budding particles, and 
their function is exerted in the next cycle of replication. However, the HIV-1 protein Vif 
counteracts APOBEC3G function binding and subsequently inducing polyubiquitylation, 
leading to proteosomal degradation of A3G to diminish the pool of A3G available that  
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Figure 1-6. HIV-1 replication cycle. Taken from A. Engelman and P. Cherepanov (2012).
The structural biology of HIV-1: mechanistic and therapeutic insights. Nature Reviews
Microbiology 10, 279–290(2012) doi:10.1038/nrmicro2747
 
could be incorporated into the nascent particles. Moreover, Vif protein recruits cullin5-
elongin B/C-Rbx ubiquitin ligase, serving as an adaptor to recruit the ligase complex to its 
substrate (Yu et al. 2003). Moreover, the Asp-Pro-Asp motif at positions 128-130 in A3G 
are critical for Vif interaction (Huthoff et al. 2007). 
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1.4 HIV-1 genome structure 
HIV-1 posseses the genetic structure shared by all retroviruses: gag, pol and env, but also 
encodes 6 additional genes: vpu, vpr, vif, tat, rev and nef (Figure 1-7). These genes are 
involved in many roles, such as controlling virus gene expression, transporting virus 
components within the cell or modifying the host immune response (Bohne et al. 2007). 
There are three open reading frames along the HIV-1 genome that overlap each other, 
allowing the control of gene expression in multiple pathways. At first, Vif and Nef proteins 
are generated upon early infection to counteract antiviral activity from the host cell and 
downregulate multiple cell surface markers inclusing CD4 (Mlcochova et al. 2015). The 
Vpu protein counteracts the host protein tetherin reducing the levels at the infected cell 
surface (Neil et al. 2008; Van Damme et al. 2008). Thus, Vpu also reduces the levels of 
tetherin within infected cells when is overexpressed (Bartee et al. 2006). However, the role 
of Vpr protein still controversial, but it mediates many processes related to evade immune 
response and the persistence of HIV-1 infection (Conti et al. 1998), and also induces G2 
cell cycle arrest interacting with the DNA binding protein 1 (DCAF-1) factor, leading to 
immune cell dysfunction (Belzile et al. 2007). Moreover, Vpr could be also involved in 
pathogenesis (Gibbs et al. 1994) 
 
 
 
 
 
 
 
 
Figure 1-7. HIV-1 genome organization and open reading frames. Adapted from Virology: 
Principles and Applications, John Carter, Venetia Saunders 
 
The HIV regulatory proteins Tat (trans-activator of transcription) and Rev (regulator of 
expression of viral proteins) are produced in early stages after infection and stimulate viral 
transcription and viral RNA transport respectively.  
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1.4.1 HIV-1 Long Terminal Repeat (LTR) 
HIV-1 encodes 9 genes in total that are flanked by two Long Terminal Repeats (LTRs) at 
the 5’ and 3’ ends, where the 5’ LTR controls viral gene expression by acting as a 
promoter (Klaver et al. 1994). These two LTRs are essential to perform the reverse 
transcription mechanism (section 1.3.2). Each HIV-1 LTR is ~634bp in length, composed 
of three regions (as a provirus): unique to the 3’ end (U3), R region (R) and unique to the 
5’ end (U5). Before reverse transcription takes place, the 5’end of the RNA genome only 
encodes the R-U5 region, and the 3’end encodes the U3-R (Figure 1-7 and Figure 1-8). 
However, the U5 and U3 regions are duplicated at both ends of the genome during reverse 
transcription, where the resultant dsDNA provirus contains two identical copies of the 
tandem U3-R-U5 (Figure 1-8). 
The U3 region contains cis-acting binding sites for cellular transcription factors, but viral 
transcription starts (by definition) at the start of the R region, which is also essential for 
viral reverse transcription (Ohi et al. 2000; Berkhout et al. 2001). There are two secondary 
RNA structures in the R region, such as the TAR loop and the polyadenyation signal that 
are required for efficient initiation and termination of viral transcription. The U5 region 
possesses several elements involved in many relevant functions: the primer binding site 
(PBS), the dimerization site (DIS), the splice donor (SD) and the packaging signal (ψ) 
(Figure 1-8). A cellular tRNA (Lys3) binds to the PBS of the viral genome, acting as an 
RNA primer for reverse transcription. The DIS joins the two molecules of single stranded 
viral RNA, generating a ‘kissing-loop’ stabilizing the joint. The SD region is essential for 
viral RNA splicing, and the packaging signal interacts with Gag proteins to incorporate the 
full-length viral genomes into the nascent virions (Dahiya et al. 2014). 
The HIV-1 LTR also presents DNA binding elements for cellular transcription factors that 
that activate or repress the viral gene expression (Montano et al. 1996). There are two 
adjacent NF-kappa β sites located in the U3 region: the NF-kappa β protein allows the 
virus to be responsive to the activation state of the infected T cell. The mechanism of 
activation of NF-kappa β involves the formation of reactive oxygen intermediates that 
trigger the phosphorylation and degradation of IkB (Deptala et al. 1998), which triggers the 
translocation of NF-kappa β to the nucleus where it induces the expression of T-cell 
specific genes. (Stroud et al. 2009; Valentin et al. 1989). Mutations or deletion of the NF- 
 
1- Introduction 21 
 
kappa β sites within HIV-1 LTR abolish reporter gene activation and host transcription 
factors such as nuclear factor of activated T-cells NFAT1 and NFAT5 are unable to 
activate HIV-1 transcription through these sites (Kinoshita et al. 1997; Cron et al. 2000). 
Additional binding sites for constitutive transcription factors such as SP-1, Lef, Ets, and 
for inducible transcription factors NF-AT and AP-1 are also encoded within the LTR. The 
three SP-1 binding sites are essential for the function of the LTR, and removal of these 
sites results in a huge decrease in transcription levels (Harrich et al. 1989). The HIV-1 
LTR is unable to reach sufficient levels of viral transcription independently, but when 
HIV-1 Tat protein binds to the LTR it enhances viral transcription ~200-300 fold 
(Southgate et al. 1991). In the absence of Tat, the stimulation of viral transcription (carried 
out by cellular transcription factors) leads to the generation of short transcripts. Host 
proteins such as cyclin T1 (cycT1) and cyclin-dependent kinase 9 (CDK9) are recruited to 
form a complex with Tat that stimulates viral transcription. The secondary RNA structures 
of the LTR are essential for HIV-1 replication, and conformational changes severely affect 
the viability of the virus (Mueller et al. 2014).  
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Figure 1-8. HIV-1 LTR structure. There are several secondary RNA structures along the LTR. The 
R region contains the TAR loop and the polyadenylation signal, meanwhile the U5 region encodes 
the primer binding site (PBS), the dimerization site (DIS), the splice donor (SD) and the packaging 
signal (ψ). Adapted from Kun Lu, Xiao Heng and Michael F. Summers. J Mol Biol.2011 Jul 22; 
410 (4):609-633, L J Chang, E McNulty. 
 
 
1.5 Origin and evolution of HIV-1 
 
Human immunodeficiency virus (HIV), the causative agent of acquired immunodeficiency 
syndrome (AIDS) was identified in 1983 by Luc Montagnier and Françoise Barré-
Sinoussi, revealing a novel lymphadenopathy-associated virus (LAV) from a patient 
suffering from AIDS (Barré-Sinoussi et al. 1983). There are two main types of human 
immunodeficiency viruses, which are designated HIV-1 and HIV-2. The closest relatives 
of HIV-1 are simian immunodeficiency viruses (SIVs) infecting wild-living chimpanzees 
(Pan troglodytes troglodytes) and gorillas (Gorilla gorilla gorilla) in west central Africa 
(Letvin et al. 1985).  Recent phylogenetic studies have revealed that  
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Figure X. A) HIV-1 LTR structure. There are several secondary RNA structures
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chimpanzees were the original host, and that multiple HIV-1 have resulted from 
independent cross species transmission events (Sharp et al. 2010, Rambaut et al. 2004) 
(Figure 1.9). HIV-1 strains are classified into 4 groups with different prevalence: group M, 
N, P and O. The most prevalent infections in the world are related to the group M (>90%), 
meanwhile groups N and O are restricted to central Africa countries such as Cameroon 
(Triques et al. 1999).  
 
HIV-1 is closely related to chimpanzee SIV (SIVcpz), originally from Western and Central 
African species (Gao et al. 1999). These regions contain two different chimpanzee sub-
species respectively: Pan troglodytes troglodytes and Pan troglodytes schweinfurthii. 
Interestingly SIVcpz from P.troglodytes shares many similarities with HIV-1 M group, and 
HIV-2 is more similar to SIV infecting Sooty mangabeys (SIVsm), from West Africa. 
(Sharp et al. 2011). For a long time, it was suspected that SIVs caused little disease in their 
natural hosts (in contrast to HIV-1 and AIDS in humans). However, recent studies have 
revealed new insights about SIV pathogenicity: some chimpanzees infected with SIVcpz 
(as humans infected with HIV-1) present a progressive CD4+ T-cell loss, lymphatic tissue 
destruction and premature death (Sharp et al. 2010). This evidence suggests that SIV 
infections could affect lifespan of chimpanzees and severely affect their health in the wild 
in a similar way as AIDS does in humans. HIV-1 is a diverse and rapidly evolving 
pathogen, and the extensive genetic variation of HIV-1 lineages differs between individual 
hosts, representing a major roadblock to vaccine development (Maldarelli et al. 2013). This 
variability is explained by the high frequency of errors introduced during reverse 
transcription in each replication cycle (average error rate per detectable nucleotide 
incorporated of ~1/1700) and also recombination (Roberts et al. 1988), increasing the 
genetic variability of the population, likely contributing to the evasion of specific immune 
responses (Mostowy et al. 2011).  
 
A great deal of recombination has occurred among diverse SIV lineages during the 
evolution of primate lentiviruses, and individuals infected with more than one genetically 
distinct HIV-1 tend to harbour hybrid viruses (Courgnaud et al. 2002; Chen et al. 2006). 
However, there is little evidence supporting a relationship between genetic diversity and 
pathogenesis. The viral population present within a infected person consists of a complex 
mixture of heterogeneous strains, with different antigenic and phenotypic features 
(Meyerhans et al. 1989). Thus, the high frequency of recombination in HIV assists the  
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Figure 1-9. Phylogeny of lentiviruses. This tree shows the evolutionary relationship
among Pol sequences derived from mammalian lentiviruses. HIV-1 and HIV-2
appeared after independent cross-transmission events from SIVs. The exogenous
retroviruses are depicted in black; the endogenous retroviruses are shown in blue and
HIV-1, HIV-2 and SIVmac are highlighted in red. Host species are shown at the right.
Image taken from Sharp, P. M., & Hahn, B. H. (2011). Origins of HIV and the AIDS
pandemic. Cold Spring Harbor Perspectives in Medicine, 1(1), 1–22.
https://doi.org/10.1101/cshperspect.a006841
 
virus in adapting to and overcoming selective pressures, hampering the development of 
antiretroviral therapies (Domingo et al. 2000). However, HIV-1 exhibits reduced viral 
diversity following transmission to a new host and only one (or a few viruses) establish the 
initial infection within the new individual (transmission bottleneck) (Joseph et al. 2015).  
 
Figure 1-9. Evolution of primate lentiviruses. This tree shows the evolutionary 
relationship among Pol sequences derived from mammalian lentiviruses. HIV-1 and 
HIV-2 appeared after independent cross-transmission events from SIVs. The 
exogeno  retroviruses are depicted in black; the endogenous r troviruses are shown i  
blue and HIV-1, HIV-2 and SIVmac are highlighted in red. Ho t species are shown at 
the righ . Image taken from Sharp, P. M., & Hahn, B. H. (2011). Origins of HIV and 
the AIDS pandemic. Cold Spring Harbo  Persp ctives in Med cine, , 1–2 . 
ht ps:/ doi.org/10.1101/cshperspect.a006841 
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1.6 Regulatory proteins of HIV-1 
The human immunodeficiency virus type 1 encodes regulatory genes that are not present in 
other retroviruses such as murine leukemia virus (MLV). However, the origins of HIV-1 
regulatory genes tat and rev remain unknown (Magin et al. 1999). The tat and rev genes 
are mainly involved in viral transcription and transport/stability of the viral RNA 
respectively. Both genes are essential to complete the viral life cycle, and their absence 
negatively affects viral transcription and the export/stability of full-length (unspliced) viral 
genomes from the host-cell nucleus. 
Multiple obstacles preventing HIV- 1 replication in non-human cells are related to Rev 
and Tat proteins; Rev is mainly involved in RNA transport within the host cell (after the 
HIV genome has been transcribed), but Rev also seems to have additional functions such 
as stabilizing viral transcripts (Kashanchi et al. 1994).  
 
1.6.1 Trans-activator of transcription (Tat) and the Tat-TAR complex 
 
The human immunodeficiency virus Tat protein ensures high levels of HIV transcription 
mediated by human transcription elongation factor (P-TEFb), which interacts with Tat and 
phosphorylates the C-terminal domain (CTD) of RNA polymerase II facilitating higher 
processivity of RNA polymerase II during the elongation phase. (Zhou et al. 2002). The 
formation of a ternary complex between TAR RNA, Tat, CDK9 and cyclinT1 is essential 
to enhance viral transcription. In the absence of Tat, viral transcription levels are 
considerably reduced because the polymerase engages poorly with the LTR, causing the 
complex to frequently ‘stall’. However, the viral genome can be completely transcribed in 
its absence, albeit extremely inefficiently (Shen et al. 2000). 
When viral transcription is initiated after the integration of the dsDNA provirus into the 
host genome, a short RNA (∼65 bp in length) is synthesized. This 65bp RNA contains an 
RNA regulatory signal loop called transactivator response element (TAR), located within 
the 5’LTR of the viral genome (Jeang et al. 1990). The TAR loop acts as a binding site for 
essential cellular co-factors, such as the P-TEFb, a kinase complex including a regulatory 
cyclin T1 subunit (CycT1) and a catalytic kinase subunit (CDK-9) (Figure 1-10) (Price et 
al. 2006). Both subunits are recruited to the TAR-Tat complex through direct interactions 
with Tat (Rana et al. 2002). Mutations altering the upper stem-loop of TAR severely affect  
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reverse transcription. However, when the upper stem-loop of TAR is replaced by 
alternative structures, the RNA packaging is notably reduced (Parry et al 2000; Berkhout et 
al. 2012). 
 
 
 
 
 
 
 
 
 
Figure 1-10. TAR-Tat interaction complex with human co-factors Cyclin-T1 and Cdk-9. The R 
region of the HIV-1 LTR contains a RNA loop where Tat protein binds to enhance viral 
transcription. Diagram adapted from Tackling Tat (1999), J. Mol. Biol. 293, 235±254 
 
 
 
1.6.2 Differences between human cyclinT1 (hCycT1) and murine cyclinT1 
(mCycT1) 
 
The human cofactor cyclinT1 plays an essential role during HIV-1 replication. Murine 
cells are not permissive to HIV-1 replication despite the similarities between murine 
cyclinT1 (mCycT1) and human cyclinT1 (hCycT1). The amino acid sequence of human 
and murine cyclinT1 are  90% identical, where a single tyrosine in place of a cysteine at 
residue 261 (C261) (in mCycT1) drastically impairs the ability of Tat to interact with 
mCyclinT1 (Cullen et al. 1998). Apparently, the binary complex lacking mCyclinT1 does 
not efficiently support transcriptional elongation (Yedavalli et al. 2003), impairing viral 
replication. 
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CDK9. The R region of the HIV-1 LTR contains a RNA loop where Tat protein
binds to enhance viral transcription. Diagram adapted from Tackling Tat (1999), J.
Mol. Biol. 293, 235±254
Sp1NFκβ
U3 U5
R
TAR
CycT1
Tat
Cdk-9
1- Introduction 27 
 
The Tat and hCyclinT1 interaction is important, but there are additional residues that are 
critical to facilitate binding of the complex to TAR RNA (trans-activator response 
element). There are zinc interactions involved in Tat-cyclinT1 interaction, where zinc- 
independent complexes dramatically reduce the ability of this complex to bind TAR RNA 
(Garber et al. 1998). However, there are also additional cellular proteins involved in HIV-1 
transcription, such as the chaperone Hsp7, which generate complexes that stabilize the 
cyclinT1-P-TEFb complex and also contribute to the folding of hCyclinT1 (O’Keeffe et al. 
2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-11. Amino acid sequence comparison of hCycT1 and mCycT1. The identical amino acids 
are boxed and the conserved cyclin box indicated. The crucial single residue at position 261is 
indicated by an asterisk. The sequence of murine CycT1 has been deposited in the 
DDBJ/EMBL/GenBank database (accession No. AF095640). Figure taken from Bieniasz, P. D., 
Grdina, T. A., Bogerd, H. P., & Cullen, B. R. (1998). Recruitment of a protein complex containing 
Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. The EMBO Journal, 
17(23), 7056–65. https://doi.org/10.1093/emboj/17.23.7056 
Recruitment of cyclin T1/P-TEFb by HIV-1 Tat
Fig. 1. Amino acid sequence comparison of human and murine CycT1. Identical amino acids are boxed and the conserved cyclin box indicated. The
single residue here shown to control the ability of hCycT1 to mediate Tat function is indicated by an asterisk. The sequence of murine CycT1 has
been deposited in the DDBJ/EMBL/GenBank database (accession No. AF095640).
Sharp, 1991; Okamoto et al., 1996; Parada and Roeder,
1996; Yang et al., 1996). In addition, Tat associates with a
CTD kinase activity (TAK) in nuclear extracts (Herrmann
and Rice, 1995). The identity of T K has been reported as
CDK7, a component of TFIIH (Cujec et al., 1997; Garcia-
Martinez et al., 1997), and by others as CDK9, a component
of positive transcription elongation factor-b (P-TEFb)
(Mancebo et al., 1997; Yang et al., 1997; Zhu et al., 1997).
While depletion of either protein from nuclear extracts
abrogates Tat transactivation in vitro, the ability of a panel
of kinase inhibitors to block Tat transactivation correlates
more closely with inhibition of CDK9, rather than of CDK7
(Mancebo et al., 1997). Nevertheless, considerable data
suggest that a direct interaction between Tat and TFIIH
could represent a critical step in the Tat-mediated activation
of the HIV-1 LTR promoter (Blau et al., 1996; Parada and
Roeder, 1996; Cujec et al., 1997; Garcia-Martinez et al.,
1997).
7057
Recently, a human protein, cyclin T1 (hCycT1), that
interacts with Tat and can mediate loop-specific binding
of Tat to TAR in vitr , was identified (Wei et al., 1998).
Im ortantly, hCycT1, which is one of three known cyclin
partners for CDK9 and a component of the transcription
elongation factor P-TEFb (Peng et al., 1998), is encoded
on human chromosome 12 and can rescue Tat function in
murine cells when overexpressed (Wei et al., 1998). While
these data demonstrate that CycT1 is a critical cofactor
for Tat function, it has remained unclear why, or indeed
whether, the murine form of CycT1 (mCycT1) is unable
to support Tat function.
In this report, we describe the cloning of the murine
homolog of cyclin T1 (mCycT1) and demonstrate that
overexpression of mCycT1, which is ~90% identical to
hCycT1, fails to rescue Tat function in murine cells and
inhibits TAR-dependent Tat function in human cells.
Although both human and murine CycT1 can interact
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1.6.3 Regulator of the expression of the viral proteins (Rev) and the Rev 
Response Element (RRE) 
 
The transition from early to late transcripts is mediated by the HIV-1 Rev protein, which is 
mainly involved in the nuclear export of incompletely spliced/unspliced viral RNA. Rev is 
a 19-kDa phosphoprotein located predominantly in the nucleus (Cochrane et al. 1990) and 
is composed of several domains. The N-terminal region encodes the nuclear localization 
signal (NLS), responsible for Rev nuclear location. The N-terminal domain also has a 
nuclear inhibitory signal (NIS), which controls the distribution and activity of Rev (Kubota 
et al. 1998). The C-terminal domain mediates the Rev effector functions in vivo encoding 
the nuclear export signal (NES) that interacts with cellular proteins involved in viral 
mRNA export (Malim et al. 1989). The RRE, located downstream the env gene, is 
essential to export the full-length viral RNAs towards the cytoplasm (Kjems et al. 1992). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-12. Predicted secondary structure for RRE from HXB3 strain with the major stem loops 
labeled. This structure is predicted from chemical and enzymatic probing studies in combination 
with mobility shift assays to determine the binding region for HIV-1 Rev protein. Taken from 
Fernandes, J. D., Jayaraman, B., Frankel, A. D., & Location, G. (2012). © 2012 Landes 
Bioscience. 
 
There are some instability regions within the HIV genome that are crucial in gene 
expression. These regions called (INS) are AU rich located in the main viral gene 
sequences: gag, pol, and env, requiring the presence of Rev for efficient RNA expression 
(Keating et al. 2009). The RRE is present in the unspliced and singly spliced viral 
transcripts, but is absent from the multiply spliced transcripts. In addition, it is necessary 
for the formation of a RRE-Rev complex to export the unspliced and singly spliced viral 
mRNAs (Suhasini et al. 2009).  
© 2012 Landes Bioscience.
Many simple retroviruses, most notably
Mason-Pfizer monkey virus (MPMV),
do not encode a Rev-like protein,
but instead have evolved a cis-acting
RNA element, the constitutive transport
element (CTE),48 that directly binds to
components of the host mRNA export
machinery.49 The MPMV CTE is ~220
nucleotides and consists of two identical
binding sites for the Nxf1 protein.48,50
Although the CTE can substitute for
Rev-RRE in HIV-1, export is significantly
diminished in these viruses. Wild-type like
export activity can be restored by engin-
eering tandem repeats of the CTE,50,51
suggesting that affinity in this case is
enhanced through additional sequence-
specific interactions rather than through
a specific structural arrangement of dis-
similar but cooperative binding sites, as for
the Rev-RRE complex.
Summary
Th RRE is an essential viral RNA
element carefully selected by many evolu-
tionary cycles to balance specificity and
adaptability Although stem IIB serves as a
high affinity anchor point, binding to the
secondary binding sites on the RRE need
not be driven by high affinity for the
nucleotide sequence, but rather by the
architecture of the entire complex. From
this viewpoint, the RRE can be seen as a
scaffold directing the orientation and
contacts of the similarly pliable RNA
binding surface of Rev. In this way, the
virus is able to encode a complex and
specific mechanism to achieve nuclear
export without the large evolutionary
penalties of maintaining the sequence of
multiple high affinity binding sites.
Methods
Sequences were retrieved from the HIV
sequence database (www.hiv.lanl.gov) for
all isolates aligned to nucleotides 7709–
8063 of the HIV-1 HXB2 sequence.
Non HIV-1 sequences were removed,
and sequences were realigned over the
RRE using Clustal X 2.1. Analyses were
performed using Consensus Maker (www.
hiv.lanl.gov) and JalView.
Figure 3. Predicted secondary structure of a minimal functional RRE (sequence from HXB3 strain)
with the major stem loops labeled. Stem IIB is a well-characterized high-affinity site for Rev necessary
but not sufficient for RRE function. Stem IA is a recently identified secondary binding site for Rev.
Figure 4. Schematic representation of how an export-competent Rev-RRE complex might form. Rev
molecules assemble onto the RRE scaffold to form an oligomeric assembly. In the “jellyfish” model,
the jellyfish head comprises Rev oligomers and RRE; the Rev-NESs form the tentacles that interact
with Crm1 (shown in space-filled model) making the complex export-ready. Images of the Rev-RRE
oligomer and jellyfish model have been reproduced with permission from Daugherty et al.29
www.landesbioscience.com RNA Biology 9
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The RRE is extremely well conserved across subtypes of the major group M, with 
conservation pressure from both the RNA structure and the overlapping Env protein 
reading frame (Fernandes et al. 2012), and chemical and enzymatic probing studies 
confirmed the secondary structure  and in combination with mobility shift assays, 
established its importance in sequence-specific Rev-binding (Kjems et al. 1991). 
Moreover, the accuracy of secondary structure prediction structures can be improved using 
experimental mapping data that provide information about the pairing status of single 
nucleotides using high-throughput sequencing from transcriptomes (Spasic et al. 2018). 
 
1.6.4 Chromosomal maintenance 1 (CRM1) 
 
There are cellular cofactors, such as the Chromosomal Maintenance 1 (CRM1) and 
importin-β that are involved in the formation of the RRE-Rev complex (Figure 1-12 and 
Figure 1-13). CRM1 is a nuclear transport receptor regulated by Ran GTPase that engages 
with the NES of Rev allowing the export of viral mRNA, meanwhile the importin-β 
imports Rev protein to the nucleus (Fukuda et al. 1997; Truant et al. 1999). The formation 
of the multimeric complex (Rev/RRE and CRM1) enables the export of full-length and 
singly spliced viral mRNAs to the cytoplasm (Figure 1-13). 
However, substitutions between nearly indentical orthologs of CRM1 restrict HIV 
replication in different species that may impair key post-transcriptional properties in 
murine cells (Booth et al. 2014; Nagai-Fukataki et al. 2011). The ability of human CRM1 
(hCRM1) to stimulate HIV-1 production requires a species-specific configuration of amino 
acids on the convex surface of CRM1, and recent phylogenetic analysis show that this 
feature could be conferred only in higher primates (Sherer et al. 2011). Moreover, this 
configuration of amino acids within hCRM1 can be transferred into murine CRM1 
(mCRM1), overcoming the deficiences of mCRM1 to generate virus particle production in 
murine cells. However, the mCRM1 fails to engage Rev multimers to form Rev-RNA 
multimeric complexes that are required for nuclear export (Aligeti et al. 2014). The major 
block to HIV-1 mRNA nuclear export in rodent cells is weak interactions between 
mCRM1 and Rev/RRE complexes occurring within the nucleus. Thus, the hCRM1 could 
also be playing additional Rev-independent roles in the HIV-1 replication cycle. 
The HIV export mechanism relies on the host protein CRM1 to export its unspliced and 
partially spliced RNA transcripts. Recent findings have implicated a DEAD-box RNA  
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helicase termed  DDX3 as a member of the export complex that can bind to CRM1 
(Yedavalli et al. 2004). DDX3 promotes nuclear export and translation of the HIV-1 
unspliced mRNA, and knockdown of DDX3 was shown to strongly inhibit HIV-1 
replication. An important issue regarding binding of DDX3 to CRM1 is the uncertainty in 
the sequence of events ocurring throughout the assembly and dissasembly of HIV-1 
mRNA export complex, and DDX3 may associate with the HIV-1 Rev-CRM1 export 
complex at later step of transport (Mahboobi et al. 2015). Thus, DDX3 promotes 
translation of viral mRNAs containing the HIV-1 5’ LTR, especially with the 
transactivation response element (TAR) and also interacts with HIV Tat protein. Moreover, 
the DDX3 is recruited to the TAR hairpin by interaction with viral Tat to facilitate HIV-1 
mRNA translation (Lai et al. 2013). However, recent studies have shown DDX3 as an 
HIV-1 sensor that bound abortive HIV-1 RNA after HIV-1 infection and induced dendritic 
cells maturation and type I interferon responses via the signaling adaptor MAVS and 
DDX3 is crucial in translation initiation of HIV-1 mRNA in dendritic cells (Gringhuis et 
al. 2017). 
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Figure 1-13. RNA processing along HIV-1 life cycle. Rev attaches the
RRE located in the viral RNA and the host factor CRM1 for nuclear
import and export. This complex is essential for full-viral RNA export,
but small RNA transcripts are exported in a Rev independent manner.
Diagram adapted from Nucleic Acids Research, 2013, Vol. 41, No. 20
9471–9483 doi:10.1093/nar/gkt727, Characterization of novel inhibitors
of HIV-1 replication that function via alteration of viral RNA processing
and rev function
total protein synthesis. Rather, at !45 uM, 8-Aza induced
significant alterations in viral RNA splicing as well as a
block in viral RNA export because of a shift in Rev
subcellular distribution.
In the case of splicing, treatment with 8-Aza resulted in
a significant reduction in accumulation of the incom-
pletely spliced (US and SS) viral RNAs with a slight
increase in MS viral RNA levels, consistent with induction
of oversplicing or a reduced stability of the incompletely
spliced viral RNAs. In addition, we detected a shift in the
pattern of splice site usage within th viral MS RNAs with
a dramatic increase in the generation of Nef1 RNA, cor-
responding to the joining of the first 50ss of HIV-1 (SD1)
to the last 30ss (SA7), and a reduction in Nef2 RNA levels.
Analysis of the effect of 8-Aza on host RNA splicing
revealed some perturbations, but only to a limited
number of the splicing events analysed and none to the
same extent as observed for HIV-1. In light of the known
incorporation of 8-Aza into RNA, it may be acting to
alter recognition of splicing regulatory sequences by host
Figure 7. 8-Aza and 5350150 inhibit HIV-1 replication by altering viral RNA processing. This diagram outlines the stages of RNA processing during
the HIV-1 life cycle. This study demonstrates that 8-Aza and 5350150 are potent inhibitors of HIV-1 replication that perturb viral RNA processing, a
stage of the virus life cycle not targeted by current anti-retroviral therapies. 8-Aza and 5350150 inhibit the virus by altering specific pre-mRNA
splicing events under the control/influence of the host. This includes (i) inducing oversplicing of HIV-1 pre-mRNA (depicted by an increasingly
yellow arrow), which reduces both US and SS mRNA levels (with the exception of 5350150 on SS mRNA), and (ii) altering the localization of HIV-1
Rev, resulting in sequestration of incompletely spliced (US and SS) RNAs to the cell nucleus. Both of these mechanisms lead to a reduction in US
and SS viral mRNAs available for translation, perturbing the synthesis of a subset of HIV-1 regulatory and accessory factors as well as structural
proteins/enzymes necessary for new virion assembly and infection. This study confirms that small molecule inhibitors that alter viral RNA processing
can potently inhibit HIV-1 replication, signifying the potential of directing novel therapeutics to this stage for control of this dise se.
Nucleic Acids Research, 2013, Vol. 41, No. 20 9481
Downloaded from https://academic.oup.com/nar/article-abstract/41/20/9471/2414802
by guest
on 07 June 2018
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1.7 Rev-like proteins founded in retroviruses 
A key issue for retroviruses is how they transport unspliced genome-length RNA to the 
cytoplasm within infected cells. The post-transcriptional events of RNA include the 
presence of the regulated assembly of the ribonucleoprotein complex (RNP) involved in 
post-transcriptional, processing, transport and translation events. The expression of viral 
proteins from unspliced, incompletely spliced and fully spliced transcripts result essential 
for retroviruses to develop strategies of control the extent of RNA splicing. However, the 
wide range of retroviruses comprises different mechanisms of RNA export and transport 
that involve viral cis and trans-acting elements. The simple retroviruses present cis-acting 
RNA sequences that recruit cellular trans-acting factors, and also trans-acting viral factors. 
However, complex retroviruses have evolved unique mechanisms to export unspliced 
mRNAs using viral proteins that interact with cellular RNA transport machinery. 
The majority of cellular mRNA export is facilitated by the recruitment of the export factor 
NXF1 (Nxf1-Nxt1/Tap-p15) via TREX-1, recruited in a splicing dependent manner to 
allow the mRNA to traverse the nuclear pore complex (NPC) (Viphakone et al. 2012). 
There are adapter proteins such as CRM1, which is involved in RNA export through the 
NPC to the cytoplasm and SR proteins that recruit Nfx1 to be spliced mRNA in human 
cells (Huang et al. 2004). Some retroviruses like HIV use the CRM1 pathway, forming a 
Rev-RRE-CRM1 complex that permits full length viral RNAs to be exported towards the 
cytoplasm.  
 
1.7.1 Constitutive transport element (CTE) 
The CTEs are highly conserved cis-acting elements encoded in simian Betaretroviruses 
that stimulate nuclear export of spliced mRNAs (Ernst et al. 1997). The major 
representative of this group is the Mason-Pfizer monkey virus (MPMV), which uses the 
CTEs (located between the env gene and the 3’ LTR) to export efficiently its viral mRNA 
within the host cell. The CTEs represent inverted direct repeat sequences that adopt stable 
stem-loop conformations, where the nucleotide sequence is crucial (Rizvi et al. 1996). The 
absence of trans-acting RNA regulatory proteins in MPMV suggests the likely existence of 
different host requirements for the HIV-1 Rev system and the CTE. Moreover, the CTE 
can promote the export of HIV-1 derived RNAs dependent on Rev-RRE (Ernst et al. 1997;  
 
1- Introduction 33 
 
Wodrich et al. 2001). Thus, the CTE binds to the cellular trans-acting factor NXF1/Tap, 
which directs nuclear export of the RNA- protein complex to the cytoplasm. 
1.7.2. DRI and DR2 elements of avian retroviruses 
The presence of cis-acting elements are also present in other retroviruses such as the Rous 
sarcoma virus (RSV), which encodes two repeated regions flanking the src gene: the 
downstream region called DR2 and a second repeat located upstream (DR1). Both repeated 
regions are involved in viral RNA transport and are conserved in other avian retroviruses 
(Czernilofsky et al. 1983). The cis-acting DR elements manage retroviral RNAs to one 
export pathway or another, and the absence of DR elements severely impairs RSV 
replication in avian cells, but some unspliced RNAs are exported and translated in their 
absence (Simpson et al. 1997). Moreover, the lack of DR elements negatively affects the 
levels of packaged virion RNA, impairing cytoplasmic accumulation of unspliced viral 
RNA that is necessary for synthesis of virion proteins and packaging of viral RNA (Ogert 
et al. 1996). Thus, avian leukosis virus (ALV) particles can be formed in mammalian cells 
when the HIV-1 RRE is provided (in cis) and Rev (in trans), allowing the RNA export via 
the CRM1 pathway (Nasioulas et al. 1994).  
1.7.3 Jaagsiekte sheep virus (JSRV) 
The JSRV is a simple betaretrovirus encoding a regulatory protein called Rej, which is 
responsible for the correct synthesis of Gag polyprotein from unspliced RNA and required 
for translation of unspliced viral RNA (Nitta et al. 2009). The Rej protein interacts with a 
Rej-responsive element (RejRE) located at the end of the 3’end of env gene, which is 
involved in viral RNA transport and cytoplasmatic accumulation within infected cells. This 
mechanism of RNA transport reminds the HIV-1 RNA transport pathway via Rev-RRE 
interaction. 
1.7.4 Regulator of export of mouse mammary tumor virus (MMTV) 
 
The mouse mammary tumor virus (MMTV) encodes a functional homolog of the HIV-1 
nuclear export trans-activator Rev that is also involved in nuclear transport of viral RNA. 
Functional homologs have been founded in other betaretrovirus such as the human 
endogenous retrovirus K (HERV-K). The regulatory protein from MMTV was termed 
Rem (Indik et al 2008; Dudley et al. 2005). Moreover, the location of Rem within the  
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MMTV genome correlates to other Rev-like proteins and can also replace the Rev/RRE 
complex. However, Rem requires the presence of MMTV env-U3 junction and the CRM1 
pathway to be functional (Cullen 2003). 
1.7.5 HERV-K 
The HERV-K encodes a nuclear RNA export factor termed K-Rev that is the functional 
equivalent of HIV Rev protein. Thus, the K-Rev protein interacts with a cis-acting element 
called K-RRE that allows the nuclear export of viral RNA, and its sequence is conserved 
across known HERV-K genomes (Yang et al. 2000). Moreover, the HERV family also 
encodes an accessory protein termed Rec (Lower et al. 1995) whose functions are similar 
to those of Rem in mouse mammary tumor virus (MMTV) or Rev in human 
immunodeficiency virus (HIV). 
1.7.6 FIV Rev 
There are sequence similarities between the C-terminal domain of HIV-1 RRE and FIV 
RRE according to the nuclear export signal. In primate lentiviruses this is a conserved 11 
amino acid, leucine rich region that mediates binding to CRM1, but in FIV the region is 
longer, and the leucines are spaced further apart and are interspersed with other 
hydrophobic residues (Dong et al. 2009). However, the mechanism of RNA export in FIV 
is closely related to HIV-1 pathway where the generation of the Rev-RRE-CRM1 complex 
is essential to transport unspliced viral RNAs outside the nucleus.  
1.7.7 HTLV  
The human T-cell leukemia virus (HTLV) encodes a viral protein Rex that allows the 
transport of genome-length unspliced mRNA and partially spliced mRNAs to be exported 
from the host nucleus towards the cytoplasm by an interaction with a cis-acting element 
(RxRE) within the viral genome (Younis et al. 2005). Thus, Rex is regulated by 
phosphorylation to ensure efficient viral gene expression and provide the best conditions 
for virion production. Some RNA species can be exported to the cytoplasm in a Rex 
independent manner, but this fact severely affect viral mRNA trans-activation. 
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1.8 Antiretroviral drugs  
 
The current antiretroviral treatments fail to erradicate HIV infection in patients despite the 
combination of different drugs targeting several proteins of the virus. However, the 
HAARTs increase lifespan from infected patients and also prevent HIV transmission by 
controlling the viral load (reducing the plasma viremia) to preserve the immunologic 
function. Generally the best therapy for HIV infection comprises a combination of several 
classes of drugs such as integrase, protease and reverse transcriptase inhibitors and fusion 
inhibitors to counteract viral infection. Current HIV therapies are designed to target 
different viral proteins to counteract HIV infection in different steps of the replication 
cycle simultaneously. The reverse transcriptiase inhibitors (RTIs) target the viral RT, 
impairing the transformation of the viral RNA genome into dsDNA within infected cells.  
The RTIs comprise two group of analogues of deoxynucleotides that interfere with the 
viral dsDNA synthesis during reverse transcription: nucleoside analog reverse-
transcriptase inhibitors (NARTIs), nucleotide analog reverse-transcriptase inhibitors 
(NtARTs) and non-nucleoside analog reverse-transcriptase inhibitors (NNRTIs). The 
NARTIs and NNRTIs compete with the natural deoxynucleotides to be incorporated in the 
growing viral DNA chain. Thus, the NARTIs lack a 3′-hydroxyl group on the deoxyribose 
moiety and after their incorporation into the nascent DNA strand impede the next incoming 
deoxynucleotide, which cannot form the next 5′–3′ phosphodiester bond needed to 
continue the extension of the DNA chain. The NARTIs also impair cellular DNA synthesis 
acting as chain terminator for viral and cellular DNAs, resulting in the appearance of 
toxicity and side effects. However, the NNRTIs have a different mode of action, blocking 
reverse transcriptase binding directly to the viral enzyme and blocking its capacity to 
perform reverse transcription. 
Moreover, the HIV protease inhibitors represent one of the most important antiretroviral 
groups due to lower level of resistance compared to NNRTI therapy (Riddler et al. 2008). 
The protease inhibitors interact with the HIV protease to impede its function, which is 
essential in viral maturation. However, the HIV protease inhibitors induce side affects at 
long-term such as dyslipidemia or cardiovascular diseases (Bozzette et al. 2003). These 
side effects have been reduced in new protease inhibitors such as RO1, which also has 
about 5 to 10 higher fold efficiency compared to other protease inhibitors. 
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Other drugs employed in HIV therapies are the fusion inhibitors that block the HIV 
envelope from merging with the host CD4 cell membrane, preventing HIV from entering 
the CD4 cells. The fusion inhibitors are used in combination therapy when other treatments 
previously failed. Enfuvirtide is a peptide based on the HIV gp41 sequence that prevents 
the creation of an entry pore for the capsid of the virus by gp41 direct interaction. 
Moreover, Enfuvirtide is the only approved fusion inhibitor for clinical usage, and prevents 
membrane fusion by competitively binding to gp41 and blocking the formation of the post-
fusion structure (Lalezari et al. 2003). There are also CCR5 antagonist such as Maraviroc 
to impede HIV entry. Finally, integrase inhibitors target the viral integrase and are divided 
in two groups: integrase strand transfer inhibitors (INSTIs) and integrase binding inhibitors 
(INBIs). The INSTIs are currently used in clincal therapies, blocking the insertion of viral 
dsDNA into the host cell DNA, meanwhile the INBIs interact directly with the viral DNA-
IN formation binding directly to the complex, but they still experimental. 
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1.9 HIV-1 animal models for research 
 
The development of an effective vaccine against HIV-1 represents a difficult and 
ambitious aim, with limited reported success despite 20 years of intensive research (Finzi 
et al. 1999; Whitney et al. 2004; Burton et al. 2017). Currently, there is not an appropriate 
animal model to study HIV- 1 in vivo, although humanized mice are able to allow HIV-1 
replication and other macaque models exist (Borkow 2005). Simulating the conditions of 
HIV infection in animal models is a hard process because current animal models are 
unable to reproduce HIV-1 infection in vivo.  
1.9.1 Humanized mice 
 
Humanized mouse models have been used for HIV-1 research, but they require surgical 
procedures to implant human cells to make them susceptible to HIV infection. Thus, they 
cannot be bred, and murine cells are unable to sustain viral replication under normal 
conditions (Feinberg et al. 2002). Moreover, the RNA instability of HIV- 1 severely 
affects the synthesis of Gag precursors in murine cells, and Tat is inactive because Tat 
requires the presence of human factors not present in mice to transactivate the LTR. 
Alternatively, there may be additional, as yet unidentified, factors that restrict HIV-1 
replication in murine cells. Transgenic mice are susceptible to infection, but HIV- 1 
cannot replicate in murine CD4 T cells and the viral loads are almost undetectable in these 
animals (Hatzijioannou et al. 2012). The knockout mice lacking HIV-1 restriction factors 
have revealed new insights about mechanisms to counteract the infection and the discovery 
of novel restriction factors such as tetherin (Neil et al. 2008; Liberatore et al. 2011). 
However, the current humanized mice models still have many limitations to approach, 
such as the limitation to determine the potential of drugs that could prevent vaginal HIV-1 
transmission, or the persistence of murine innate immunity (Vaselinovic et al. 2014). 
No humanized mice models have demonstrated humanization of the gut mucosa, and rectal 
transmission effects of HIV-1 infection on human cells in the GALT can not be evaluated 
using humanized bone marrow liver thymus (BLT) mice models (Denton et al. 2009). 
Despite HIV research in humanized mice has entered new insights and manners of 
investigation they present limitations such as the lack of a full repertoire of human  
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Figure 1-14. Human immune system mouse models. These
animal models are currently used in cancer research, but they
are also useful to investigate how the immune system reacts
against viral infections in vivo. Taken from Theodora
Hatzijioannou and David T. Evans (2012). Animal models for
HIV/AIDS research. Nature Reviews Microbiology. 2012 Dec;
10(12): 852-867.doi: 10.1038/nrmicro2911
 
immune cells and a functioning immune system. Thus, humanized mice need surgical 
procedures to implant human cells, but the innate immunity from mice persist and 
humanized mice are unable to generate humoral immune responses that lead to class 
switching from immunoglobulin M (IgM) to immunoglobulin G (IgG) antibody production 
after infection (Akkina 2013). In addition,  engrafted humanized mice poorly develop 
lymph nodes and germinal centers (Yu et al. 2017; Brehm et al. 2013).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-14. Human immune system mouse models. These animal models are currently used 
in cancer research, but they are also useful to investigate h w the immune system reacts 
against viral infections in vivo. The conjoint hum  thymus–liver organ formed following 
injection of human fetal liver and thymus cells in o the ouse renal capsule. The engraftment 
is achieved by injec ing human hematopoietic (CD34+) stem cells derived from cord blood, 
fetal liver or adult blood. These mice produce human i mune cells that disseminate to 
numerous sites, among which are the peripheral bl od, liver, lung, vagina and rectum. 
Diagram Taken from Theodora Hatzijioannou and David T. Evans (2012). Animal models for 
HIV/AIDS research. Nature Reviews Microbiology. 2012 Dec; 10(12): 852-867.doi: 
10.1038/nrmicro2911 
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1.9.2 Macaques and SHIVs 
 
There are other alternatives to humanized mice such as macaques, which currently 
represent the ‘best’ models to investigate HIV-1 in vivo. The stHIV strains (substitution of 
SIV genes with those from HIV-1) are currently used in macaques, reflecting more 
accurately the features of the virus responsible for the AIDS. Rhesus macaques are 
normally non-permissive due to TRIM5 (Stremlau et al. 2004). TRIM5α is a post-entry 
restriction factor that is constitutively expressed in primate cells, and upregulated by type I 
interferon (IFN) (Nisole et al. 2008). Thus, old world monkey cells express a fusion 
protein TRIM5 generated by transposition of a cyclophilin A mRNA within a TRIM5 
locus named TRIMCyp, which specifically interferes with HIV-1 uncoating process. 
However, current investigations have not determined the induction of TRIMCyp by IFN. 
Therefore, pig-tailed macaques are commonly used in HIV-1 research, but require CD8 
depletion to progress to simian AIDS (Joag et al. 1996).  
However, rhesus and pig-tailed macaques infected with simian immunodeficiency virus 
(SIV) or SIV/HIV chimeras encoding (SHIVs) are the most representative animal models 
(Hatzijioannou et al. 2009). There are several types of SHIVs, classified by the HIV-1 gene 
substitution: SHIVs expressing HIV-1 pol, SHIVs expressing HIV-1 env and simian tropic 
HIV-1 (stSHIVs, HIV-1 engineered to replicate in macaques). The stSHIV represent a 
useful tool to overcome intrinsic barriers for viral replication, but more intensive research 
is essential to approach the entire potential of stHIV-1 strains to transform non-human 
primates for HIV-1 vaccine development. The SHIV models have been useful to determine 
pathogenesis and transmission of HIV-1, and also to test vaccines in infected animals. 
However, there are limitations to SHIV infection in macaques, such as the low genetic 
diversity that HIV-1 subtype B envelope displays in these animals and the presence of the 
HIV-1 regulatory genes tat and rev (Ndungu et al. 2001), which are encompassed by the 
env gene. Moreover, the SHIVs lack the HIV-1 gene vpu, having vpx instead, which 
counteracts the restriction factor SAMHD1 present in macrophages and dendritic cells 
(Hrecka et al. 2011) altering the cell tropism relative to HIV-1. SAMHD1 is a 
deoxynucleoside triphosphohydrolase expressed in myeloid cells that hydrolyzes the 
cellular deoxynucleotide triphosphates to a level below that which is required for reverse 
transcription. The Vpx protein recruits SAMHD1 to a cullin4A-RING E3 ubiquitin ligase 
(CRL4), which targets the enzyme for proteasomal degradation (Hofmann et al. 2012).  
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The huge genetic variability of HIV-1 has hampered approaches to develop a vaccine, 
despite the advances made in primate models (Kimata 2014). A major problem remains the 
absence of a cheap and simple animal model capable of determining whether a vaccine 
could be curative against HIV-1 infection in humans. Although therapeutic control of HIV 
replication allows the immune system to partially restore and delays disease progression, 
the cure of HIV infection remains still unachievable. However, there is an HIV-infected 
patient with acute myeloid leukemia that received two stem cell transplants in 2007 and 
2008 from a donor naturally immune to HIV, and has remained off antiretroviral therapy 
since the transplant. This patient is considered cured of HIV-1 infection, but still raising 
controversial opinions whether there is no trace of the virus in his body or whether he 
simply no longer needs treatment (Allers et al. 2018). The HIV-infected patients 
homozygous for CCR5 gene variant (CCR5Δ32/Δ32) are naturally resistant to CCR5-
tropic strains, but the cured patient presented CXCR4-tropic variants before the transplant, 
so it is reasonable to hypothesize that HIV from the viral reservoir may reseed the body 
once the immune system has efficiently been restored with X4 HIV-susceptible target cells 
(Hütter et al. 2009).  
However, the success of HIV-1 curative therapies requires the usage of animal models, but 
their current limitations severely impede the potential of vaccine development to cure HIV 
infection. Perhaps we could transfer the discoveries from the ‘cured’ patient into animal 
models to investigate and reveal new insights about a cure that we could export to humans. 
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Figure 1-15. A) Schematic representation of HIV-1, SIV and SHIVs viral genomes. The HIV-1
genes are coloured in red, and the SIV genes in blue. B) Macaque species currently used in AIDS
research and their geographical location. The geographical range of the rhesus macaque (Macaca
mulatta) exceeds that of all other primate species except humans, extending from western India and
Pakistan across China. Distinct populations of rhesus macaques can be differentiated on the basis of
mitochondrial DNA sequences or SNP. Figures taken from Hatziioannou, T., & Evans, D. T.
(2012). Animal models for HIV/AIDS research. Nature Reviews Microbiology, 10(12), 852–867.
https://doi.org/10.1038/nrmicro2911
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1.10 Lentiviral vectors and self inactivating vectors (SIN) 
 
A self-inactivating (SIN) vector is a retroviral derived vector containing a non-functional 
or modified 3' Long Terminal Repeat (LTR) sequence. This sequence is copied to the 5' 
end of the vector genome during reverse transcription, resulting in a transcriptional 
inactivation of the provirus after the first cycle of replication (Yu et al. 1986). The SIN 
vectors were generated to develop gene transfer experiments in order to investigate the 
regulation of gene expression, also providing a safe alternative to be employed for gene 
therapy. The recombination events required for these vectors to develop a replication 
competent genome during the first cycle of replication (Gage et al. 1998) are unlikely, and 
SIN lentiviral vectors can transduce non-dividing cells, integrating into the host 
chromosome. 
 
There were other lentiviral vectors used before SIN vectors were created: first and second 
generation lentiviral vectors. This classification is based on the safety features that each 
type of vector possesses, where the essential genes required for virus production are split 
across several plasmids (3 for 2nd generation and 4 for 3rd generation vectors). Each 
lentiviral vector encodes the following components: a lentiviral transfer plasmid (the 
vector or vector-genome) encoding the insert of interest, a packaging plasmid and an 
envelope. The generation of lentiviral vectors could be potentially used to approach novel 
human gene therapies and vaccines. Moreover, the use of lentiviral and retroviral vectors 
for human gene therapy has been supported by preclinical and clinical trials (Bif et al. 
2013). However, lentiviral vector safety is still uncertain and they could upregulate the 
expression of genes flanking the integration site, especially when carrying strong 
enhancer/promoter sequences in internal positions (Ramezani et al. 2008) or cause 
insertional mutagenesis. Three generations of HIV-based lentiviral vector packaging 
systems have been developed for production of lentivectors by transient transfections, 
where the structural and enzymatic components of the virion come from HIV-1. However, 
the envelope glycoprotein is derived from vesicular stomatitis virus (VSV) due to the high 
stability and pantropic features of its G protein. 
 
The 1st generation of lentiviral vectors encompasses all HIV-1 genes except env gene, and 
the 2nd generation of lentiviral vectors lack HIV-1 accessory genes from the packaging 
plasmid (nef, vpr, vpu and vif), increasing the safety threshold compared to the first  
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generation of lentiviral vectors. The regulatory genes tat and rev are also encoded, 
fulfilling transcriptional and post-transcriptional functions. 
 
The third generation of lentiviral vectors provide an improved biosafety compared to 
second and first lentiviral vectors, only encoding HIV-1 gag, pol and rev genes, and the 
5’LTR HIV promoter has been substituted by a chimeric promoter to ensure transcription 
in the absence of Tat. However, it is easier to work with one packaging plasmid such as the 
pCVR1_NLGP, which encodes the HIV-1 gag, pol, tat, and rev genes. Thus, there are self 
inactivated vectors (SIN) that present a deletion in the enhancer region of the 3’U3 of the 
LTR, generating an aberrant LTR at the 5’ U3 end after reverse transcription during the 
first cycle of replication. This feature reduces the likelihood of SIN vectors recombining 
(compared to first and second generation of lentiviral vectors) and also makes them much 
safer. Crucially, the resultant provirus after RT is transcriptionally inactive and unable to 
be converted into a full length RNA. In addition, the 3rd generation of lentiviral vectors 
reduces the risk of tumorigenesis via promoter insertion (Cesana et al. 2014) and reduces 
the probability of regenerating a replication competent lentivirus (RCL). Thus, this system 
efficiently generates stable packaging cell lines with selected characteristics. 
 
In summary, animal models are a powerful tool to investigate and develop novel 
approaches to eradicate the virus from infected patients despite their limitations. The aim 
of this project was to develop an HIV-1 replication competent clone able to replicate in 
murine cells to overcome the limitations in current animal models preserving the ‘identity’ 
of HIV. The development of an HIV-1 clone able to replicate in mice is a challenging 
proposal. The lack of human co-factors in mice impedes function of the HIV-1 accessory 
proteins Tat and Rev, hampering HIV-1 replication. However, Tat and Rev function can be 
replaced by constitutive/chimeric promoters, codon-optimized proteins and the constitutive 
transport element (CTE), without disrupting the amino acid sequence of the virus. We 
propose the generation of an HIV-1 clone able to replicate in mice to assist in antiviral 
drug development by minimally manipulating the genomic 'identity' of the virus. 
Moreover, changing the current perspective of adapting the host to the virus (current 
animal models) instead adapting the virus to the host (our aim) could solve most of the 
issues related to mice and macaques models, contributing to the generation of an HIV-1 
clone that could be used to develop curative vaccines and therapies in animal models. 
 
. 
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2. Materials  
 
2.1 Cell culture 
 
2.1.1. Bacterial strains 
 
The bacterial strain employed in this project for maintenance and growth of plasmid stocks 
was Escherichia coli DH10B. Competent DH10B bacteria were generated in the lab using 
a protocol described in section 2.4.6.1. 
2.1.2 Antibiotics 
 
All antibiotics employed in this thesis were provided by Melford Laboratories. Ampicillin 
(200mg/ml stock concentration) and Kanamycin (100mg/ml stock concentration) were 
used for bacterial selection. Puromycin and Neomycin (G418) were used to select 
transduced cell lines. Gentamicin (20µg/ml final concentration) was added into all cell 
culture media to prevent contamination in the cell lines employed in this project. 
2.1.3 Eukaryotic cell lines 
HEK-293T: cell line originally derived from human embryonic kidney cells. They are 
highly transfectable and useful to generate a variety of viral particles. This “packaging cell 
line” is cultured in DMEM (Dulbecco’s modified Eagle’s medium) with 10% fetal calf 
serum (FCS) and gentamicin [20µg/ml final concentration]. Reference: ATCC cell data 
sheet HEK-293T. 
TZM-bl: Hela cells expressing HIV-1 receptor (CD4) and co-receptors (CCR5/CXCR4). 
These cells are highly permissive to infection by HIV, SIV and SHIV, and contain an 
integrated reporter gene for firefly luciferase and E. coli β-galactosidase under control of 
an HIV-1 LTR, which enables simple and quantitative analysis of Tat expression using 
either β-gal or luciferase as a reporter. They are maximally sensitive to HIV infection by 
including DEAE-dextran (10 and 100 µg/ml final concentration) in the infection medium 
(adapted from NIH AIDS Reagents data sheet). TZM-bl are cultured in DMEM with 10% 
fetal calf serum (FCS) and gentamicin [20µg /ml final concentration]. Reference: 
Montefiori - Protocol for Measuring Neutralizing Antibodies Against HIV-1, SIV and SHIV 
Using a Luciferase Reporter Gene Assay in TZM-BL Cells (2006). 
NIH-3T3: cell line established from primary mouse embryonic fibroblast cells which are 
sensitive to murine leukaemia virus. NIH-3T3s a suitable transfection host and highly  
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sensitive to sarcoma virus focus formation and leukaemia virus propagation and has 
proven to be very useful in DNA transfection studies. Cultured in DMEM with 10% fetal 
calf serum (FCS) and gentamicin [20 µg/ml final concentration]. Reference: ATCC cell 
data sheet NIH-3T3. 
 
p/m40 AK: murine cells derived from a thymic lymphoma that grew out of a p53 null 
mouse.  AK are the initials of Anna Kilbey PhD, who made the cell line. They are cultured 
in RPMI (Roswell Park Memorial Institute medium) with 50µM of β-mercaptoethanol 
(final concentration), 10% fetal calf serum (FCS) and gentamicin [20µg/ml final 
concentration]. Reference: Blyth et al., 1995 Oncogene 10: 1717-1723. 
 
PM1: clonal derivative of HUT 78. These cells express HIV-1 CD4 receptor, CXCR4 co-
receptor and also CCR5 receptor at lower levels. PM1 are permissive for growth of 
macrophage and T-cell trophic viruses. Cultured in RPMI with 10% fetal calf serum (FCS) 
and gentamicin [20µg /ml final concentration]. Taken from NIH AIDS Reagents data 
sheet. 
AA-2: AK-dCK subclone of AA cells derived from the WIL-2 human splenic EBV +B 
lymphobastoid cell line. AA-2 are an isolated from the spleen of a Caucasian male with 
hereditary spherocytic anemia, expressing high levels of HIV CD4 receptor. This cell line 
is remarkably permissive for HIV-1 infection, extremely sensitive to virus cytopathic 
effects and highly permissive for HIV infection. Cultured in RPMI with 10% fetal calf 
serum (FCS) and gentamicin [20µg /ml final concentration]. Reference: NIH AIDS 
Reagents data sheet. 
RAW 264.7: murine macrophages. This line was established from a tumour induced by 
Abelson murine leukaemia virus. High efficiency for DNA transfection, sensitivity to RNA 
interference, and supports replication of murine noroviruses. When this line was 
established, it was described as not secreting detectable virus particles and negative using 
the XC plaque formation assay. Based on a published study by Dr. Janet W. Hartley in 
2008, this line was demonstrated to express ecotropic and polytropic MuLV, and is 
positive using the XC plaque assay for virus replication. The base medium for this cell line 
is DMEM plus fetal calf serum (10%) and gentamicin [20µg /ml final concentration]. 
Reference: ATCC cell data sheet RAW 264.7. 
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2.2 Molecular biology 
 
2.2.1 Oligonucleotides 
 
The synthetic oligonucleotides were provided by Integrated DNA Technologies at 25nM 
scale with standard desalt purification. Oligonucleotides were designed using DNA 
Dynamo Sequence Analysis Software. Sequences are shown in Table 2.1. 
 
2.2.2 Enzymes 
 
Standard PCRs were carried out using Pfu Turbo DNA Polymerase® (Agilent 
Technologies, 600250), and Brilliant III Ultra Fast QPCR Master Mix® (Agilent 600880) 
was used for qPCR assays. Reverse transcription assays were developed using Superscript 
III® ( Invitrogen 18080044) and also the RNase Out Ribonuclease Inhibitor (Invitrogen 
10777.019).  
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 Table 2.1. Oligonucleotides 
NAME SEQUENCE
WV-001-3LTR-NHG-XhoI-F CTCTCTCTCGAGTGGAAGGGCTAATTCACTCCCAACG
WV-002-3LTR-U5-NotI-RC AGAGAGGCGGCCGCTGCTAGAGATTTTCCACACTGACTAAAAGGG
WV-003-3LTR-PGK-XhoI-F CTCTCTCTCGAGAATTCTAGGGTAGGGGAGGCGCTTTTCCCAAGGC
WV-004-3LTR-CMV-XhoI-F CTCTCTCTCGAGGTTGACATTGATTATTGACTAGTTATTAATAG
WV-005-3LTR-CMV-R-NotI-RC AGAGAGGCGGCCGCTGAAGCACTCAAGGCAAGCTTTATTGAGGC
WV-006-deltat-1 AAGCAAAGATCATCAGGGATTATGG
WV-007-deltat-2 TTTGTTATGAAACAAACTTAAGCTTAGGCTCACTTACTGGATGCTACCAGGGCTCTAGT
WV-007-deltat2 TTTGTTATGAAACAAACTTAAGCTTAGGCTCACTTACTGGATGCTACCAGGGCTCTAGT
WV-008-deltat-3 ATCCAGTAAGTGAGCCTAAGCTTAAGTTTGTTTCATAACAAAAGCCTTAGGCATCTCCT
WV-009-deltat-4 ACACATGGCTTTAGGCTTTGATCCC
WV-010-tat-F CTCTCTGGCCGAGAGGGCCATGGAGCCAGTAGATCCTAGACTAG
WV-011-Tat RC TCTCGGCCAGAGAGGCCCTATTCCTTCGGGCCTGTCGGGTCCCCTCGGGATTGGGAGGTGGGTT
GCTTTGATAGAGAAACTTGATGAG
WV-012-deltat 2-II TTCCAGGGCTTTATCTAGGATCTACTGGCTCCGTTTCTTGCTCTCCTCTGTCGAGTAAC
WV-013-deltat 3-II GCAAGAAACGGAGCCAGTAGATCCTAGATAAAGCCCTGGAAGCATCCAGGAAGTCAGCC
WV-014-seq LTR F GACCGCCGCCGGGATCACTCTCGGC
WV-015-3LTR-F GCGCGATCACATGGTCCTGCTGGAGTTCG
WV-015-seq LTR F2 GCGCGATCACATGGTCCTGCTGGAGTTCG
WV-016-SYNGP_seq-RC GCCACGGTGTTGTACAGGCTGCGCAGCTCCTCGC
WV-017-SYNGP_seq-F GCGGATCGTGGACATCATCGCGACCGACATCCAGAC
WV-018-CLTR-Eco-RC AGAGAGGAATTCTGCTAGAGATTTTCCACACTGACTAAAAG
WV-019-CMV-NotI-F CTCTCTGCGGCCGCGTTGACATTGATTATTGACTAGTTATTAATAG
WV-020-CLTR-HpaI-RC AGAGAGGTTAACCTGCTAGAGATTTTCCACACTGACTAAAAG
WV-021-5CLTR seq GGCCTTTTGCTCACATGGCTCGACAG
WV-022-3CLTR seq RC CGCCAGCCCGGATCGATCCTTATCGG
WV-023-IRES_GFP-F CTCTGCGGCCGCCTCGAGCCGCCCCTCTCCCTCCCCCCCCCCTAAC
WV-024-IRES_GFP-RC CTCTCTCGCGGCCGCGAATTCCTGATTATGATCTAGAGTCGCGG
WV-025-gag.1-NdeI-F GGCAGTACATCAAGTGTATCATATGCCAAGTACG
WV-026-gag 2"-RC GCCGCCCGACAGTACCGACGCTCTCGCACCCATCTCTCTCCTTCTAGCCTCCGCTAGTC
WV-027-gag 3"-F TAGAAGGAGAGAGATGGGTGCGAGAGCGTCGGTACTGTCGGGCGGCGAGCTGGACCGCT
WV-028-gag 4-MluI-RC TTTCCTAGGGGCCCTGCAGTTGCGG
WV-029-env seq 5' F GGCGTAATCTGCTGCTTGCAAACAAAAAAACC
WV-030-env seq 5' RC CTCAAGGATCTTACCGCTGTTGAGATCCAG
WV-031-signal weave sq-F CGCGTTACATAACTTACGGTAAATGGCCCGC
WV-032-signal weave sq-RC GAGGGGTCGCTGCCAAAGAGTGATCTGAG
WV-033-signal weave sq-F'' GCAGTGGCGCCCGAACAGGGACTTGAAAGC
WV-034-signal weave sq-RC'' CGTTTTGTAGAACCGGTCCACGTAGTCGCG
WV-035-psi seq GCCTTCCCTTGTGGGAAGGCCAGATCTTCC
WV-036-psi seq RC GTCGAGAGAGCTCCTCTGGTTTCCC
WV-038 CTCTAGCAGAATTCGCCACCATGGGCGCCGTTAAC
WV-039-IRES-GFP.NotI F GCGGCCGCCTTCGAATTCTGCAGTCGACGGTACCGCG
WV-040-3CLTR XhoI.NotI RC CTCTCTCTGCGGCCGCCTCGAGTTTACTTGTACAGCTCGTCCATGCCGAGAG
WV-041-IRES-EGFP NotI F CTCTCTGCGGCCGCGCCCGGGATCCGCCCCTCTCCCTC
WV-042-IRES-EGFP XhoI NotI RC CTCTCTGCGGCCGCCTCGAGTTACTTGTACAGCTCGTCCATGCCGAG
WV-043-3CLTR XhoI F CTCTCTCTCGAGTCAATATTGGCCATTAGCCATATTATTC
WV-044-IRES-EGP seq F CAGAATTTCCGGGTCTACTACAGGGACAGCAG
WV-045-3CLTR RC seq GGCGATCGGTGCGGGCCTCTTCGCTATTAC
WV-046-co env seq 1 CTGAGTGGGTGGAGACTGAAGTTAGGCCAGC
WV-047-co env seq 2 CATCACCACCAGCATCAGGGATGAGGTGCAG
WV-048-co env seq 3 CATCAACATGTGGCAGGAGGTGGGCAAGGC
WV-049-co env seq 4 CACGTCCACCTCCATCTCTTCCTCAGCACC
WV-050-MLV/HIV LTR 1 XhoI CTCTCTCTCGAGTGGAAGGGCTAATTTGGTCCCAAAAAAGACAAG
WV-051-MLV/HIV LTR 2 CCTGACCTTGATCTGAACTTCTCTTCTTTGTAGTACTCCGGATGCAGCTC
WV-052-MLV/HIV LTR 3 AGAGAAGTTCAGATCAAGGTCAGGAACAGATGGAACAGCTGAATATGGGCC
WV-053-MLV/HIV LTR 4 CACTCCCCAGTCCCGCCCAGGCCACAAGCAGAAGCGCGCGAACAGAAGCGAG
WV-054-MLV/HIV LTR 5 TGTGGCCTGGGCGGGACTGGGGAGTGGCGAGCCCTCAGATGCTACATATAAGC
WV-055-MLV/HIV LTR 6 XbaI GAGAGAGTCTAGAGTCCCTGTTCGGGCGCCAC
WV-056-restriction sites psi-IG-3CLTR-F TCGAGTTAATTAACCTGCAGGGGCGCGCCGCGATCGCT
WV-057-restriction sites psi-IG-3CLTR-RC TCGAAGCGATCGCGGCGCGCCCCTGCAGGTTAATTAAC
WV-058-CTE-F CTCTCTGTCGACTTAATTAAGGATCCACCTCCCCTGTGAGCTAGACTGGAC
WV-059 CTE-RC AGAGAGGTCGACCCTGCAGGGCTAGCAGATCTACACATCCCTCGGAGGCTGCGCCTG
WV-059 CTE-RC AGAGAGGTCGACCCTGCAGGGCTAGCAGATCTACACATCCCTCGGAGGCTGCGCCTG
WV-060-MLV/HIV LTR 6 NotI AGAGAGGCGGCCGCGTCCCTGTTCGGGCGCCAC
WV-061 seq SYNGP 01 CTGTCGGGTTTCGCCACCTCTGACTTGAG
WV-062 seq SYNGP 02 CGAGTCCTGCGTCGAGAGAGCTCCTCT
WV-063 seq SYNGP 03 GTCAGTGTGGAAAATCTCTAGCAGTG
WV-064 seq SYNGP 04 GGATCGTGTGCATCCGGTGCACGCAG
WV-065 seq SYNGP 05 GGCTGTTGGAAATGTGGAAAGGAAGG
WV-066 seq SYNGP 06 GATTGGGCCTGAGAACCCGTACAACAC
WV-067 seq SYNGP 07 GTTGAACTGGGCCAGTCAGATTTACCCAG
WV-068 seq SYNGP 08 CACCACCAACCAGAAGACTGAGCTGCAGG
WV-069 seq SYNGP 09 CAAGGTTATCCTGGTAGCCGTCCATG
WV-070 seq SYNGP 010 GCTCTCCTCAAGCGTATTCAACAAGGG
WV-071 seq SYNGP 011 CAGCCACAACGTCTATATCATGGCCGAC
WV-072 seq SYNGP 013 GCAATTGTTGTTGTTAACCTGCTAGAG
WV-073 seq SYNGP 014 GACCGAGATAGGGTTGAGTGTTGTTC
WV-074 seq SYNGP 015 CTGGAATAGCTCAGAGGCCGAGGCG
WV-075 seq SYNGP 016 CTCTTCGTCCAGATCATCCTGATCGAC
2 - Materials and methods 49 
 
 
WV-075 seq SYNGP 016 CTCTTCGTCCAGATCATCCTGATCGAC
WV-076 seq SYNGP 017 GAGACGGTCACAGCTTGTCTGTAAGC
WV-077 seq SYNGP 018 CTGTGACTGGTGAGTACTCAACCAAGTC
WV-078 seq SYNGP 019 CAGTGAGGCACCTATCTCAGCGATCTGTC
WV-079 seq SYNGP 020 CTCATAGCTCACGCTGTAGGTATCTCAG
WV-080 seq SYNGP 021 CGATAGTTACCGGATAAGGCGCAGCG
WV-081 seq SYNGP 022 CTE-POLY TCAATAATCAATGTCAACAGCGATC
WV-082-CSGW delta NheI 01 CTCTCTGAATTCCTGCAGCCCCGATAAAATAAAAG
WV-083-CGSW delta NheI 02 AAGACCCCACCTGTAGGTTATGGCAAGCTGGCTGCAGTAACGCCATTATTGCAAGGCAT
WV-084-CSGW delta NheI 03 ATGCCTTGCAATAATGGCGTTACTGCAGCCAGCTTGCCATAACCTACAGGTGGGGTCTT
WV-085 CSGW delta NheI 04 AGAGAGGGATCCCCCCCGGGCGACTCAGTCTGTCG
WV-086 CSGW HpaI CTCCCCCTGAACCTGAAACATAAAATGAATGC
WV-087 CSGW SpeI RC TCTTTGGGAGTGAATTAGCCCTTCCAACTAGTAAGTTTGTAGTACATATTTAACAAATA
WV-088 CSGW SpeI F TATTTGTTAAATATGTACTACAAACTTACTAGTTGGAAGGGCTAATTCACTCCCAAAGA
WV-089 CSGW NruI RC AGAGAGTCGCGATCTAATTCTCCCCCGCTTAATAC
WV-090 CSGW psi BclI F GGCGACTGGTGAGTACGCCTGATCAAAAATTTTGACTAGCGGAGGCTAGAAGGAGAGAG
WV-091 CSGW psi BclI RC CCGCTAGTCAAAATTTTTGATCAGGCGTACTCACCAGTCGCCGCCCCTCGCCTCTTGCC
WV-092-MLV repeated seq F GAAGAGAAGTTCAGATCAAGGTCAG
WV-093-MLV repeated seq RC GGACCGCATCTGGGGACCATCTGTTC
WV-094 KpnI LTR/MLTR F CTCTCTGGTACCTGGAAGGGCTAATTTGGTCCC
WV-095 NheI LTR/CLTR RC AGAGAGGCTAGCTGCTAGAGATTTTCCACACTGAC
WV-096 NheI MLTR RC AGAGAGGCTAGCGTCCCTGTTCGGGCGCCACTG
WV-097 KpnI CLTR F CTCTCTGGTACCTTGACATTGATTATTGAC
WV-098 5' SpeI MLTR F CTCTCTACTAGTTGGAAGGGCTAATTTGGTCC
WV-099 5' NruI MLTR RC AGAGAGTCGCGAGTCCCTGTTCGGGCGCCAC
WV-100 5' SpeI CLTR F CTCTCTACTAGTGTTGACATTGATTATTGACTAG
WV-101 5' NruI CLTR RC AGAGAGTCGCGATGCTAGAGATTTTCCACACTGAC
WV-102 5 LTR seq CGTCCAGGTCTGAAGATCAGCGGCCG
WV-103-CSGWseq TGGAGGCTGCATCCATGACACAGGC
WV-104 CSGWdelNheI ApaI F GGTGATTGGCTACCGTGGCGGCAACTG
WV-105 5 CLTR psi NruI RC AGAGAGTCGCGATACCGACGCTCTCGCACCCATCTC
WV-106 5 CLTR SpeI F CTCTCTACTAGTGTTGGCATTGATTATTGACTAG
WV-107 5MLTR SpeI F CTCTCTACTAGTTGGAAGGGCTAATTTGGTCCC
WV-108 GAGGAGACCAAAGGGAAAGCGAAAGTTGTCCCTGTTCGGGCGCCACTGCTAGAG
WV-109 TTGAAAGCGAAAGGGAAACCAGAGGAGCTCTCTCGACGCAGGACTCGGCTTGC
WV-110 3LTR seq RC GCCATCTCCTTGCATGCACCATTCCTTG
WV-111 3MLTR seq F GACGTCCTTCTGCTACGTCCCTTCGG
WV-112 Rev exon 1 SfiI F CTCTGGCCACTAGGGCCATGGCAGGAAGAAGCGGAGACAGCGACGAAGAGCTCATCAGAACAG
TCAGACTCATCAAGCTTCTCTATCAAAGCAACCCACCTCCCAATCCCGAGGGGACCCG
WV-113 Rev exon 2 SfiI RC AGAGGGCCCGGCGGGCCCTATTCTTTAGTTCCTGACTCCAATAC
WV-114 Rev exon 1 SfiI F CTCTGGCCGAGAGGGCCATGGCAGGAAGAAGCGGAGACAGCGACGAAGAGCTCATCAGAACAG
WV-115 Rev exon 2 SfiI RC AGAGGGCCTCTCTGGCCCTATTCTTTAGTTCCTGACTCCAATAC
WV-116 4CTE F PstI CTGTACAAGTAACTCGACTTAATTAACTGCAGACCTCCCCTG
WV-117 4CTE RC SbfI AATTAACTCGACCCTGGCAGGGCTACCTGCAGGACACATCCCT
WV-118 RRE flexi F PstI CTCTCTCTGCAGCAGGAGCTTTGTTCCTTGGGTTC
WV-119 RRE flexi RC SbfI AGAGAGCCTGCAGGAGGAGCTGTTGATCCTTTAG
WV-120 CTE F CTCTCTCTGCAGGTAACTCGACTTAATTAAGGATCCACC
WV-121 CTE MluI RC CTCTCTCTGCAGACGCGTTTAATTAACTCGACCCTGGCAGGGCTAGCAGATC
WV-122 MLV-R-U5 SpeI-KpnI F CTCTACTAGTGGTACCGAATGAAAGACCCCACCTGTAGGTTTG
WV-123 MLV-R-U5 2 CTCAGATCTGGTCTAACCAGAGAGACCCAATGAAAGACCCCCGCTGACGGGTAGTC
WV-124 MLV-R-U5 3 GGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGG
WV-125 MLV-R-U5 NruI-NheI RC AGAGAGTCGCGAGCTAGCTGCTAGAGATTTTCCACACTGACTAAAAG
WV-126 MLV-R-U5 XhoI F CTCTCTCGAGGAATGAAAGACCCCACCTGTAGGTTTG
WV-127 MLV-R-U5 NotI RC AGAGGCGGCCGCTGCTAGAGATTTTCCACACTGACTAAAAG
WV-128 SFFV EcoRI F CTCTCTGAATTCCCGATAAAATAAAAGATTTTATTTAG
WV-129 SFFV NdeI-MfeI RC AGAGAGCAATTGCATATGCCCGGGCGACTCAGTCTGTCGG
WV-130 lack U3 KpnI RC AGAGAGGGTACCAGTACAAGCAAAAAGCAGATC
WV-131 lack U3 KpnI F CTCTCGGTACCTTTAAGACCAATGACTTACAAGGC
WV-132 U3 lack NheI F CTCTCTGCTAGCGCATCTAGAATTAATTCCGTG
WV-133 U3 lack NheI RC AGAGAGGCTAGCGATGACCCTGCTGATTGGTTCGC
WV-134 NHG-3MLTR F CATGGTCCTGCTGGAGTTCGTGACCGC
WV-135 NHG-3MLTR RC GTCCCTGTTCGGGCGCCACTGCTAGAG
WV-136 NHG-5MLTR RC CATCTCTCTCCTTCTAGCCTCCGCTAGTC
WV-137 NHG-5MLTR F TGGAAGGGCTAATTTGGTCCCAAAAAAGACAAG
WV-138 tat exon 1 F CTTACGGGGATACTTGGGCAGGAGTG
WV-139 tat exon 1 RC CTTTCTGCACCTTACCTCTTATGCTTG
WV-140 tat exon 2 F GATGTTCATCAAATATTACAGGGCTGC
WV-141 tat exon 2 RC GAGTAAGTCTCTCAAGCGGTGGTAGC
WV-142 CCR5 F SfiI CTCTCTGGCCATTAAGGCCATGGATTATCAAGTGTCAAGTCCAATC
WV-143 CCR5 RC SfiI AGAGAGGGCCGAGGCGGCCTCACAAGCCCACAGATATTTCCTGC
WV-144 gag SpeI F CTCTCTACTAGTATGGGCGCCCGCGCCAGCGTGCTG
WV-145 NdeI pol RC AGAGAGCATATGCTAATCCTCATCCTGTCTGCTCGCC
WV-146 NdeI F GAGAGATGGGTGCGAGAGCGTCAGTACATATGGGGGGAGAATTAGATCGCGATG
WV-147 NdeI RC CATCGCGATCTAATTCTCCCCCCATATGTACTGACGCTCTCGCACCCATCTCTC
WV-148 gag NdeI F CTCTCTCATATGATGGGCGCCCGCGCCAGCGTGC
WV-149 XhoI F CTCTCTCGAGGGAATTAATTCGAGCTCGG
WV-150 NheI RC AGAGGCTAGCCAGATCCTCTACGCCGGACCTCT
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WV-150 NheI RC AGAGGCTAGCCAGATCCTCTACGCCGGACCTCT
WV-151 4CTE BamHI F GCAGGTAACTCGACTTAATTAAGGATCCACCTCCCC
WV-152 4CTE XhoI RC AGAGAGCTCGAGTCGACCCTGGCAGGGCTAGCAGATCTACACATCCCTCGGAG
WV-153 XhoI F CTCTCTCGAGACTCGACTTAATTAAGGATCCACCTCCCCTGTGAG
WV-154 TAATGAGTCTGACTGCCTTAGGAGGTCTATCGTCGCTGTCTCCGCTATCTTCCTGCCAT
WV-154 RC REV TAATGAGTCTGACTGCCTTAGGAGGTCTATCGTCGCTGTCTCCGCTATCTTCCTGCCAT
WV-155 XhoI CTE F CCCCGAAAAGTGCCACCTCGAGTCGACTTAATTAAGGATC
WV-156 XhoI CTE RC GCTATGACCATGATTACGCCAAGCTCTAGCTCGAGGTCGACCCTGGCAGGGCTAGCAG
WV-157 REV F GTAAGTAATACATGTAATGCAACCTATACAAATAGCAATAGTAGCATTAGTAGTAGC
WV-158 REV RC GGTTGCATTACATGTATTACTTACAGGAGATGCCTAAGGCTTTTGTTATGAAACAAAC
WV-159 PacI-MluI F GGCCAACTCATGACGCGTAGATCTTAGCCACTTTTTTTAATTAAAGGGGGGACTCGAG
WV-160 PacI-MluI RC CTCGAGTCCCCCCTTTAATTAAAAAAAGTGGCTAAGATCTACGCGTCATGAGTTGGCC
WV-161 CD4 SfiI F CTCTGGATCCGGCCAGAGAGGCCATGAACCGGGGAGTCCC
WV-162 CD4 SfiI RC AGAGGCGGCCGCGGCCTCTCTGGCCTCAAATGGGGCTACATGTC
WV-163 3LTR seq GTAGCATCTGGCTTACTGAAGCAGAC
WV-164 EGFP seq F CCGACAAGCAGAAGAACGGCATCAAG
WV-165 CTCTCTCGAGACTAGTTGGAAGGGCTAATTCAC
WV-166 TGCAACTGCAAGAGGGTTTATTGGATACACGGGTACCCGGGCGACTCAGTCAATCGGAGGACTG
GCGCAGTACAGGCAAAAAGCAGCTGCTTATATG
WV-167 GTATCCAATAAACCCTCTTGCAGTTGCAAGTAGTGTGTGCCCGTCTGTTGTGTG
WV-168 GAGAGGCTAGCTCGCGATCTAATTCTCCCCCGC
WV-169 EGFP qPCR F GGAGCGCACCATCTTCTTCA
WV-170 EGFP qPCR RC AGGGTGTCGCCCTCGAA
WV-171 LTR-R XhoI F CTCTCTCGAGTGGAAGGGCTAATTCACTCC
WV-172 LTR-R Noti RC AGAGGCGGCCGCTGCTAGAGATTTTCCACAC
WV-173 SFFV-GFP F CTCTAGATCTGAATTCCTGCAGCCCCG
WV-174 SFFV-GFP RC AGAGAAGCTTGGCGGCCGCTTTACTTGTAC
WV-175 CXCR4 BamHI 1 CTCTGGATCCATGGAGGGGATCAGTATATAC
WV-176 CXCR4 2 GCATAGAGGATGGGGTTCAGACAACAGTGG
WV-177 CXCR4 3 CCACTGTTGTCTGAACCCCATCCTCTATGC
WV-178 CXCR4 NotI 4 AGAGGCGGCCGCTTAGCTGGAGTGAAAACTTG
WV-179 SFFV seq F CCTGAAATGACCCTGCGCCTTATTTG
WV-180 CD4 seq CTCCTTCCCACTCGCCTTTACAG
WV-182 CXCR4 BglII F CTCTAGATCTATGGAGGGGATCAGTATATAC
WV-183 CXCR4 BglII RC AGAGAGATCTTTAGCTGGAGTGAAAACTTG
WV-184 LNCX SphI F CTCTGCATGCCCGACGGCGAGGATCTCG
WV-185 LNCX 2 RC CGTAATTGATTACTATTACGAGATCTAGAGTCCCGCTCAGAAGAAC
WV-186 LNCX 3 F GTTCTTCTGAGCGGGACTCTAGATCTCGTAATAGTAATCAATTACG
WV-187 LNCX 4 BglII RC AGAGAGATCTGAGTCCGGTAGCGCTAGCGGATC
WV-188 LNCX XhoI RC AGAGCTCGAGATCTGAGTCCGGTAGCGC
WV-189 NHG 3LTR seq CTCTGACGGCAGTTTACGAGAGAGATG
WV-190 5' LTR seq (NHG) F TATTACCACTGCCAATTACCTGTGG
WV-191 CXCR4 WV SfiI F CTCTGGCCGAGGCGGCCATGGAGGGGATCAGTATATACAC
WV-192 CXCR4 WV SfiI RC AGAGGGCCATTAAGGCCTTAGCTGGAGTGAAAAC
WV-193 EGFP SfiI F CTCTGGCCGAGGCGGCCATGGTGAGCAAGGGCGAGGAGC
WV-194 EGFP SfiI RC AGAGGGCCATTAAGGCCTTACTTGTACAGCTCGTCCATGC
WV-195 PCR 4 RC AGAGGAATTCTTATTATGGCTTCCACTCC
WV-196 PCR 3 F GGCGAGCAGACAGGATGAGGATTAGCACATGGAAAAGATTAGTAAAACACC
WV-197 PCR 2 RC GGTGTTTTACTAATCTTTTCCATGTGCTAATCCTCATCCTGTCTGCTCGCC
WV-198 PCR 1 F CTCTGAATTCGTTGGCATTGATTATTGACTAG
WV-199 EcoRI RC GAATTCACTACTAAGTTTGTAGTACATATTTAAC
WV-200 EcoRI F GTTAAATATGTACTACAAACTTAGTAGTGAATTC
WV-201 RC CTGTTTTAACCCTGCAGGATGTGGTATTC
WV-202 NdeI F CTCTCATATGATGGGTGCGAGAGCGTCGGTATTAAG
WV-203 NotI RC AGAGGCGGCCGCTTAATCCTCATCCTGTCTACTTGCC
WV-204 CXCR4 seq CTGCCTGGTATTGTCATCCTGTCCTG
WV-205 psi gag NdeI F CTCTCATATGAAAAATTTTGACTAGCGGAGGCTAG
WV-206 CpG BssHII 1 F CTCTGCGCGCACGGCAAGAGGCGAGGGGCGGCGACTGGTGAGTACGCCAAAAATTTTGACTAG
CGGAGGCTAGAAGGAGAGAGATGGGTGCGAGAGCGTCGGTATTAAG
WV-207 CpG RC 2 GGTGTTTTACTAATCTTTTCCATGTGTTAATCCTCATCCTGTCTACTTGCC
WV-208 CpG RC 3 GGCAAGTAGACAGGATGAGGATTAACACATGGAAAAGATTAGTAAAACACC
WV-209 CpG EcoRI 4 RC AGAGGAATTCTTATTATGGCTTCCACTCCTG
WV-210 seqGP CAGTTCATGCAGGCCCAATAGCAC
WV-211 seqGP CTCAGATCACTCTTTGGCAGCGACC
WV-212 seqGP GACTTGTATGTGGGCAGTGACCTG
WV-213 seqGP GACAGACAGGGGAAGACAGAAGGTAG
WV-214 seqGP CAGCAGTCCAGATGGCTGTCTTCATTC
WL-191 NHG BamHI F TATTCATAATGATAGTAGGAGGCTTGG
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PROMEGA (UK) New England Biolabs (UK)
Catalog Number Catalog Number
Alkaline Phosphatase, Calf Intestinal (CIAP) M1821
ApaI R6361
BamHI R6021
BglII R6081
EcoRI R6011
EcoRV R6351
HindIII R0104
HpaI R6301
KpnI R6341
MluI R6381
NdeI R6801
NheI R6501
NotI R6431
PacI R0547
PstI R6111
SalI R6051
SbfI R0642
SfiI R0123
SnaBI R0130
SpeI R6591
XbaI R6181
XhoI R6161
 
 
2.2.3 Cloning 
 
2x Ligation buffer (Promega, C671) and T4 Ligase (Promega, C1263) were used for 
restriction digest cloning reactions. Restriction enzymes were purchased from Promega 
and New England Bio Labs, shown in Table 2.2. 
 Table 2.2. Restriction enzymes 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.4 Plasmids 
 
All plasmids used in this thesis are shown in Table 2.3 
 Table 2.3. Plasmids 
Plasmids Description Source
pCNCG MLV-derived vector expressing EGFP from the CMV promoter Generous gift from G. Towers
HIV-1-derived vector that provides the cis-acting information required for RNA packaging
into virions and for subsequent reverse transcription and for subsquent reverse transcription A. Thrasher, Institute of 
pCSGW and integration. It expresses GFP from an internal CMV promoter and the U3 region has  Child Health, University
been removed from the 3'LTR College London, UK
pCSGW_4CTE pCSGW encoding 4 copies of the Constitutive Transport Element preceeding the Made during PhD
3' ΔU3 region from the 3' LTR
pCSGW_Flexi_GP_4CTE Made during PhD
_3LTR
pCSGW_Flexi_GP_4CTE Made during PhD
_3CLTR
pCSGW_Flexi_GP_4CTE Made during PhD
_3MLTR
pCSGW_Flexi_ΔU3 Made during PhD
p5CLTR_Flexi_ΔU3 pCSGW-Flexi encoding a 5'CLTR Made during PhD
p5MLTR_Flexi_ΔU3 pCSGW-Flexi encoding a 5'MLTR Made during PhD
pCSGW encoding codon-optimized HIV-1 gag-pol genes, an IRES-GFP and 4 copies  
of the Constitutive Transport Element preceding the 3' CLTR 
pCSGW encoding codon-optimized HIV-1 gag-pol genes, an IRES-GFP and 4 copies  
of the Constitutive Transport Element preceding the 3' MLTR 
pCSGW derivative including a unique SpeI site in the 5528 position; the NheI site 
located at position 7842 has been deleted. These modifications facilitate the insertion of 
different LTRs at the 5' and 3' ends 
pCSGW encoding the codon-optimized HIV-1 gag-pol genes, an IRES_GFP and 4 copies 
of the Constitutive Transport Element preceding the 3' LTR 
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pCRV1_NL_gag-pol 
pFlexi_3LTR pCSGW-Flexi encoding a complete 3'LTR Made during PhD
pFlexi_3CLTR pCSGW-Flexi encoding a 3'CLTR Made during PhD
pFlexi_3MLTR pCSGW-Flexi encoding a 3'MLTR Made during PhD
p5CLTR_Flexi_3LTR pCSGW-Flexi encoding a 5'CLTR and 3'LTR Made during PhD
p5CLTR_Flexi_3CLTR pCSGW-Flexi encoding a 5'CLTR and 3'CLTR Made during PhD
p5MLTR_Flexi_3LTR pCSGW-Flexi encoding a 5'MLTR and 3'LTR Made during PhD
p5MLTR_Flexi_3MLTR pCSGW-Flexi encoding a 5'MLTR and 3'MLTR Made during PhD
Expresses the HIV-1 structural proteins under the control of the CMV immediate-early
promoter. The gag region encodes genes which comprise the capsid proteins; the pol Cell biolabs
region encodes the reverse transcriptase and integrase proteins
pDEST40 Expression vector designed to allow high-level, constitutive expression of the gene of Invitrogen
interest in a variety of mammalian hosts 
'
'
'
' '
' '
   '   '   
   '   '   
           
.             
       
i  t  i  t  ll  i l l, tit ti  i   t    it
i t t i   i t   li  t  
Made during PhD
Made during PhD
pDEST40_4CTE pDEST40 encoding 4 copies of the CTE from MPMV Made during PhD
pHBXB2_env Construct expressing HXB2 gp160 NIH AIDS Reagent Program
Contains the internal ribosome entry site (IRES) of the encephalomyocarditis virus
pIRES2_EGFP (ECMV) between  the MCS and the enhanced green fluorescent protein (EGFP) coding ClonTech
region. This permits both the gene of interest (cloned into  the MCS) and the EGFP
gene to be translated from a single bicistronic mRNA
pLNCX2 Mouse Moloney murine sarcoma virus vector used for transduction of AddGene
several cell lines. Contains a Neomycin resistance gene
pLNCX_CXCR4 pLNCX2 derivative encoding a HIV-1 CXCR4 co-receptor AddGene
pLPSG Mouse Moloney murine sarcoma virus vector used for transduction of AddGene
several cell lines. Contains a Neomycin resistance gene
pLPSG-CD4 pLPSG derivative encoding a HIV-1 CD4 receptor AddGene
NIH AIDS Reagent Program
pNHG Replication-competent HIV-1 clone in which Nef was replaced with EGFP Accession number JQ585717
pNHG_3LTR pNHG derivative encoding a polylinker preciding the 3'LTR Made during PhD
pNHG_3CLTR pNHG derivative encoding a 3' CLTR instead the 3'LTR Made during PhD
pNHG_3MLTR pNHG derivative encoding a 3' MLTR instead the 3'LTR Made during PhD
pDEST40_tat 
pDEST40_rev 
pDEST40 encoding tat gene 
pDEST40 encoding rev gene 
Made during PhD
Made during PhD
Made during PhD
Made during PhD
Made during PhD
Made during PhD
Made during PhD
Made during PhD
Made during PhD
pNL4-3 Full-length replication-competent HIV-1 clone NIH AIDS Reagent Program
pNHG_Δtat-F_3LTR pNHG encoding a frameshift mutation in the first exon of tat 
pNHG_Δtat-F_3CLTR pNHG encoding a frameshift mutation in the first exon of tat and a 
3'CLTR 
pNHG_Δtat-F_3MLTR pNHG encoding a frameshift mutation in the first exon of tat and a 
3'MLTR 
pNHG_Δtat-D_3LTR pNHG encoding a 43nt deletion in the first exon of tat in the first exon 
of tat 
pNHG_Δtat-D_3CLTR pNHG encoding a 43nt deletion in the first exon of tat and a 3'CLTR 
pNHG_Δtat-D_3MLTR pNHG encoding a 43nt deletion in the first exon of tat and a 3'MLTR 
pNHG_Δtat-D_ Δrev_4CTE  
_3LTR 
pNHG encoding a 43nt deletion in the first exon of tat. The rev exon 1 
has been removed and 4CTEs are preceding the 3' LTR 
pNHG_Δtat-D_Δrev_4CTE 
 _3CLTR 
pNHG encoding a 43nt deletion in the first exon of tat. The rev exon 1 has 
been removed and 4CTEs are preceding the 3' CLTR 
pNHG_Δtat-D_Δrev_4CTE  
_3MLTR 
pNHG encoding a 43nt deletion in the first exon of tat. The rev exon 1 has 
been removed and 4CTEs are preceding the 3' MLTR 
NIH AIDS Reagent 
Program 
Catalog number 12363 
NIH AIDS Reagent 
Program 
Catalog number 12363 
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The composition of plasmids generated for this thesis are represented in Figure 2-1. 
 
 
Figure 2-1. Plasmids maps employed in this thesis 
 
NHG clones 
Generous gift from G. Towers
pSIV-MPCG Simian Mason-Pfizer D-type retrovirus (MPMV/6A), complete genome Accession number M12349.1
pSYNGP Synthetic HIV-1 Gag-Pol sequences which have been codon-optimized for NIH AIDS Reagent Program
those highly expressed human genes
p5CLTR_SYNGP pSYNGP derivative including a CMV-R-U5 (CLTR) at the 5'end Made during PhD
p5CLTR_SYNGP_3CLTR pSYNGP derivative including a CLTR at the 5' and 3' end Made during PhD
p5CLTR_Ψ_SYNGP_IRES pSYNGP derivative including a 5'CLTR, the HIV-1 packaging signal and an IRES_GFP Made during PhD
_GFP
p5CLTR_Ψ_SYNGP_IRES pSYNGP derivative including a 5'and 3' CLTR, the HIV-1 packaging signal and an IRES Made during PhD
_GFP_3CLTR _GFP
Synthetic HIV-1 gp120 sequence in which most wild-type codons were replaced with
pSYNGP120JR-FL codons from highly expressed human genes(syngp120). In vitro expression of syngp120 NIH AIDS Reagent Program
is considerably increased in comparision to the wild-type sequence
p96ZM651gp160-opt Expression vector encoding gp160 Env protein which is a codon-optimized form NIH AIDS Reagent Program
of the 96ZM651.8 clone
pCMV-VSV-G VSV-G envelope protein, for use with lentiviral and MuLV vectors. AddGene, 8454
16863 nt pNHG 
LTR gag 
pol 
vif 
vpr 
rev 
tat 
vpu 
env 
rev 
tat 
GFP LTR 
15419 nt pNHG-3LTR 
LTR gag 
pol 
vif 
vpr 
rev 
tat 
vpu 
env 
rev 
tat 
GFP LTR 
LTR gag 
pol 
vif 
vpr 
rev 
tat 
vpu 
env 
rev 
tat 
GFP CLTR 
15567 nt pNHG-3CLTR 
XhoI 
XhoI 
NotI, XbaI 
NotI, XbaI 
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pNHG_Δtat-D_3LTR 
LTR gag 
pol 
vif 
vpr 
rev 
Δtat-D 
vpu 
env 
rev 
tat 
GFP LTR 
LTR gag 
pol 
vif 
vpr 
rev 
Δtat-D 
vpu 
env 
rev 
tat 
GFP 
LTR gag 
pol 
vif 
vpr 
rev 
Δtat-D 
vpu 
env 
rev 
tat 
GFP 
CLTR 
MLTR 
pNHG_Δtat-D_3CLTR 
pNHG_Δtat-D_3MLTR 
15560 nt 
15376 nt 
15702 nt 
XhoI 
NotI, XbaI 
XhoI 
NotI, XbaI 
XhoI 
NotI, XbaI 
LTR gag 
pol 
vif 
vpr 
rev 
tat 
vpu 
env 
rev 
tat 
GFP MLTR 
15708 nt pNHG-3MLTR 
pNHG_Δtat-F_3LTR 15418 nt 
LTR gag 
pol 
vif 
vpr 
Δtat-F 
vpu 
env 
rev 
tat 
GFP LTR 
rev 
pNHG_Δtat-F_3CLTR 
LTR gag 
pol 
vif 
vpr 
Δtat-F 
vpu 
env 
rev 
tat 
GFP 
rev 
CLTR 
15566 nt 
pNHG_Δtat-F_3MLTR 
LTR gag 
pol 
vif 
vpr 
Δtat-F 
vpu 
env 
rev 
tat 
GFP 
rev 
MLTR 
15708 nt 
XhoI 
NotI, XbaI 
XhoI 
XhoI 
NotI, XbaI 
NotI, XbaI 
XhoI 
NotI, XbaI 
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SYNGP clones 
 
5CLTR-SYNGP 
5CLTR-SYNGP-3CLTR 
9298 bp 
10078 bp 
CLTR CO gag 
CO pol 
Poly A 
CLTR CO gag 
CO pol 
CLTR 
EcoRI SnabI 
EcoRI SnabI HpaI 
NotI 
pSYNGP 9757 bp 
CMV CO gag 
CO pol 
Poly A 
SnabI 
5CLTR-SYNGP-Ψ-IRES-EGFP-3CLTR 11545 bp 
CLTR CLTR CO gag 
CO pol 
IRES_GFP 
Ψ 
5CLTR-SYNGP-Ψ-IRES-EGFP 
CLTR CO gag 
CO pol 
IRES_GFP 
10923bp 
Ψ 
XhoI 
NotI 
EcoRI SnabI 
XhoI 
NotI 
EcoRI SnabI 
HpaI 
pNHG-Δtat-D- Δrev-4CTE-3LTR 16116 bp 
LTR gag 
pol 
vif 
vpr 
Δrev 
Δtat-D 
vpu 
env 
rev 
tat 
GFP LTR 
4 CTE 
pNHG-Δtat-D- Δrev-4CTE-3CLTR 16187 bp 
LTR gag 
pol 
vif 
vpr 
Δrev 
vpu 
env 
rev 
tat 
GFP CLTR 
4 CTE 
Δtat-D 
XhoI 
NotI, XbaI 
XhoI 
NotI, XbaI 
PacI 
PacI 
PacI 
PacI 
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CSGW clones 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
p5CLTR-Flexi-3LTR 
p5CLTR-Flexi-3CLTR 
9987 bp 
10307 bp 
Ψ CLTR 
Ψ CLTR 
LTR SFFV GFP WPRE RRE 
CLTR SFFV GFP WPRE RRE 
NheI KpnI NruI 
SpeI 
NheI KpnI NruI 
SpeI 
5CLTR-SYNGP-Ψ-IRES-EGFP-3CLTR 11545 bp 
CLTR CLTR CO gag 
CO pol 
IRES_GFP 
Ψ 
SbfI, XhoI 
NotI 
EcoRI SnabI 
HpaI 
4 CTE 
pCSGW 
p5CLTR-Flexi-ΔU3 
9666 bp 
9767 bp 
LTR SFFV GFP Ψ 
ΔU3 
CLTR Ψ 
R-U5 RRE WPRE 
SFFV GFP 
ΔU3 
R-U5 WPRE RRE 
NheI 
pCSGW-Flexi-ΔU3 9665 bp LTR SFFV GFP Ψ 
ΔU3 
R-U5 WPRE RRE 
NruI 
SpeI 
NheI NruI 
SpeI 
KpnI 
KpnI 
p5MLTR-Flexi-ΔU3 
pFlexi-3LTR 
9915 bp 
9738 bp 
MLTR Ψ 
LTR Ψ LTR 
SFFV GFP 
ΔU3 
R-U5 WPRE RRE 
SFFV GFP WPRE RRE 
pFlexi-3CLTR 
pFlexi-3MLTR 
10007 bp 
10145 bp 
LTR Ψ CLTR 
LTR Ψ MLTR 
SFFV GFP WPRE RRE 
SFFV GFP WPRE RRE 
NruI 
SpeI 
KpnI NheI 
NheI NruI 
SpeI 
KpnI 
NheI NruI 
SpeI 
KpnI 
NheI KpnI NruI 
SpeI 
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p5MLTR-Flexi-3LTR 
p5MLTR-Flexi-3MLTR 
9915 bp 
10403 bp 
MLTR Ψ 
MLTR MLTR 
SFFV GFP WPRE 
Ψ SFFV GFP WPRE 
RRE 
RRE 
LTR 
NheI KpnI NruI 
SpeI 
NheI KpnI NruI 
SpeI 
pCSGW-4CTE 10435 bp 
LTR SFFV GFP Ψ 
ΔU3 
R-U5 WPRE RRE 
4 CTE 
LTR SFFV GFP Ψ WPRE RRE 
4 CTE 
LTR 
NheI KpnI 
SbfI 
SbfI 
pCSGW_Flexi_-4CTE-3LTR 10631 bp 
LTR SFFV Ψ WPRE RRE 
4 CTE 
CO gag 
CO pol IRES_GFP 
p5LTR_Ψ_Flexi_GP_IRES_GFP_4CTE_LTR 15494 bp 
LTR 
CLTR SFFV Ψ WPRE RRE 
CO gag 
CO pol IRES_GFP CLTR 
p5CLTR_Ψ_Flexi_GP_IRES_GFP_4CTE_3CLTR 15816 bp 
NheI KpnI 
4 CTE 
NheI KpnI 
NdeI 
NotI 
NdeI 
NotI NruI 
SpeI 
NruI 
SpeI 
MLTR SFFV Ψ WPRE RRE 
CO gag 
CO pol IRES_GFP MLTR 
p5MLTR_Ψ_Flexi_GP_IRES_GFP_4CTE_3MLTR 15909 bp 
4 CTE 
KpnI NheI 
NdeI 
NotI NruI 
SpeI 
LTR SFFV Ψ WPRE RRE 
4 CTE 
WV CO gag 
WV CO pol IRES_GFP 
p5LTR_Ψ_Flexi_WV-GP_IRES_GFP_4CTE_ΔU3 15285 bp 
ΔU3 
R-U5 
KpnI NheI 
SpeI 
NruI 
NdeI 
NotI 
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All constructs developed during this thesis were successfully sequenced to confirm that 
their sequences were correct. 
 
 
 
2.2.5 Antibodies 
 
The primary antibody used in this thesis was mouse anti-p24 (183-H12-5C, 2mg/ml stock 
concentration; 1:50 final concentration) produced from an hybridoma of Balb/c mouse 
splenocyte x SP2-0 myeloma from the National Institutes for Health AIDS Reagents 
Program (catalog number 1513). The fluorescently labelled secondary antibody was GAM 
goat anti-mouse [IRDye800 Thermo Scientific, 0.5 mg/ml stock concentration; 1:10000 
final concentration]. Both antibodies were used for Western blot assays. 
 
CLTR CMV-R-U5 chimeric promoter (R and U5 regions from HIV LTR)
CO gag codon-optimized gag  gene for humans
CO pol codon-optimized pol  gene for humans
CTE constitutive transport element from Mason-Pfizer monkey virus (MPMV)
env envelope
gag group-specific antigen (MA, CA, p2, NC, p1 and p6)
GFP green fluorescent protein
IRES_GFP cassette of an internal ribosomal entry site preceding a GFP gene
LTR long terminal repeat
MLTR MLTR-R-U5 chimeric promoter (R and U5 regions from HIV LTR)
pol polymerase (PR, RT, RNase H and IN)
poly A polyadeliantion signal of SV40
R R region from HIV LTR
rev regulator of the expression of virion proteins
RRE Rev response element from HIV
SFFV spleen focus forming virus promoter
tat trans -activator of transcription
U5 U5 region from HIV LTR
vif virion infectivity factor
vpr viral protein R
vpu viral protein U
WPRE Woodchuck hepatitis virus post-transcriptional regulatory element
WV CO gag codon-optimized gag  gene for humans with reduced CpG number
WV CO pol codon-optimized pol  gene for humans with reduced CpG number
Δrev complete deletion of rev  exon 1 
Δtat-D deletion of 43 nucleotides in tat  exon 1
Δtat-F frameshift mutation in tat  exon 1
ΔU3 deletion in HIV U3 region
Ψ packaging signal of HIV-1
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2.3 Chemicals and buffers 
 
2.3.1 Cell culture 
 
 
1X DMEM – Dulbecco’s modified Eagle medium 1X High glucose (4500mg/L) with 
sodium pyruvate (110 mg/L), [Invitrogen 41966-029], 10% fetal calf serum (FCS), 
Gentamicin (20µg /ml final concentration). 
1X RPMI - Roswell Park Memorial Institute medium 1640 with L-Glutamine [Invitrogen 
21875-034], 10% fetal calf serum (FCS), Gentamicin (20µg /ml). 
1000x Ampicillin (100 mg/ml) – Melford Laboratories 
1000x AMP (100 mg/ml) - Melford Laboratories 
1000x G418 (100 mg/ml) – Gentamicin, Melford Laboratories 
Puromycin – Melford Laboratories 
Trypsin 0.05% EDTA – purchased from Sigma-Aldrich 
Formal saline fixative (FS) - Sigma-Aldrich, UK. 4% formaldehyde final concentration 
LB Broth - provided from EO Labs, pH 7.0 REF BM5300, 350ml 
LB Agar - provided from EO Labs, pH 7.0 REF BM5280, 300ml 
SOC recovery medium - 20g Bacto Tryptone, 5g Bacto Yeast Extract, 2ml of 5M NaCl, 
2.5ml of 1M KCl, 10ml of 1M MgCl2, 10ml of 1M MgSO4, 20ml of 1M glucose (1 litre 
final volume) 
Phosphate Buffered Saline (PBS) - MgCl2 and CaCl2 free; Sigma-Aldrich 
Terrific broth (TB) buffer for competent cells preparation- PIPES 10mM, KCl 250mM, 
CaCl2 15mM, 1mM MnCl2; pH 6.7, [1L final volume] 
Polyethylenimine (PEI-25000) - provided by Polysciences, USA 
 
 
2.2.2 Protein analysis 
 
4x NuPage Sample Buffer - Tris 3.4g, SDS (8%), EDTA dehydrate 0.024g, glycerol  
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(40%), blue bromophenol; pH 8.5; β-mercaptoethanol (1.5%) added before use. NuPage 
Novex BT GEL 4-12% 1.0MM - (Invitrogen) 
 
2.3.2 DNA analysis 
 
TAE Buffer - Tris 245.375g, Acetic acid (17.5%), EDTA dehydrate (18.5g) 
Agarose – 0.8-1.5% (w/v) diluted in 1x TAE (A9539 Sigma-Aldrich) 
DNA loading buffer - 0.4% orange G, 0.03% bromophenol blue, 0.03% xylene cyanol FF, 
15% Ficoll® 400, 10mM Tris-HCl (pH 7.5) and 50mM EDTA (pH 8.0); Promega. 
P1 buffer* - Tris 3.03g, EDTA dihydrate 1.86mg, pH 8.0. RNase was added at 100µg/ml 
P2 buffer* - SDS (20%), NaOH 4g 
P3 buffer* - Potassium acetate 147.25g, and Acetic acid until reach pH 5.5 
Neutralisation solution – provided by Pure Yield Plasmid Midiprep System (Promega) and 
Plasmid Midi Kit (Qiagen,12143). 
 
*Qiagen Midi Kit buffers were used to purify our plasmids from E.coli DH10B strain 
 
2.3.3 RNA extraction 
 
Viral RNA was extracted and purified from virions using a QIAamp Viral RNA Kit 
(Qiagen-52904) following the manufacturer’s instructions. 
 
2.3.4 Western blot reagents 
 
20x MOPS - MOPS 104.6g, Tris 60.6 g, SDS (2%), EDTA Free Acid (0.6%); pH 7.7 
[500ml final volume] 
10x Transfer buffer - Tris 120g, glycine 576.9 g. Prior to use add absolute ethanol (20%) 
PBS Tween-20 – washing buffer 1% final concentration (Sigma-Aldrich) 
Nitrocellulose Membranes – Invitrogen, 77012 
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2.4 Methods 
 
2.4.1 Cell culture 
 
Adherent mammalian cell lines were cultured in 10cm plates (Corning) and split every 3-4 
days at 90-100% confluency. Firstly the monolayer was washed gently once with PBS, and 
then trypsin 0.05% EDTA (ethylenediaminetetraacetic acid) was added to detach the 
adherent cells through incubation at 37°C for 5-8 minutes. Cells were re-suspended in 5 ml 
of fresh medium and centrifuged at 1200 rpm for 5 minutes. The supernatant was removed 
and cells were resuspended in 10 ml of fresh medium, split into new 10 cm plates and 
mantained at 37°C with 5% CO2. 
Suspension cell lines were mantained in 75cm2 and Split every 3-4 days, spliting into a 
new 75cm2 flask with fresh media. 
 
2.4.2. Transfection of human and murine cells 
 
Human and murine cell line transfections were carried out when the cells were at ~80% 
confluency. Transfections were made in 6 well plates/10 cm plates using PEI-25000 
(polyethylene glycol) as a transfection agent (4µl PEI / µg of DNA). Transfection volumes 
are shown in Table 2.4. 
Table 2.4. Transfection volumes 
 
2.4.3 Assays for viral particle production and infectivity production and infectivity 
 
Single cycle of replication viruses were generated by co-transfection of multiple plasmids 
in HEK-293Ts and NIH-3T3 cells. Cells were seeded at 1x106 per well in 6-well plate 24 
hours prior to transfection. The transfection solution was mix by pulse-vortexing 20 times 
during 20 seconds and added to the culture 25-30 minutes later. Cell culture media was 
changed 24 hours post-transfection, and the supernatant containing infectious viral 
particles was harvested at 48 or 72 hours post-transfection using 0.45 µm 25mm diameter 
syringe filters (Sartorius Minisart®) and inoculated onto target cells. The infectivity assays 
were developed in human and murine cell lines by serial dilutions (1:3) made out in 96  
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well plates to determine the titre of the viruses measuring GFP expression by flow 
cytometry (Guava® EasyCyte, Merck Millipore) (Figure 2-2). 
 
 
 
 
 
 
Figure 2-2. Experiment protocol to generate replication competent HIV-1 particles or single cycle 
of replication viruses in HEK-293T cells. GFP expression can be detected 24 hours post-
transfection (h.p.t.). Viral particles are harvested 48 h.p.t. and inoculated to a target cell culture 
(AA-2 or PM1). Human lymphocytes are spinoculated for 1 hour and then incubated at 37°C. 
FACS analysis is carried out 48 hours post-infection (h.p.i.). 
 
 
2.4.4 Cloning 
 
2.4.4.1 NHG clones 
 
The backbone used to develop these clones was pNHG, an HIV-1 replication competent 
genome (Accession number JQ585717) that carries a GFP gene instead of nef. Firstly, a 
polylinker containing unique sites for XhoI, NotI and XbaI sites was cloned preceding the 
3’LTR. The sites XhoI and NotI were used to insert all LTRs: LTRwt (U3-R-U5) was 
amplified using the oligos WV-001, WV-002. The CMV-R-U5 (CLTR) was generated 
using pCRV1-NLGP as template and the oligos WV-002 and WV-004. The chimeric HIV-
MLV LTR (MLTR) was cloned by PCR using pNHG and pCNCG as templates, with the 
oligos WV-050, WV-094, WV-098, WV-051, WV-052, WV-053, WV-054, WV-095, 
WV-127. Latter oligos present different restriction sites that were used to clone the MLTR 
into other plasmids. 
The mutations in tat exon 1 (Δtat) were made following two different strategies: a) 
Removing the tat start codon and introducing stop codons along the sequence to generate a 
frameshift (tat-F); b) Deletion of 43 nucleotides to impede a reversion of the tat expression 
(tat-D). Both mutations were cloned by PCR by cleavage with NdeI with the oligos: WV-
006, WV-007, WV-008, WV-009, WV-012 and WV-013, using pNHG as template. The 
mutation in rev (Δrev) was developed by PCR to completely remove exon 1. This strategy 
also removed 76 nucleotides of the tat exon 1 due to overlapping sequences. The oligos for  
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Δrev were WV-006, WV-141 and WV-157 and WV-158 prior to insertion by cleavage 
with EcoRI and BamHI. Prior to insertion of the CTE into NHG we cloned by PCR a 
polylinker containing MluI and PacI sites with the oligos WL-191, WV-159 and WV160 
digesting with BamHI and XhoI. Then four copies of CTE were inserted using PacI. 
 
2.4.4.2 SYNGP clones 
 
The 5’CMV promoter already present in pSYNGP was replaced by the CLTR from 
pCRV1-NLGP using the oligos WV-018 and WV-019 and digested with SnabI (Promega 
R6791) and EcoRI (Promega R6011). The 3’CLTR was cloned using the oligos WV-019 
and WV-020 by digestion with NotI and HpaI (R6301). 
The HIV-1 packaging signal (Ψ) was cloned into SYNGP constructs by PCR using the 
following oligos: WV-025, WV-026, WV-027 and WV-028, using pNL4-3 as a template 
by cleavage with NdeI and MluI (R6381). Afterwards, the IRES-GFP cassette was 
introduced by PCR from pIRES2-GFP with the oligos WV-041 and WV-042 digesting 
with XhoI and NotI.  
Four copies of the Constitutive Transport Element (CTE) were amplified by PCR using 
Psiv-MPCG (MPMV proviral clone) as template and the oligos WV-058, WV-059. One 
copy was cloned into the pDEST40 expression vector by cleavage with SalI (Promega 
R6051). The resultant vector, DEST40-CTE was digested with BglII (Promega R6081) and 
NheI (Promega R6501) to insert one copy of the CTE digested with BamHI and NheI. This 
step was repeated twice to generate 4 copies of the CTE in cis in DEST40. The 4CTEs 
were cloned into SYNGP digesting with SbfI. 
Several restriction sites were introduced in SYNGP following the last copy of the CTE 
(preceding the 3’LTR) with a polylinker synthesized by annealing the oligos WV-056 and 
WV-057. The annealing reaction was composed of 10µl of each primer, 2.5µl 2M NaCl 
and 50µl H2O to 50µl final volume. Then, the reaction was boiled for 5 minutes and cool 
down slowly at room temperature and cloned into our constructs digesting with XhoI. 
 
2.4.4.3 CSGW-flexi clones 
 
 
The system developed to determine the functionality of the LTRs in this project is called 
Flexi, which used pCSGW as a template. Several modifications were made in pCSGW to  
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allow us to test different LTRs in an easy way. Accordingly, it was necessary to remove 
the NheI site located in the SFFV promoter by PCR using the oligos: WV-082, WV-083, 
WV-084 and WV-085. A unique SpeI site was introduced at the beginning of the 5'LTR by 
PCR using the oligos WV-086, WV-087, WV-088 and WV-089 by cleavage with BamHI 
and EcoRI. An additional BclI site was also introduced immediately before the HIV-1 
packaging signal. At this point, the several 5'LTRs were cloned into CSGW-flexi digesting 
with HpaI (Promega) and NruI (Promega R7091); about the 3'LTRs cloning, the digestion 
was made with KpnI (Promega R6341) and NheI. In order to introduce the different LTRs 
at the 5' end, the CLTR was amplified by PCR with oligos WV-094 and WV-095; about 
the MLTR, the oligos employed were WV-094 and WV-096. At the 3'end, the CLTR was 
amplified by PCR using the oligos WV-097 and WV-101; the oligos used for the MLTR 
were WV-098 and WV-099. 
 
2.4.4.4 CSGW_GP clones 
 
The SFFV-gag-pol cassette was subcloned from 5CLTR _Ψ_ SYNGP_ IRES_ GFP_ 
4CTE_3CLTR into CSGW_4CTE by cleavage with EcoRI and NotI. The CLTR and 
MLTR promoters were cloned in the same manner as CSGW_Flexi clones, using the 
unique restriction sites located at both ends. 
 
2.4.4.5 DEST40 clones 
 
HIV-1 tat and rev genes were cloned into this expression vector. The tat gene was cloned 
by PCR with the oligos WV-010 and WV-011 by cleavage with SfiI (DEST40-tat). The rev 
gene cloning followed the same strategy as before, but the oligos were WV-114 and WV-
115 (DEST40-rev). Both strategies removed the introns of both genes. The Constitutive 
Transport Element (CTE) was cloned by PCR using pSARM4 as a template with the oligos 
WV-155 and WV-156, which contain several restriction sites.  DEST40 vector was 
digested with BamHI and NheI, while the CTE was digested with BglII and NheI. This 
strategy was repeated twice to achieve four copies in total (DEST40-4CTE). 
 
 
 
2.4.4.6 MLV based retroviral vectors for ex vivo gene transfer 
 
HIV-1 receptor CD4 was cloned into pLPSG by PCR using the oligos WV-161 and WV-
162 by cleavage with SfiI. To clone the SFFV-CXCR4 cassette into pLNCX2, we  
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introduced a BglII site in by PCR using the following oligos: WV-184, WV-185 WV-186, 
WV-188, WV-175 and WV-178. Then, the SFFV-CXCR4 cassette was digested with 
BglII, generating the pLNSX-CXCR4. Viral particles were generated following the 
protocol described in Figure 2-2. The gag-pol genes are provided by pMLV-GP (1µg) and 
envelope by pCMV-VSV-G (100ng) (1:100 ratio). After 48 hours post infection the p/m40 
AK were subjected to selection with the antibiotics described in section 2.1.2. 
 
2.4.5 Ligation reactions 
 
After vector digestion the plasmid was dephosphorylated using CIAP (Calf Intestinal 
Alkaline Phosphatase, Promega M1821). Restriction digestion volumes were 40 µl total, 
adding 5 µl of 10X calf intestinal alkaline phosphatase buffer (CIAP) and 4.5 µl of CIAP 
enzyme. The reactions were incubated for 2 hours at 37°C following an incubation at 55°C 
during 10 minutes. Samples were purified from an agarose gel after electrophoresis and 
transferred into gel extraction columns (Purelink Quick Gel Extraction Kit, Invitrogen 
K210012) following manufacturers instructions. Ligation reactions were carried out adding 
5 µl of 2x Rapid DNA Ligation buffer (Promega, C671) and 0.5 µl T4 DNA Ligase 
(Promega, C1263) per reaction. Vector/insert ratio used was 1:3.5, and the reactions were 
incubated for 1-3 hours before the transformation using DH10B.  
 
2.4.6 Bacteria transformation 
 
Bacteria were incubated with the plasmid of interest on ice for 30 minutes and subjected to 
a heat shock for 45 seconds at 42 °C. Then, bacteria were cultured in liquid phase SOC 
media during 45 minutes prior to transferal to a solid phase LB agar plate (100µg/ml final 
concentration of ampicillin/kanamycin) that was incubated overnight. 
 
2.4.6.1 Chemically competent Escherichia coli DH10B bacteria preparation 
 
E. coli DH10B competent bacteria were prepared (by Walter Vera) using the following 
protocol: 
1. Streak the host bacteria on an agar plate without selection.  
2. Incubate at 37°C overnight. 
3. Pick a single colony to inoculate several starter cultures (20ml) without selection. 
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4. Shake at 37°C for 8 hours. 
5. Add starter culture to 1.4L of LB in a conical flask and shake at 18°C until O.D. 
reaches 0.6 (~16-24h).  
6. Put culture on ice for 10 min. Then split into 6 centrifuge bottles (200x6 and 
leftover) and pellet the bugs at 2000g for 10 min at 4°C. 
7. Discard supernatant. 
8. Resuspend all pellets in 6x75 ml of ice-cold TB (The six bottles must be combined 
into two at this stage). Incubate for 5 minutes. 
9. Spin at 2000g for 10 min at 4°C.  
10. Discard supernatant. 
11. Resuspend the pellet in 40ML 7% TB-DMSO and transfer all volume into one. Sit 
the culture on ice for another 10 min. 
12. Snap-freeze the bugs in liquid nitrogen/ethanol ice bath. 
13. Aliquot the bugs e.g. 250-300ul/tube bath and store at -80°C. 
 
2.4.7 Miniprep cultures, DNA extraction and restriction digestion 
 
Miniprep cultures were performed to determine the presence of the insert within the 
plasmid. Bacterial colonies were picked and deposited in a replica agar plate with 
antibiotic resistance and resuspended in 1ml LB with Ampicillin or Kanamycin. Then 
cultures were incubated at 30°C at 240 rpm for 10-12 hours. Plasmid extraction from 
bacteria was performed using the following protocol: 
 
1. Spin down minicultures for 5-10 minutes at 13.000 rpm  
2. Aspirate LB growth medium  
3. Add 200 µl of buffer P1 to each tube.  Resuspend pellet. 
4. Add 200 µl of buffer P2 to each tube. Heat SDS prior to use to ensure it is in 
solution.  Mix by inversion following addition of P2. 
5. Incubate for 10-15 minutes at room temperature. 
6. Add 250 µl of buffer P3 and mix by inversion. 
7. Centrifuge at 13000 rpm for 10-15 minutes and add 1 ml ethanol into new 1.5 ml 
tubes. 
8. Carefully remove the supernatant from the centrifugation avoiding the pellet and 
transfer this supernatant to the ethanol.  Shake the tube to mix and place at -20 °C  
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for 15-30 minutes. 
9. Spin at 13000 rpm for 10 minutes, aspirate supernatant alcohol and wash with 200 
µl of 70% ethanol. 
10. Centrifuge at 13.000 rpm for 2-5 minutes 
11. Aspirate supernatant to remove all ethanol, air dry the tubes until totally dry and 
resuspend in 50 µl of MiliQ water. 
 
The extracted DNA was digested with restriction enzymes to determine the digestion 
pattern of the plasmid including the insert. Samples were prepared in 10 µl final volume 
and incubated for 3-4 hours at 37 or 50°C (depending of the enzyme features). Digested 
samples were run into agarose gels as described in section 2.4.12. 
 
2.4.8 Midiprep cultures 
 
Midiprep cultures were carried out to generate plasmids stocks containing the insert of 
interest. Colonies were picked from the replica plate and inoculated into 250 ml of LB with 
Ampicillin/Kanamycin and cultured at 240 rpm and 30°C for 10-12 hours. DNA 
extractions from the bacteria were performed using the Plasmid Midi Kit (Qiagen,12143) 
following manufacturer instructions. 
 
 
2.4.9 RNA extraction and purification 
 
Supernatant containing viral particles were DNase treated for 1 hour at 37°C to remove 
plasmid background from the transfection. Then, viral particles were purified using 20% 
sucrose cushions in 1.5ml tubes and centrifuged at 14000 rpm for 4 hours at 4°C. The 
RNA extraction was carried out using a QIAamp Viral RNA Kit (Qiagen-52904) following 
the manufacturer instructions. 
 
2.4.10 Reverse transcription and qPCR assays 
 
The synthesis of cDNA was carried out using a SUPERSCRIPT III Kit (Invitrogen 
18080044); the RNase Out Ribonuclease was provided from Invitrogen-10777.019. The 
random oligos were provided from Promega (Oligo(dt15) Primer-C1101). The qPCR 
design was performed following a protocol developed to determine the titre of lentiviral 
vectors: Comparison of lentiviral vector titration methods; BMC Biotechnology 2006, 6:34  
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doi:10.1186/1472-6750-6-34 (2006). The oligos and the GFP probe design were identical: 
5'- GGAGCGCACGATCTTCTTCA-3' and 5'-AGGGTGTCGCCCTCGAA-3'; the 5’Taq-
Man probe 5'-FAM-CTACAAGACCCGCGCCGAGGTG-TAMRA-3'. Q-PCRs were 
developed using Brilliant III Ultra-Fast QPCR Master Mix (Agilent-600880). 
qPCR reactions 
Forward primer (10µM) 0.5 µl per reaction 
Probe (5µM)    0.5 µl per reaction + 2µl of cDNA 
ROX/dye (1:500)   0.3 µl per reaction  
 
2.4.11 PCR 
 
PCRs were carried out using Pfu Turbo DNA Polymerase® (Agilent Technologies, 
600250) in 50µl reaction volumes containing the following components: 
5 µl of 10x Reaction buffer 
1 µl of dNTPs (10µM) 
1.5 µl forward oligonucleotide 
1.5 µl reverse oligonucleotide 
1 µl DNA template 
39 µl H2O 
1 µl Pfu polymerase 
 
Primer annealing temperature was determined by primer Tm. Extension time was 
determined by the length of the amplicon (1 minute/kb using Pfu Turbo polymerase). 
DMSO was added to the reaction when GC contents were 60-70% to avoid secondary 
structures formation in oligonucleotides. 
 
2.4.12 Agarose gel electrophoresis  
 
This technique was performed to separate DNA fragments for either visual analysis or gel 
purification. Agarose solution was prepared in TAE buffer, transferred into a horizontal gel 
tank and fully covered with TAE as running buffer. Loading dye was added to samples 
(Promega) in 1:6 ratio dye/simple. Either 1kb DNA ladder was used to determine the size 
of DNA fragments (Promega, G5711 ) or 100bp DNA ladder (Promega, G2101). Agarose  
Initial denaturation    96°C 5 minutes 
Denaturation              96°C 30 seconds 
Annealing             55°C 30 seconds/1 minute 
Elongation             72°C 1 minute/kb 
Extra elongation         72°C 2 minutes 
Hold              4°C 
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gels were run at 120 V until DNA separation was achieved. DNA fragments were observed 
using a UV transilluminator and purified from the gel using a Purelink Quick Gel 
Extraction Kit, Invitrogen K210012) following manufacturer instructions. 
 
2.4.13 Western blot analysis  
 
Transfected HEK-293T cells were treated in protein sample buffer and sonicated for 45 
seconds at 4 kg/m2. Filtered supernatants containing viruses were purified by 
centrifugation on sucrose cushions (20%) in 1.5 ml tubes and centrifuged at 13000 rpm 
during 4 hours at 4°C. Viruses were resuspended in 50 µl of protein sample buffer. All 
samples were heated at 70°C for 5 minutes and resolved on 4-12% Bis-Tris acrylamide 
gradient gels (Life Technologies, UK). Proteins were separated by electrophoresis at 140 V 
for 1.5 hours in MOPS buffer and transferred onto nitrocellulose membranes (Invitrogen™ 
Nitrocellulose Membranes) for liquid blotting transfer technique overnight. The 
membranes were blocked with 50% heat inactivated bovine calf serum-PBS solution 
(50%) for 30 minutes shaking at 20 oscillations/minute at room temperature. Then 
membranes were probed with antibodies diluted in 50% FCS-PBS. The membranes were 
washed with PBS-Tween solution (1%) after each antibody incubation step and prior 
revealing the results using a LiCor Odyssey Scanner with Image Studio Software.. The 
secondary antibody was GAM goat anti-mouse [IRDye800 Thermo Scientific (1:10000)]. 
 
2.4.14 TZM-bl assays 
 
This cell line contains integrated reporter genes for firefly luciferase and E. coli β-
galactosidase under control of an HIV-1 LTR. The aim of this assay is to detect HIV-1 Tat 
protein expression, which binds to the LTR stimulating transcription of the lacZ gene, 
originating the α-fragment. The β-galactosidase binds to the α-fragment and hydrolyses the 
X-Gal generating a blue precipitate where Tat has been expressed.  (Figure 2-3). TZM-bl 
cells were seeded in 96 well plate (1x105 cells/well) and infected with viruses generated in 
HEK-293Ts. The plate was incubated for 48 hours and fixed in 2.5% glutaraldehyde 
(Sigma-Aldrich, UK). The fixative was removed and wells were washed twice with PBS 
before adding the X-Gal staining solution. Finally, the plate was incubated at 37°C in the 
dark for 4 hours.  
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Figure 2-3. Diagram of a standard TZM-bl assay. TZM-bl cells are a reporter cell line presenting 
an E. coli β-galactosidase gene under control of an HIV-1 LTR (Tat dependent) to measure Tat 
expression after a single round of infection. TZM express HIV-1 receptor and co-receptor (CD4 
and CXCR4 respectively). Diagram adapted from Akrit Sodhi, Silvia Montaner & J. Silvio 
Gutkind, Nature Reviews Molecular Cell Biology 5, 9981012 (December 2004). 
 
 
2.4.15 Cell preparation for flow cytometric analysis  
 
Suspension cells were transferred into 96 well plates in an equal volume (100:100) of 2.5% 
glutaraldehyde (Sigma-Aldrich, UK) and 10.000 events were collected using a Guava 
EasyCyte flow cytometer (Merck Millipore) measuring the percentage of GFP-positive 
infected cells. To analyse adherent cells, the media was removed and replaced by trypsin 
0.05% EDTA (Sigma-Aldrich) and then transferred into 96 well plates in an equal volume 
(100:100) of 2.5% glutaraldehyde. 
 
 
X-Gal solution 
 
5.3 ml PBS 
300 µl 100mM K4Fe (CN)6 
300 µl 100mM K3Fe (CN)6 
6 µl MgCl2 (1M) 
60 µl X-Gal (50mg/ml) 
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3.1 Results 
 
3.1.1 CLTR and MLTR chimeric promoters support transcription and reverse 
transcription 
 
In order to free HIV-1 from Tat-dependence, we needed to generate Tat-independent 
LTRs.  Several approaches have been taken previously to enhance viral gene expression in 
lentiviral vectors, such as pCVR1_NLGP (Figure 3-1), which encodes a CLTR chimeric 
promoter (CMV-R-U5). This construct is potentially Tat-independent and engenders high 
levels of expression due to the replacement of the U3 region in 5´LTR with a CMV 
promoter (Figure 3-2). This idea was followed for the generation of the MLTR (MLV-R-
U5) by inserting heterologous enhancer elements into the HIV-1 LTR (Chang et al. 1993). 
The MLTR encodes enhancer sequences derived from the MLV LTR promoter that 
stimulates transcription in a Tat-independent manner (Figure 3-1).  
 
The aim of this project was to generate an HIV-1 clone able to replicate within murine 
cells, and the MLTR was a good candidate to pursue because MLV is adapted to the 
murine host. In summary, the CLTR and MLTR promoters should be able to enhance viral 
gene expression in the absence of Tat, leading to the generation of sufficient viral RNA 
levels to express viral proteins and genomic RNA necessary to complete the viral 
replication cycle. We were able to generate lentiviral vectors in our lab by co-transfecting 
the essential viral genes into HEK-293Ts to produce high amounts of virions. It is 
necessary to provide the gag, pol and env genes in trans alongside a lentiviral genome 
including LTRs that can be reverse transcribed and subsequenty integrated into the host 
genomic DNA . These vectors were originally designed for gene therapy requiring efficient 
transgene expression. 
 
HIV-1 structural proteins are provided during transfection from pCVR1_NLGP (gag-pol 
expression plasmid derived from NL4-3 analagous to p8.9 commonly used in lentiviral 
vector generation), pCMV_VSV-G (a VSV-G envelope expression plasmid)  and a 
lentiviral vector genome encoding plasmid CSGW. HIV-1 Tat and Rev proteins are 
encoded in pCVR1_NLGP together with the structural HIV-1 gag-pol genes.  
(Figure 3-2) (Demaison et al. 2002).  
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Figure 3-2. HIV-1 LTR, CLTR and MLTR composition.B) Composition of the different LTRs 
employed in this thesis. The CLTR contains a CMV promoter replacing the U3 region, and the 
MLTR encodes the Moloney enhancer sequences from the MLV promoter into the U3 region. 
Adapted from  M Martin J. Virol. 1993, 67(2):743 and Morita E, Arii J. Christensen D, Votteler J, 
Sundquiste WI. Biotechniques 2012 Aug ;0(0):1-5. doi : 10.2144/000113909 and Diagram adapted 
from Retroviruses. Coffin JM, Hughes SH, Varmus HE, editors. Cold Spring Harbor (NY): Cold 
Spring Harbor Laboratory Press; 1997. 
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Figure 3-1. Diagram showing the elements encoded in pCSGW, pCVR1_NLGP and pCMV_VSV-
G. Transfecting these 3 plamids together we can generate pseudotyped HIV-1 lentiviral particles of 
one single cycle of replication. 
 
 
 
Viral particles generated are pseudotyped with the VSV envelope glycoprotein, which is 
‘pantropic’ and has been demonstrated to increase lentiviral vector titres (Cronin et al. 
2005). Following infection and reverse transcription, the CSGW vector genome will 
integrate into the host genomic DNA and express a GFP reporter transgene (driven by an 
internal SFFV promoter, located between both HIV-1 LTRs). The post-transcriptional 
regulatory element of Woodchuck Hepatitis virus (WPRE) within CSGW enhances 
expression of transgenes (Zufferey et al. 1999). After integration, RNA derived from the 
CSGW provirus cannot be packaged into the nascent VLPs because CSGW is a self 
inactivating (SIN) vector.  SIN vectors do not possess a U3 region in their 3’ LTR.  
Consequently, following reverse transcription and integration, the integrated proviral 
genome does not harbour any U3 sequences and therefore cannot drive expression of the 
RNA vector genome as the RNA pol II promoter elements reside within the U3 region 
(Zufferey et al. 1998). Even if a lentiviral vector is not SIN, it cannot complete subsequent 
cycles of replication because the gag-pol genes and the envelope glycoprotein are supplied 
in trans. This combination of three plasmids offers a convenient system to investigate the 
CLTR and MLTR characteristics as the GFP reporter gene expression is driven from an 
internal promoter (and is therefore independent of the proviral LTRs) and the system is 
replication incompetent facilitating comparative experiments limited to one round of 
infection that can be completed at containment level 2 (CL2) (Knight et al. 2010). 
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Figure X. Diagram showing the elements encoded in CSGW, CVR1_NLGP and CMV_VSV-G. 
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The CSGW plasmid was modified to test the CLTR and MLTR, prior to including them in 
replication competent viruses (due to lengthy refurbishment of the MacRobert CL3 
laboratories of the Richard Elliott Biosafety Laboratory CL3, it was necessary to, where 
posible, conduct experiments at CL2).  Thus, modification of CSGW facilitated 
examination of chimeric LTRs at CL2. The “Flexi” CSGW vector is a derivative of the 
parental vector CSGW, where restriction sites were modified at the 5´ and 3´end (of each 
LTR) to enable manipulation of LTRs at both ends of the vector (Figure 3-3). 
 
 
 
 
 
 
 
 
Figure 3-3. Location of the additional SpeI site at the beginning of 5’LTR in CSGW_Flexi_ΔU3, 
which is absent in CSGW. We removed the NheI site at position 7842 (within the SFFV internal 
promoter) in CSGW and preserve the NheI site at the end of the 3’LTR, unique after this 
mutagenesis to originate to generate the CSGW_Flexi_ΔU3 vector. 
 
 
There is evidence suggesting that enhancer elements can replace long terminal repeats in 
lentiviral vectors efficienlty, and transcription from chimeric LTRs had no effects on titre, 
infectivity, and genomic stability (Lotti et al. 2002). In this study, they used a very similar 
system to modify the HIV-1 LTR by replacing most of the U3 region with an 
autoregulatory enhancer (HS2) of the erythroid-specific GATA-1 transcription factor,  
which controls the expression of the gene of interest (GFP). An internal promoter (PGK 
instead of SFFV) drives the expression of a constitutive reporter gene, generating an 
efficient transduction of 70% in human and murine cells. The modification of the HIV-1 
LTR provides a more efficient vector design, employing several transcription enhancer 
elements to stimulate viral transcription of the gene of interest. These data also support the 
hypothesis that generating a Tat-independent virus by including our CLTR and MLTR 
chimeric promoters into CSGW vector is potentially possible.  
 
In pCSGW ‘flexi’, the 5´LTR can be replaced using unique SpeI and NruI sites to include 
the CLTR or MLTR, to examine the ability of the modified promoters to drive 
transcription. The ΔU3 3´LTR in CSGW is effectively copied in the 5′ LTR after reverse 
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transcription and integration of the ΔU3 provirus results in the transcriptional inactivation 
of the proviral LTR (self inactivation). A similar strategy was used at the 3´end, where 
unique KpnI and NheI sites flank the 3’ LTR. By inserting  LTRs at the 3´end allows 
chimeric LTRs to be examined for their ability to support reverse transcription (necessary 
for completion of the first cycle of replication) (Figure 3-4, panel A).  Crucially, transgene 
expression is driven by the internal SFFV promoter and should be relatively immune to 
variation in the nature of the 5’ LTR. 
 
The CSGW_Flexi clone had a similar titre compared to the parental CSGW construct, 
highlighting that a G→A substitution in position 7845 to remove the NheI site, and the 
addition of the SpeI site in position 5530 (G→C) had little effect on the fitness of this 
vector. Importantly, the CLTR and MLTR promoter supported transcription and reverse 
transcription efficienlty in the CSGW_Flexi clone (Figure 3-4, B, lanes 1 and 2). However, 
the viral titre was decreased when the 5´and 3’ LTRs were modified in CSGW_Flexi 
clones (Figure 3-4, B, lanes 3 to 11). The HIV-1 structural proteins were provided in trans 
transfecting CMV_NLGP vector (Figure 3-2) and the Gag/p55 expression was not affected 
by the various CSGW_Flexi clones in transfected HEK-293T cells (Figure 3-4, C).  
 
In all cases, VLPs were efficiently generated in the presence of all the clones, suggesting 
that the infectivity reduction could be related to packaging of the vector genome within the 
nascent particles, or inefficiency in completing any of the early steps of the viral 
replication cycle (such as reverse transcription, chromosomal integration or transgene 
transcription) that precede reporter gene expression (Figure 3-4, D) (Verdin et al. 1993; 
Bokhoven et al. 2009). 
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Figure 3-4. Multiple CSGW clones encoding HIV LTRs, or chimeric CLTR and MLTR. Molecular 
weight is shown in kDa. (A) CSGW clones used in this experiment. The ‘X’ represents a deletion of a 
NheI site, and the ‘arrows’ indicate restriction sites employed to modify the 5´and 3´LTRs. The 
envelope is provided by pCMV-VSV-G and the gag-pol HIV-1 genes by pCVR1-NLGP. (B) Mean 
titre of CSGW clones in PM1 cells 48 h.p.i. The DNA transfected amounts were 1µg of each CSGW 
vector, 1µg of pCMV_NLGP and 100ng pCMV_VSV-G. The error bars show the standard deviation 
for each titre (triplicates) (C) WB analysis (p55 and p24) of cell lysates from transfected HEK-293T 
cells 48 h.p.t. (D) WB analysis for p24 from purified VLPs collected after centrifugation of sucrose 
cushions from the supernatant of transfected HEK-293Ts 48 h.p.t. The primary antibody was mouse 
anti-p24. 
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3.1.2 A 118 base pair fragment preceding the 3´end of CSGW is involved in 
viral infectivity 
 
Because substituting the 3’ΔU3 LTR with a complete LTR led to a greater than 10-fold 
reduction in infectious titre (Figure 3-4, panel B), we examined the cloning strategy used 
to generate these clones to ensure this reduction was caused by a defect in the cloning 
strategy.  Reviewing the cloning strategy to modify the 5´and 3´LTRs revealed a deletion 
of 118 base pairs preceding the 3´ΔU3 LTR when CSGW_Flexi was generated. This 
sequence does not appear to encode any relevant genetic features (Figure 3-4, panel A). 
However, removing this 118 nucleotides could explain why CSGW_Flexi clones had 
reduced infectivity, suggesting that this region plays a role in virus production, perhaps 
improving the efficiency of minus strand transfer in infected cells (Velpandi et al. (1992), 
Piekna-Przybylska et al. 2008). 
We decided to introduce this 118 bp sequence back into all the CSGW_Flexi clones 
encoding the chimeric LTRs to determine if viral fitness was restored by repeating the 
same experiment as Figure 3-4. The viral titre of the 5´CLTR_Flexi clone was practically 
equal compared to titres derived from the CSGW and CSGW_Flexi clones (Figure 3-6, B, 
lanes 1 to 3), meanwhile the 5´MLTR titre was decreased by ~1 log compared to CSGW 
and 5´CSGW_Flexi (controls). The 5´MLTR_Flexi titre was also reduced by ~1 log 
compared to the 5´CLTR_Flexi clone (Figure 3-6, B, lanes 3 and 4). 
 
The addition of a competent 3´LTR replacing the 3´ΔU3 LTR did not affect reverse 
transcription (Figure 3-6, panel B, lanes 5,6 and 7). A reduction of GFP expression in 
target cells could be related to a reduction in reverse transcription in CSGW_Flexi clones, 
but we have not determined the RT levels for each vector in our experiments. However, the 
5´CLTR_Flexi_3CLTR titre was decreased by ~1 log (Figure 3-6, panel B, lane 9). The 
5´MLTR_Flexi_3LTR and 5´MLTR_Flexi_3MLTR had the lowest titre (Figure 3-6, panel 
B, lanes 10 and 11), a predicted result considering the titre reduction of 5´MLTR_Flexi 
clone, where the MLTR drove transcription more poorly than the 5´LTR and 5´CLTR 
(Figure 3-6, panel B, panel B). In summary, the CSGW_Flexi clones including the 118 bp 
fragment possessed similar titres to CSGW and CSGW_Flexi clones (excepting the 
5MLTR_Flexi, 5CLTR_Flexi_3CLTR, 5MLTR_Flexi_3LTR and 5MLTR_Flexi_3MLTR 
clones) compared to the clones lacking the 118 bp (Figure 3-6, panel B). 
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However, the 5´CLTR_Flexi_3CLTR, 5´MLTR_Flexi_3LTR and 5´MLTR_Flexi_3MLTR 
clones had a pronounced reduction in their titre compared with the rest of the clones used 
in this experiment. The LTR replacements at the 5´and 3´with CLTRs or MLTRs severely 
affected the infectivity of 5´CLTR_Flexi_3CLTR, 5´MLTR_Flexi_3LTR and 
5´MLTR_Flexi_3MLTR clones (Figure 3-6, panel B, lanes 9-11). 
HIV-1 gag and pol genes are encoded within the CMV_NLGP non-replication competent 
vector. Gag polyprotein posseses several domains (Figure 3-5): the amino-terminal domain 
is called matrix (MA), which binds the celular membrane and recruits the HIV-1 Env 
protein (Sundquist et al. 2012). The central domain (CA) is involved in virion assembly, 
generates the viral capsid and interacts with the viral RNA genome to be packaged into the 
nascent particles (Hope et al. 2015). The nucleocapsid domain (NC) is the major RNA-
binding domain of Gag, coating the viral RNA. The carboxy-terminal of Gag contains the 
p1 and p6, which harbour binding sites for HIV-1 accessory protein Vpr (Le Rouzic et al. 
2005).  
 
 
 
 
 
 
Figure 3-5. Diagram of HIV-1 Gag polyprotein, which is processed into MA (p17), CA (p24), p2, 
NC (p7), p1, and p6. Adapted from Kim et al. 2001, Proc Natl Acad Sci USA 18;98(26):15239-44. 
 
When Gag polyprotein is synthesized, Gag protein expression alone is sufficient to drive 
the assembly of immature viral particles, and the protease (PR) is subsequently activated to 
cleave Gag polyprotein to separate matrix, capsid and nucleocapsid proteins (Fun et al. 
2012). Both Gag and CA are multifunctional proteins during virion morphogenesis 
(Ganser-Pornillos et al. 2008). We are able to detect Gag precursor Pr55 (55kDa) 
expression within the host cell 48 hours post-transfection by western blot, and also  
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determine Gag intermediates generated after HIV-1 protease cleavage (Figure 3-6, panel 
C). 
We used CVR1_NLGP vector again to provide the HIV-1 structural proteins in this 
experiment (Figure NLGP). Gag expression was similar for all CSGW_Flexi clones 
including the 118 bp fragment (Figure 3-6, panel C). Some Gag intermediate products 
were observed in the cell lysates  from transfected HEK-293T cells, especially when the 
3´end was modified (Figure 3-6, panel C, lanes 5-11). In addition, capsid expression was 
very similar in all CSGW_Flexi clones, and p24 expression was higher than p25 (bottom 
and upper band respectively in CA lane) (Figure 3-6, lanes 1 to 11). The p25 detectable in 
HIV-1 infected cells is composed of four species with related isoelectric points and related 
to the phosphorylated state of p25. The VLPs collected from the supernatant of transfected 
HEK-293T cells 48 hours post-transfection were filtered and purified using 20% sucrose 
cushions to pellet the virions. Then, we used western blotting to detect the amount of VLPs 
generated in the presence of each CSGW_Flexi clone, which were very similar for all 
CSGW_Flexi clones (Figure 3-6, panel D).  
 
These experiments shown the ability of the  CLTR and MLTR chimeric promoters to carry 
out transcription and reverse transcription efficiently, but we still observe substantial 
reductions in the viral titres compared to the HIV-1 LTR (Figure 3-6, panel B). Thus, we 
have not determined reverse transcription levels and these results can not confirm that RT 
levels are not affected in CSGW_Flexi clones. However, we did not measure directly the 
reverse transcription levels for each CSGW clone, so we could only determine the 
efficiency of transcription and reverse transcription based on GFP expression after 
transfection and GFP expression in the target cells (PM1). We could have performed 
reverse transcription assays to determine the reverse transcription levels in our clones, and 
also investigate the RNA species within the transfected cells. Unfortunately, these 
experiments will consume much time and we decided to continue our investigations with 
the CLTR and MLTR to achieve Tat Independence in human cells before we move to 
murine cells. The presence of tat and rev genes within pCVR1_NLGP plasmid obscures 
our ability to determine the ability of the CLTR and MLTR to drive transcription and 
reverse transcription in a Tat and Rev independent manner. It is necessary to remove the 
HIV-1 regulatory genes from the experiment to investigate the real ability of the CLTR 
and MLTR. We can solve this issue by replacing pCVR1_NLGP for pSYNGP, which 
encodes the HIV-1 gag and pol genes codon-optimized for humans and lacks tat and rev  
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genes, so we will be able to repeat these experiments again within a Tat and Rev free 
environment. 
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Figure 3-6. CSGW clones encoding HIV LTR, CLTR, MLTR and the 118 bp region from CSGW 
backbone. Molecular weight is shown in kDa (A) Location of the 118 bp region in CSGW. (B) 
Mean titre of CSGW clones encoding the 118 bp region in PM1 cells 48 h.p.i. Three plasmids 
were transfected to obtain the virions: pCSGW clone (wt-CSGW as control), pCMV_VSV-G to 
generate the envelope and pCVR1_NLGP to provide gag-pol HIV-1 genes. The DNA transfected 
amounts were 1µg of each CSGW vector, 1µg of pCMV_NLGP and 100ng pCMV_VSV-G. The 
viral titre was determined by flow cytometry measuring GFP expression in PM1 cells. The error 
bars show the standard deviation for each titre (triplicates) (C) WB analysis (p55 and p24) of cell 
lysates from transfected HEK-293T cells 48 h.p.t. (D) WB analysis for p24 from purified VLPs 
collected after centrifugation of sucrose cushions from the supernatant of transfected HEK-293Ts 
48 h.p.t. The primary antibody was mouse anti-p24. 
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3.1.3 Viral particles derived from SYNGP clones are efficiently made in 
human and murine cells.  Codon optimization and chimeric CLTR facilitate 
Tat and Rev independent VLP production from human and murine cells 
 
The aim of this project was to generate infectious particles in mice in a Tat and Rev 
independent manner.  To achieve this ambitious aim, it is necessary to replace HIV-1 Rev 
function, involved in RNA stability and transport (Pollard et al. 1998). HIV-1 regulatory 
proteins cannot exert their function in murine cells, and viral RNA levels are insufficient to 
complete the viral life cycle (Barbara et al. 1993). The codon-optimized HIV-1 gag-pol 
genes (encoded in SYNGP) increase the amount of gag-pol RNAs within human cells due 
to the adaptation of HIV gag and pol genes to the human codon bias, leading to high 
expression levels of gag-pol viral RNAs generating infectious progeny in the absence of 
Rev (Kotsopoulou et al. 2000). Previous results demonstrated that chimeric CLTR and 
MLTR LTRs were functional in CSGW_Flexi clones when HIV-1 gag-pol, tat and rev 
genes were provided by  pCVR1_NLGP, and the envelope by pCMV_VSV-G (Figure 3-
6).  
 
Following this result we decided to substitute pCVR1_NLGP by pSYNGP to determine if 
single cycle of replication viruses are generated in a Tat and Rev independent manner (in 
both human and murine cells). The single cycle of replication viruses were generated by 
transfecting pCSGW (vector genome), pCMV_VSV-G (VSV-G envelope expression 
plasmid) and SYNGP (a GagPol expression plasmid which replaces pCVR1_NLGP) in 
human HEK-293T and murine NIH-3T3 cells. We reasoned that the codon-optimized gag-
pol genes and the CLTR could replace Rev and Tat function and permit the generation of 
infectious particles from murine cells. 
 
To attempt this experiment, the CMV promoter located at the 5´end of the parental 
pSYNGP vector was replaced with the CLTR by cleavage with SnabI and EcoRI to 
introduce the CLTR. Another CLTR was cloned at the 3´end of pSYNGP, causing the 
effective deletion of the poly A signal in pSYNGP during the cloning process (Figure 3-7, 
panel A). The lack of tat and rev genes in pSYNGP made it possible to investigate the 
viability of these promoters in a Tat and Rev free enviroment using this 
5CLTR_SYNGP_3CLTR clone (Figure 3-7, panel A). Gag/CA expression levels in 
transfected human HEK-293T cells were higher for the control (NLGP), but SYNGP also 
expressed Gag/CA efficienlty (Figure 3-7, upper panel B).  However, in murine NIH 3T3  
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cells, Gag synthesis was barely detectable and correspondingly, very little capsid 
expression was detected when gag-pol genes were provided by NLGP (Figure 3-7, bottom 
panel B, lane 1). Regardless of whether NLGP or SYNGP was used, CA/p24 expression 
was higher compared to p55 in human and murine cell lines (Figure 3-7, left panel, lanes 
1-4). The human codon-optimized gag-pol genes from pSYNGP were able to rescue Gag 
and Capsid expression in transfected NIH 3T3 cells (Figure 3-7, bottom panel B, lanes 2-
4).  
 
The amount of VLPs collected from transfected HEK-293T and generated using SYNGP 
was lower compared to the amount of VLPs detected using NLGP (Figure 3-7 right panel 
C, lane 1-4). Importantly however, NIH 3T3 cells were able to generate codon-optimized 
HIV-1 particles in a Tat and Rev independent manner (Figure 3-7, right bottom panel C, 
lanes 2-4) whereas wild type gag-pol HIV-1 genes encoded in pCVR1_NLGP were unable 
to express sufficient Gag to enable the assembly of nascent VLPs in NIH 3T3 cells (Figure 
3-7, panel C). The SYNGP construct was able to generate HIV particles in murine cells 
meanwhile pCVR1_NLGP failed because of the lack of codon-optimized gag and pol 
genes in this vector. The presence of tat and rev genes encoded in pCVR1_NLGP 
contributed to the more efficient generation of VLPs than pSYNGP in human cells, but no 
marked differences were observed in Gag expression in HEK-293T transfected with NLGP 
and SYNGP (Figure 3-7, left panel B, lanes 1-4).   
 
Tat and Rev proteins are unable to exert their function in murine cells, and consequently 
gag-pol genes were not expressed from pCVR1_NLGP (which lacks codon optimization) 
in murine cells. The codon-optimization from SYNGP contributes to increase the amount 
of gag-pol RNAs within the host cell, and subsequently Gag polyprotein expression is 
rescued in NIH-3T3 murine cells (Figure 3-7, panel B and C). However, wild type HIV-1 
gag and pol genes encoded in CMV_NLGP vector (lacking codon-optimization) were 
unable to generate sufficient gag-pol RNAs in murine cells, impairing Gag production 
(Figure 3-7, panel B and C). 
 
We have demonstrated that codon optimization rescued gag-pol expression in human and 
murine cells, and VLPs can be generated efficiently. However, no infection was detected 
after the inoculation of VLPs from 5CLTR_SYNGP and 5CLTR_SYNGP_3CLTR clones 
onto PM1 cells. Gag polyprotein was generated in both cell types, and it was processed 
successfully to form CA protein p24 (Figure 3-7). Perhaps the absence of the HIV-1  
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packaging signal in 5CLTR_SYNGP and 5CLTR_SYNGP_3CLTR clones could be the 
major factor impairing viral replication within human and murine cells, and the 
5CLTR_SYNGP and 5CLTR_SYNGP_3CLTR genomes could be unable to be packaged 
into the nascent viral particles (Clever et al. 2002).  
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Figure 3-7. (A) Diagram of the constructs used in this experiment. The SYNGP clones encode 
a CLTR at the 5’end, 3’end or both. (B) WB for capsid (p24) of transfected human HEK-
293Ts and murine NIH 3T3 cells 48 hours post transfection. (C) WB analysis (p55 and p24) 
of VLPs produced from the previous cell lines 48 h.p.t. The primary antibody was mouse anti-
p24. It is remarkable that pCVR1_NLGP was unable to generate VLPs in murine cells but 
SYNGP clones could rescue p55 and p24 expression. The DNA transfected amounts were 1µg 
of CSGW vector, 1µg of pCMV_NLGP/pSYNGP vector and 100ng pCMV_VSV-G.   
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3.1.4 Introducing the HIV-1 packaging signal (Ψ) in SYNGP clones did not 
increase the efficiency of particle production 
 
The  viral particles generated by SYNGP clones could be lacking the viral genome due to 
the absence of the HIV-1 packaging signal (Ψ), which is essential to package the genome 
within the nascent particles (Jouvenet et al. 2009). Secondary structure studies have 
determined that the HIV-1 packaging signal contains several RNA loops (SL1 to SL4) 
involved in packaging the viral genome into the particles through interactions with Gag 
(Zeffman et al. 2000).  
 
Despite the absence of the HIV-1 packaging signal in 5CLTR_SYNGP and 
5CLTR_SYNGP_3CLTR clones, they efficienlty generated viral particles when CSGW 
and VSV envelope were provided in trans, as the CSGW has an intact Ψ and would be 
packaged into the particles, but no infection was detected when they were inoculated onto 
human lymphocytes PM1 (Figure 3-7). Perhaps the lack of Ψ in pSYNGP is affecting viral 
RNA stability-folding necessary for Gag-RNA interaction, causing the production of VLPs 
lacking the viral genome (Kuzembayeva et al. 2014). The HIV-1 pacakging signal adopts a 
highly branched secondary structure, which is essential to achieve the entrance of the viral 
genome within the nascent particles. The absence of Ψ in 5CLTR_SYNGP and 
5CLTR_SYNGP_3CLTR could be determinant in the absence of viral infectivity and also 
impair the the appropiate RNA folding necessary to perform Gag-RNA interaction. 
An internal ribosome entry site (IRES) was cloned into the 5CLTR_SYNGP and 
5CLTR_SYNGP_3CLTR clones, followed by a GFP reporter gene by cleavage with NotI 
and XhoI (Figure 3-8). HIV-1 harbours an IRES located within 5´UTR and the gag coding 
region, which can drive 40S ribosomal subunit recruitment and positioning on the mRNA 
either at or upstream of the start codon (Vallejos et al. 2012) and contributing to increase 
translation of the viral proteins in HIV-1 infected cells (Gendron et al. 2011). Then, we 
decided to clone the HIV-1 packaging signal into the 5CLTR_SYNGP_IRES_GFP and 
5CLTR_SYNGP_IRES_GFP_3CLTR clones to determine if the viral particles become 
infectious. We deoptimized the previously codon-optimized 21 nucletides at the beginning 
of gag to instead preserve the RNA structure of the SL4 loop (Keane et al. 2015). We 
followed this strategy to preserve as much as possible the original position that Ψ has 
within an HIV-1 genome: starting at the end of the U5 region from the 5’LTR until the first 
nucleotides of gag (Figure 3-8, panel A). (Olson et al. 2015; Paillart et al. 2014). 
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Figure 3-8. (A) Location of the HIV-1 packaging signal within predicted viral genome. Notice that 
RNA secondary structure is predicted from collection of site-directed mutagenesis experiments, 
chemical and enzymatic accessibility assays, phylogenetic studies, and free energy calculations. 
(B) SYNGP clones encoding HIV Ψ. Diagram adapted from Kun Lu, Xiao Heng and Michael F. 
Summers, structural determinants and mechanism of HIV-1 genome packaging, Journal of 
Molecular Biology, 2011 Jul 22; 410 (4):609-633. 
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The resulting vectors were named 5CLTR_Ψ_SYNGP_IRES-GFP and 
5CLTR_Ψ_SYNGP_IRES-GFP_3CLTR. We repeated the same experiment as shown in 
Figure 3-7, but using these new clones instead to determine if the addition of the Ψ was 
able to rescue the infectivity of the VLPs. 
Gag expression was not increased or reduced either in transfected HEK-293T cells or NIH-
3T3 cells (Figure 3-9, panel B). In addition, the introduction of the Ψ did not increase the 
amount of VLP production collected from the supernatant 48 hours post-transfection in 
both cell types, generating similar amounts to SYNGP clones lacking Ψ (Figure 3-9, panel 
B). We detected Gag intermediates in transfected human HEK-293T and murine NIH-3T3 
as well (Figure 3-9, panel B). However, the VLPs generated from 
5CLTR_Ψ_SYNGP_IRES-GFP and 5CLTR_Ψ_SYNGP_IRES-GFP_3CLTR constructs 
within both cell types were not infectious despite the successful generation of viral 
particles. The codon-optimized gag-pol genes from SYNGP contributed to the generation 
of more Gag protein within murine cells, meanwhile the wild type gag-pol genes from 
NLGP were not expressed from pNLGP in murine cells (Figure 3-9, panel B). The 
percentage of transfected HEK-293T cells was much higher than NIH 3T3 cells (Figure 3-
9, panel D), but codon-optimization efficiently rescued Gag expression in murine cells 
despite the low percentage of transfection (about 30-50% approximately). 
Western blots for Gag/CA demonstrated the potential of murine NIH-3T3 cells to generate 
HIV-1 Gag protein until its maturation to create the viral Capsid, suggesting that the CLTR 
was efficienlty driving the transcription of codon-optimized gag-pol RNAs (Gao et al. 
2003). HIV Gag protein was successfully cleaved and processed to generate p24 protein 
and subsequently viral particles. The formation of VLPs suggest that viral proteins 
encoded within codon-optimized pol gene could be successfully generated, but further 
investigations need to be done to determine if VLPs produced from 5CLTR_Ψ 
_SYNGP_IRES-GFP_3CLTR clone had an adecuate morphology because we can not 
determine that by western blot assays. Based on the results obtained from the CSGW_Flexi 
system, the 5CLTR_Ψ _SYNGP_IRES-GFP_3CLTR clone should be able to support 
efficient transcription and reverse transcription, potentially generating infectious viral 
particles in human cells. However, the lack of infection in the target cells using this 
construct suggests that problems exist with this strategy.  
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Figure 3-9. (A) Composition of SYNGP clones encoding CLTRs, the HIV-1 packaging signal (Ψ) 
and an IRES_GFP. (B) WB analysis (p55 and p24) using mouse anti-p24 antibody from cell lysates 
collected from HEK-293T (human) and NIH 3T3 (murine) cells 48 hours post transfection. (C) WB 
analysis for p24 from purified VLPs collected after centrifugation of sucrose cushions from the 
supernatant of transfected HEK-293Ts and NIH-3T3 cell lines 48 h.p.t. The primary antibody was 
mouse anti-p24. Molecular weight marker in kDa. The DNA transfected amounts were 1µg of 
CSGW vector, 1µg of each pSYNGP vector and 100ng pCMV_VSV-G. 
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3.1.5 DEST40-tat drives Tat expression efficiently in TZM-bl cells 
 
We wanted to investigate the absence of infectivity in 5CLTR_Ψ _SYNGP_IRES-
GFP_3CLTR clone by including Tat into the system to check if its infectivity could be 
rescued. It was necessary to clone a tat gene into another vector to facilitate Tat expression 
in trans. Tat exon 1 and 2 were cloned into the expression vector DEST40 by cleavage 
with SfiI (introns were removed). The CMV promoter encoded in DEST40 will drive 
transcription of Tat after transfection. 
 
First, we wanted to test if pDEST40-tat actually was able to express functional levels of 
Tat in TZM-bl cells, Hela cells that have been modified to detect tat expression by TZM-bl 
assay (Montefiori et al. 2006). TZM-bl cells have been genetically modified to encode a β-
galactosidase gene under the control of an HIV-1 LTR promoter. After transfection, Tat 
will stimulate transcription of the LTR, leading to production of RNA and subsequently 
the synthesis of the β-galactosidase enzyme after translation, which will hydrolyze the X-
Gal (lactose analogue),  creating a visible blue precipitate.  
 
The pDEST40-tat was transfected at increasing doses to determine the best concentration 
for Tat expression. Higher concentrations of pDEST40-tat resulted in more blue 
precipitates (Figure 3-10, panel A). Some crystals were observed in all transfections, even 
in the mock control (Figure 3-10, panel A), likely originated from the X-Gal solution 
employed in the experiment. We used the pIRES2_GFP vector as transfection control for 
all conditions (Figure 3-10, panel B), and blue foci per field were quantified to determine 
more accurately the amount of functional Tat expression (Figure 3-10, panel C).  
 
Transfection efficiency was consistent at 70-80% under all conditions in this experiment 
(Figure 3-10, panel B), demonstrating that the decrease in blue foci was not due to reduced 
transfection. Higher amounts of DEST40-tat plasmid correlated to more blue precipitates 
observed, demonstrating that DEST40-tat expressed Tat efficienlty and can be employed 
in further experiments. 
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Figure 3-10. Tat expression driven from pDEST40-tat vector. (A) TZM-bl cells transfected with 
increasing amounts of pDEST40-tat DNA. (B) Flow cytometric analysis of TZM-bl transfected 
with pDEST40-tat and pCRV1-EGFP (transfection control). The SCC-HLin (side scatter) 
determined the size and granularity of the cell population selected for this experiment. The GRN-
HLin axis determined the intensity of GFP expression in TZM-bl transfected with pCVR1-GFP 
(control). (C) Blue cells foci per field. The measurement of blue foci per field was performed in 5 
wells for each condition. 
3 – Chapter 3 93 
 
3.1.6 HIV-1 codon-optimized VLPs are infectious in a Rev independent 
manner when CSGW and DEST40_tat are provided in trans 
 
Once we demonstrated the ability of DEST40-tat to generate Tat efficienlty in TZM-bl 
cells,  we wanted to transfect this vector together with 5CLTR_Ψ _SYNGP_IRES-
GFP_3CLTR clone to determine if its infectivity could be rescued. We performed the same 
experiment as shown in Figure 3-9, but this time Tat was added in trans. No infectivity 
was detected in PM1 cells in the absence of CSGW from VLPs generated in human and 
murine cells, despite providing Tat in trans (Figure 3-11).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3-11. Mean titre of SYNGP clones and NLGP (positive control) in PM1 cells. The SYNGP 
clones were transfected into HEK-293T cells and produced VLPs were collected and purified from 
the supernatant by centrifugation of sucrose cushions 48 h.p.t. Then, VLPs were inoculated into 
PM1 cells to determine the viral titre. CSGW vector was added in trans with pCMV_VSV-G to 
determine if CSGW could rescue SYNGP clones infectivity. We transfected the same amount of 
DNA as previous experiments: [1µg of CSGW: 1µg of SYNGPwt/SYNGP vector: 100ng 
pCMV_VSV-G] 
 
However, transfecting CSGW together with SYNGP and DEST40-tat in HEK-293T cells 
generated infectious viral particles (12% of cells were infected) (Figure 3-12, panel B). 
The addition of Tat in trans rescued the infectivity of SYNGP, so we wanted to determine 
if we could obtain the same result using 5CLTR_SYNGP_Ψ_IRES_EGFP_3CLTR clone 
instead SYNGP. When 5CLTR_SYNGP_Ψ_IRES_EGFP_3CLTR clone was co-transfected 
together with CSGW and DEST40-tat, they efficiently generated infectious VLPs that  
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infected around the 6.47% of PM1 cells (target cells) (Figure 3-12, panel B). However, no 
infectious particles were generated in the absence of pCSGW when 
p5CLTR_SYNGP_Ψ_IRES_EGFP_3CLTR, pDEST40-tat and pCMV_VSV-G were co-
transfected together (Figure 3-12, panel B). The fitness of these viruses was much lower 
than NLGP viruses employed in this experiment as positive control (82.7% of infected 
cells) (Figure 3-12, panel B). It is not surprising considering the presence of the regulatory 
proteins encoded in pCVR1_NLGP. These data demonstrated that the structural genes 
expressed from 5CLTR_SYNGP_Ψ_IRES_EGFP_3CLTR were capable of packaging a 
competent genome in trans (CSGW) and be infectious (delivering transgene expression).  
The structural proteins encoded by 5CLTR_SYNGP_Ψ_IRES_EGFP_3CLTR, could, in 
principle, package the RNA expressed from the clone, which encodes two competent 
LTRs, HIV-1 gag-pol codon optimized genes and the packaging signal. Unfortunately, the 
5CLTR_SYNGP_Ψ_IRES_EGFP_3CLTR clone appeared to still be not infectious and 
more investigation needs to be done to determine which stage(s) of the virus lifecycle fails 
to be successfully completed. 
 
The CLTRs located at both ends of the vector-genome should be able to drive transcription 
and reverse transcription, but unknown problems are impairing replication of 
5CLTR_SYNGP_Ψ_IRES_EGFP_3CLTR when CSGW is not provided in trans (Figure 3-
12). Co-transfecting CSGW and DEST40-tat with the 
5CLTR_SYNGP_Ψ_IRES_EGFP_3CLTR clone resulted in infectious viral progeny, 
suggesting that CSGW was being packaged into the viral particles generated by 
5CLTR_SYNGP_Ψ_IRES_EGFP_3CLTR. This result demonstrated that gag-pol were 
efficiently generated, but the full-length viral RNAs from 
5CLTR_SYNGP_Ψ_IRES_EGFP_3CLTR could not be exported to the cytoplasm in the 
absence of Rev, remaining in the nucleus and unable to be packaged into nascent particles. 
Another possibility is that full-length RNAs were not generated within the host cell, or 
perhaps their stability was compromised in the absence of Rev. However, the absence of 
Rev did not affect the infectivity of the 5CLTR_SYNGP_Ψ_IRES_EGFP_3CLTR clone, 
which was infectious when we added with pCSGW and pDEST40-tat together with 
pCMV_VSV-G (envelope) during transfection. The amount of cells infected by 
5CLTR_SYNGP_Ψ_IRES_EGFP_3CLTR in this experiment was 6.47% (Figure 3-12, 
panel B). This lower percentage could be related to the absence of Rev in the experiment. 
The addition of Tat in trans provided sufficient viral RNA genomes to be packaged within  
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the particles, and human codon-optimization for gag-pol genes contributed to increase gag 
and pol RNA transcripts.  
 
It has been demonstrated that Rev function can be replaced using codon optimized Gag-Pol 
(SYNGP) instead of wt Gag Pol (NLGP), but the CLTR did not replace Tat function yet, 
which still needs Tat to generate infectious viral progeny that is not produced in its absence 
(Figure 3-7 and 3-9). Published evidence suggests that Tat is not only involved in viral 
transcription, possesing additional functions such as influencing HIV-1 RNA splicing, 
capping or revese transcription (Jablonski et al. 2010; Chiu et al. 2002; Charnay et al. 
2009). Replacing Tat function is a difficult aim due to its diverse contributions to viral 
replication. (Das et al. 2011).  
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Figure 3-12. (A) Diagram of the SYNGP clones employed in this experiment. pCSGW, 
pCMV_VSV-G and pDEST40-tat were also included during transfection into HEK-293T cells. 
VLPs were purified from the supernatant 48 h.p.t. by sucrose cushion centrifugation and inoculated 
into PM1 cells to determine the viral titre. (B) Flow cytometric analysis of PM1 cells infected with 
SYNGP clones 48 h.p.i. to determine the viral titre/infectivity by measuring GFP expression. The 
SCC-HLin (side scatter) determined the size and granularity of the cell population selected for this 
experiment. The GRN-HLin axis determined the intensity of GFP expression in PM1 infected cells. 
The DNA transfected amounts were 1µg of CSGW vector, 1µg of pCMV_NLGP/pSYNGP, 500ng 
of DEST40_tat and 100ng pCMV_VSV-G. 
3 – Chapter 3 97 
 
 
3.2 Discussion chapter 3  
 
In order to free HIV-1 from Tat-dependence, we needed to generate Tat-independent 
LTRs.  The aim of this project was to generate an HIV-1 clone able to replicate within 
murine cells, and the MLTR was a good candidate to pursue because MLV is adapted to 
the murine host. In summary, the CLTR and MLTR promoters should be able to enhance 
viral gene expression in the absence of Tat, leading to the generation of sufficient viral 
RNA levels to express viral proteins and genomic RNA necessary to complete the viral 
replication cycle. 
 
The genome length increase of the CSGW_Flexi clones including the CLTR or MLTR 
should not affect viral genome packaging (Figure 3-4, panel A), but could introduce novel 
RNA secondary structures impairing proper folding of the genome and hence packaging 
into the particles, or creating more unstable viral RNAs (Kumar et al. 2001).  In addition, 
previous studies have demonstrated that these promoters reach high levels of infection in 
human cells (such as pCVR1_NLGP), suggesting that the reduced viral fitness found in 
CSGW_Flexi clones is likely related to something else (Hill et al. 2001). The 
5´MLTR_Flexi clone did not drive transcription as efficiently as the 5CLTR_Flexi clone, 
suggesting that the MLTR could require further modification/adaptation to reach the same 
transcription levels as the 5´CLTR or 5´LTR (Figure 3-6, panel B, lane 4). Reverse 
transcription could be also affected in the Flexi_3MLTR clone as well, and when both 
5´and 3´MLTRs were encoded within the same vector (5MLTR_Flexi_3MLTR), it was 
severely attenuated ~10-fold (Figure 3-6, panel B, lane 11). Restoring the 118 bp fragment 
confirmed the potential of the CLTR and MLTR as possible candidates to replace the HIV-
1 LTR, which is Tat dependent (Figure 3-6).  
 
Despite the existence of reported studies that have evaluated the ability of enhancer 
elements to replace long terminal repeats in lentiviral vectors efficiently (Lotti et al. 2002), 
the transcription driven from CLTR and MLTR had effects on titre, infectivity, and maybe 
genomic stability. We also observed a reduction in the viral titre when we placed a 
3´CLTR/MLTR into CSGW_Flexi, suggesting a defect during reverse transcription in the 
target cells (Powell et al. 2015). We could have performed reverse transcription assays to 
quantify the reverse transcription levels in our CSGW_Flexi and SYNGP clones and 
investigate the RNA species within transfected cells to determine viral transcription more 
accurately. Unfortunately, these experiments will consume much time and we decided to  
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continue our investigations with the CLTR and MLTR to achieve Tat Independence in 
human cells. 
 
However, the ability of the MLTR to drive transcription and reverse transcription could be 
restricted because unknown murine co-factors could be absent in human cells (Studamire 
et al. 2010). The RNA levels in the absence of HIV-1 regulatory proteins contributed 
negatively to gene expression (Karn et al. 2012). The mechanism of function of these 
proteins is related to transcription elongation control (Tat) and RNA stability and export 
(Rev). Tat and Rev are essential to generate HIV-1 infectious particles in vitro, remaining 
important targets for drug discovery (Balachandran et al. 2017). In summary, HIV-1 
replication fails in the absence of both regulatory proteins, which are unique for HIV. 
 
The HIV Tat protein is the main regulator of viral gene expression through control of 
elongation by RNA polymerase II, and in its absence, the polymerase engages poorly and 
disengages from the DNA template prematurely, severly affecting viral transcription (Karn 
1999). The reduction in the viral titres derived from CSGW_Flexi clones persisted even in 
the presence of Tat and Rev proteins and when the CLTR and MLTR were located at the 
5´end and 3´end simultaneously (Figure 3-6, panel B), suggesting that the lower titres were 
not related to the function of the regulatory proteins, and are likely due to defects related to 
viral gene expression or the appearance of aberrant RNA species originating from the 
codon-optimization of gag and pol genes (Knoepfel et al. 2013). Even low amounts of Gag 
processing intermediates can display a trans-dominant effect on HIV particle maturation 
(Müller et al. 2009), which are more abundant in CSGW_Flexi clones encoding chimeric 
LTRs at the 3´end (Figure 3-6, panel B, lanes 5-11). The VLPs generated were almost 
equal for all CSGW_Flexi clones, revealing that the 118 bp sequence was involved 
somehow in viral gene expression, but not in Gag maturation (Figure 3-6, panel D). In 
addition, the CLTR was not sufficient to generate efficient levels of transcription in a Tat 
independent manner, suggesting that the CLTR still needs Tat to enhance viral gene 
expression to complete the viral life cycle (Figure 3-12). We know already that the CLTR 
is able to generate sufficient transcription levels when Tat is provided in cis by NLGP 
(Figure 3-4 and Figure 3-6), but the 5CLTR_Ψ _SYNGP_IRES-GFP and 5CLTR_Ψ 
_SYNGP_IRES-GFP_3CLTR clones lack Tat in cis and they are not infectious, suggesting 
the Tat dependence of the CLTR. 
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Secondary structure studies have determined that the HIV-1 packaging signal contains 
several RNA loops (SL1 to SL4) involved in packaging the viral genome into the particles 
by Gag interactions that could be altered in the 5CLTR_Ψ _SYNGP_IRES-GFP_3CLTR 
clone (Greatorex et al. 2002). The codon-optimization of gag-pol genes contributes to the 
generation of more RNA species within human cells, but maybe the modifications made to 
reach this aim introduced novel RNA loops into the viral genome that could impair their 
packaging into the nascent particles. The compactly folded tertiary structure of viral RNA 
is essential for the viability of the virus at distinct steps along the replication cycle, such as 
reverse transcription, viral transcription or packaging (Berkhout et al. 2000). The RNA 
secondary structures are essential for the packaging of the viral genome within the viral 
particles. This aspect suggests that the absence of infectivity could be related to the 
disruption in the RNA folding in the viral genome introduced by codon optimization of 
gag-pol genes, or the higher number of CpGs in SYNGP compared to NLGP (226 to 23 
respectively), which could impair viral replication kinetics (Atkinson et al. 2014; Gaunt et 
al 2016). Our results suggest that RNA secondary structures in the 
5CLTR_SYNGP_Ψ_IRES_EGFP_3CLTR clone could be affecting the packaging of the 
viral genome into the nascent particles or affecting RNA stability along the viral life cycle 
(Watts et al. 2009; Sükösd et al. 2015). However, further investigations need to be done to 
contrast these hypothesis. 
 
Finally, the absence of Rev could be affecting full length viral RNA transport towards the 
cytoplasm, which could remain within the nucleus. Despite the codon-optimized Gag being 
efficienlty expressed and assembled into nascent viral particles, full-length viral RNAs 
need Rev and co-factors such as CRM1/exportin 1 to be exported to the cytoplasm and be 
packaged into the nascent viral particles (Taniguchi et al. 2014). The RNA stability of full-
length viral and single spliced RNAs in the absence of Rev also could contribute to their 
degradation (Blissenbach et al. 2010). 
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4.1 Results 
 
4.1.1 HIV-1 codon-optimized particles containing CSGW_Flexi clones were 
infectious in human cells when Tat, Rev or both were provided in trans 
 
Following our previous results where we achieved infectious viral particles from 
5CLTR_SYNGP_Ψ_IRES_EGFP_3CLTR construct when CSGW and DEST40-tat were 
supplied in trans (Figure 3-12), we wanted to determine the potential of the CSGW_Flexi 
clones to generate infectious particles providing Tat and Rev proteins in trans during 
transfection. We transfected the CSGW_Flexi clones together with pDEST40_tat, 
pDEST40_rev, pCMV_VSV-G and pSYNGP instead of pCVR1_NLGP. We created the 
vector DEST40_rev cloning the HIV-1 rev exon 1 and 2 together by PCR, removing the 
introns following the same overlap extension PCR strategy that we used to generate the 
DEST40_tat vector (Figure 4-1). 
 
 
 
 
 
 
 
 
The CMV_NLGP vector encodes HIV-1 tat and rev genes, and we expected to determine if 
both proteins supplied in trans could rescue viral infectivity of CSGW_Flexi clones 
cotransfected with SYNGP (Figure 3-4, panel A). Importantly, the SYNGP vector lacks Tat 
and Rev proteins, and encodes human codon-optimized HIV-1 gag-pol genes (Figure 4-2). 
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Figure 4-1. Diagram of DEST40_tat and 
DEST40_rev expression cassettes. We 
used the SfiI restriction sites to introduce 
tat and rev genes lacking introns. 
Figure 4-2. Diagram of 
CVR1_NLGP and SYNGP vectors 
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We transfected the CSGW_Flexi clones from the experiment shown in Figure 4-3 together 
with pSYNGP, pDEST40_tat, pDEST40_rev and pCMV_VSV-G into human HEK-293T 
cells. Including Tat and Rev proteins in this experiment would determine if they were able 
to generate infectious viral progeny in a Tat or Rev independent manner in human cells. 
We harvested supernatant from the transfected cells 48 hours post-transfection and 
inoculated the produced virions onto human AA-2 lymphocyte cells, which are particularly 
permissive to HIV-1 replication, to measure GFP expression and determine the viral 
infectivity/titre (Figure 4-4). 
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Figure 4-3. Diagram of CSGW_Flexi clones employed in the following experiments. The ‘X’ 
represents a deletion of a NheI site, and the ‘arrows’ indicate restriction sites employed to modify 
the 5´and 3´LTRs. We can substitute the 5’LTR using SpeI and NruI restriction enzymes, and 
also substitute the 3’LTR using KpnI and NheI enzymes. 
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Either Tat or Rev in trans supported the generation of infectious progeny from nearly all of 
the CSGW_Flexi vector-genomes (Figure 4-3).  The exceptions were the 
5CLTR_Flexi_3CLTR and 5MLTR_Flexi_3LTR clones, which were not infectious when 
only Tat was provided in trans (Figure 4-4, lanes 9 and 10), with respect to these 
observations it is impotant to note that these were amongst the most attenuated vector 
systems and reductions in titre of a similar magnitude to those obtained in other clones 
could reduce infectivity to undetectable levels. Importantly however, no infection was 
detected in the abscence of both proteins for any vector genome (Figure 4-4). Interestingly, 
the 5MLTR_Flexi titre was ∼100-fold lower (when Tat or Rev were supplied in trans) and 
∼10-fold lower when both Tat and Rev were supplied in trans than the 5CLTR_Flexi and 
CSGW titres  (Figure 4-4, lane 4). This pattern was also observed when a competent LTR 
was located at the 3´end in 5MLTR_Flexi_3LTR clone (Figure 4-4, lane 10), but this titre 
reduction was not observed for the 5CLTR_Flexi_3LTR clone (Figure 4-4, lane 8).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-4. Mean titre of CSGW_Flexi clones in AA-2 cells. The CSGW_Flexi clones were 
transfected into HEK-293T with pCVR1_NLGP (HIV gag and pol) and pCMV_VSV-G 
(envelope), and HIV regulatory proteins Tat and Rev were added in trans. The VLPs were 
collected and purified from the supernatant by centrifugation of sucrose cushions 48 h.p.t. 
and inoculated into AA-2 cells to determine the viral titre of each CSGW_Flexi clone. We 
transfected the same amount of DNA as previous experiments: [1µg of pCSGW: 1µg of 
pCVR1_NLGP:: 100ng pCMV_VSV-G] 
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Indeed, The CLTR attenuated the titre most when insterted at the 3’ end whereas the 
MLTR caused the biggest decrease in titre when inserted at the 5’ end. The 5CLTR_Flexi 
titre was ∼10-fold higher than the 5MLTR_Flexi (Figure 4-4, panel A, lanes 3 and 4), but 
the Flexi_3CLTR titre was still reduced ∼1 log compared to the Flexi_3MLTR (Figure 4-4,  
panel A, lanes 6 and 7). However, the Flexi_3LTR and Flexi_3MLTR titres were very 
similar (~ 5-fold difference Figure 4-4, panel A, lanes 5 and 7).  
 
 
4.1.2 CLTR could be better at driving transcription whereas the MLTR 
efficiently supports reverse transcription 
 
We wanted to determine the ability of CSGW_Flexi clones to produce VLPs and also if 
adding Tat and Rev during transfection could rescue viral infectivity. Moreover, we 
repeated the same experiment shown in figure 4-4 (CSGW_Flexi clones, pSYNGP, 
pCMV_VSV-G, pDEST40_tat and pDEST40_rev) and performed western blot analysis 
for cell lysates (transfected HEK-293T) and VLPs purified from the supernatant 48 hours 
post-transfection by sucorose cushion centrifugation (produced in transfected HEK-293T).  
 
The CLTR and MLTR promoters were able to generate infectious particles in most 
CSGW_Flexi clones when only Tat was provided in trans (Figure 4-5, panel A). However, 
this was not the case for 5CLTR_Flexi_3CLTR and 5MLTR_Flexi_3LTR clones, which 
were not infectious under these conditions (Figure 4-5, panel A, lanes 9 and 10). As 
mentioned above, these vectors had such a low titre in the presence of Tat and Rev that a 
reduction in viral titre of 10-20-fold would reduce the titre to below the level of detection.  
Disappointingly, although the CLTR should be able to drive transcription in the absence of 
Tat, all the CSGW_Flexi clones possesed a higher titre in the presence of Tat (when added 
in trans) (Figure 4-5, panel A). 
 
The western blot analysis (using mouse anti-p24 antibody) for CSGW_Flexi clones when 
only Tat was supplied in trans (Figure 4-5, panel A) shown no differences in Gag/CA 
expression from transfected HEK-293T, and Gag intermmediates were generated for all 
CSGW_Flexi clones (Figure 4-5, bottom panel A). The production of VLPs was similar for 
all CSGW_Flexi clones, even for the 5CLTR_Flexi_3CLTR and 5MLTR_Flexi_3LTR  
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clones that were not infectious (Figure 4-5, bottom panel A).  This was not unexpected as 
pSYNGP lacks elements that would be suspected to be influenced by Tat and Rev (Figure 
4-2). 
 
Somewhat surprisingly, all the CSGW_Flexi clones were infectious when only Rev was 
added to the transfection (Figure 4-5, panel B). The  5MLTR_Flexi titre was reduced 
∼100-fold compared to the 5CLTR_Flexi (Figure 4-5, panel B, lanes 3 and 4). However, 
the modifications at the 3´end in Flexi_3CLTR and  Flexi_3MLTR clones resulted in a 
∼10-fold titre reduction compared to CSGW and Flexi titres when only Rev was added in 
trans (Figure 4-5, panel B, lanes 6 and 7). The 5CLTR_Flexi_3LTR, 
5CLTR_Flexi_3CLTR, 5MLTR_Flexi_3LTR and 5MLTR_Flexi_3MLTR titres were 
∼100-fold reduced when only Rev was added in trans compared to CSGW and 
CSGW_Flexi (Figure 4-5, panel B, lanes 9-11).   Unsurprisingly, western blot analysis did 
not shown any differences regarding Gag/CA expression in transfected HEK-293T cells, 
and VLPs amounts collected from the supernatant were also similar between all 
CSGW_Flexi clones generated when only Rev was added in the transfection (Figure 4-5, 
bottom panel B).  The observation that all the vector genomes (CSGW_Flexi clones) were 
expressed and incorporated into nascent virions in the absence of Tat was somehow 
unexpected as without Tat the transcriptional activity of the LTR is predicted to be low. 
 
Finally, when both HIV regulatory proteins were supplied during transfection the 
CSGW_Flexi clones were infectious (Figure 4-5, panel C). However, the 
5MLTR_Flexi_3MLTR was not infectious (Figure 4-5, panel C, lane 11).  Importantly the 
infectivity of this latter vector genome examined under all Tat and Rev permutations was 
quite close to background (using flow cytometry). The 5CLTR_Flexi_3CLTR and 
5MLTR_Flexi_3LTR titres were ∼10 fold and ∼100 fold reduced respectively compared to 
wild-type CSGW and CSGW_Flexi (Figure 4-5, panel C, lanes 10 and 11). 
 
The 5MLTR_Flexi titre was ∼10 fold reduced compared to 5CLTR_Flexi, following the 
same pattern previously observed when only Tat or only Rev were transfected (Figure 4-5, 
panel C, lane 3 and 4). The western blot analysis under these conditions (Tat and Rev 
together) revealed that Gag and CA expression was similar for all CSGW_Flexi clones in 
transfected HEK-293T cells, and the VLPs production was very similar as well (Figure 4-
5, bottom panel C). Thus, no differences were observed in VLP production between  
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CSGW_Flexi clones when Tat and Rev were not transfected and none of them were 
infectious (Figure 4-5, panel D). 
 
In summary, the HIV regulatory proteins Tat and Rev were able to rescue the infectivity of 
most of CSGW_Flexi clones when supplied during transfection. However, the presence or 
absence of both proteins did not affect the amount of VLPs in all conditions produced from 
SYNGP vector. Unfortunately, no infection was observed in the absence of Tat and Rev 
and further investigations need to be done to determine the infectivity problems in 
CSGW_Flexi clones under these conditions. We could have performed RNA studies for all 
CSGW_Flexi clones (from transfected HEK-293T cells) or investigate the reverse 
transcription levels to provide new insights. Moreover, we could observe high amounts of 
p25 capsid intermediate in all western blots from cell lysates (transfected HEK-293T). The 
high expression of p25 could be related to the codon-optimized gag and pol genes encoded 
in SYNGP because the p25 expression was normal when wild type gag and pol genes were 
transfected in previous experiments using pCVR1_NLGP instead SYNGP (Figure 3-4, 
panel C). Perhaps the higher amounts of viral RNAs for gag and pol genes are contributing 
to generate more p25 intermediate compared to wild type HIV gag-pol genes. 
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Figure 4-5. Mean titre of CSGW_Flexi clones obtained from GFP reporter expression from infected 
AA-2 cells. Western blot analysis (mouse anti-p24 antibody) from CSGW_Flexi clones transfected in 
HEK-293T cells and VLPs collected from the supernatant and purified by sucrose cushion 
centrifugation 48 h.p.t. The CSGW_Flexi clones were generated by transfection using pSYNGP, 
pCMV_VSV-G and the regulatory HIV proteins Tat (pDEST40_tat) and Rev (pDEST40_rev). We 
transfected the same amount of DNA as previous experiments [1µg of CSGW_Flexi clone: 1µg of 
pSYNGP: 100ng pCMV_VSV-G: 500ng DEST40_tat and 500ng DEST40_rev]; the viral titre was 
quantified 48 h.p.i. in AA-2 cells. (A) Mean titre of CSGW_Flexi clones when only Tat was added in 
trans during transfection and VLPs production from transfected HEK-293T cells 48 h.p.t. (B) Mean 
titre of CSGW_Flexi clones when only Rev was added in trans and VLPs production from 
transfected HEK-293T cells 48 h.p.t (C) Mean titre of CSGW_Flexi clones when Tat and Rev were 
added in trans and VLPs production from transfected HEK-293T cells 48 h.p.t (D) Mean titre of 
CSGW_Flexi clones when none of HIV regulatory proteins were added in trans and VLPs production 
from transfected HEK-293T cells 48 h.p.t 
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4.1.3 The CLTR is Tat responsive 
 
Since many all of the 5CLTR-containing vectors had higher titres when produced in the 
presence of Tat, we wanted to determine the Tat responsiveness of the CLTR. We 
investigated this using the 5CLTR_SYNGP_Ψ_IRES_EGFP_3CLTR clone by measuring 
the mean  fluorescence intensity (MFI) from the GFP reporter gene (expressed under 
control of the CLTR) in transfected human HEK-293T cells. Comparing the MFI in the 
presence or absence of Tat would help us to determine the difference in transcriptional 
activity. Prior to attempting this experiment, we also cloned 4 copies of the constitutive 
transport element (CTE) preceding the 3´LTR, where they exert a similar function as Rev 
protein in the Mason-Pfizer monkey virus (MPMV) (Wodrich et al. 2000), to compensate 
for the lack of Rev function. The addition of 4CTEs will enhance viral RNA transport and 
contribute to its stability. We cloned 4CTEs into 
5CLTR_SYNGP_Ψ_IRES_EGFP_3CLTR clone at position 6603 by cleavage with SbfI, 
preceding the 3’CLTR, generating the vector called SYNGP_4CTE  (Figure 4-6). During 
the cloning process we also generated a 5CLTR_SYNGP_Ψ_IRES_EGFP_3CLTR clone 
encoding 4CTEs in the opposite orientation (SYNGP_4CTE(reverse)) (Figure 4-6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CLTR CO  gag
CO pol
CLTR
Ψ 4 CTE
IRES_GFP
CLTR CO  gag
CO pol
CLTR
Ψ
4 CTE
IRES_GFP
5CLTR_SYNGP_IRES_GFP_4CTE_3CLTR 12324 bp
5CLTR_SYNGP_IRES_GFP_4CTE(reverse)_3CLTR 12324 bp
CLTR CO  gag
CO pol
CLTR
Ψ
IRES_GFP
5CLTR_SYNGP_IRES_GFP_3CLTR 11571 bp
SbfI
SbfI
Figure 4-6. Diagram of SYNGP_4CTE clones. The orientation of the CTEs is different in 
5CLTR_SYNGP_Ψ_IRES_EGFP_4CTE_3CLTR and 5CLTR_SYNGP_Ψ_IRES_ 
EGFP_4CTE(reverse)_3CLTR. 
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These new SYNGP_4CTE clones were transfected together with pDEST40_tat and 
pCMV_VSV-G in HEK-293T cells. We also transfected the EvroGen TagRFP plasmid as 
a transfection control. Then, we determined GFP expression 48 hours post-transfection by 
flow cytometry (Figure 4-7, panel B). By using this experiment set-up we were able to 
select only the transfected cells expressing RFP and GFP, and submit them to FACS 
analysis to compare their MFI in the presence and absence of Tat (Figure 4-7, panel B). 
Crucially, TagRFP levels were very similar for all of the clones tested 
(5CLTR_SYNGP_Ψ_IRES_EGFP_4CTE_3CLTR and 5CLTR_SYNGP _Ψ_IRES_ 
EGFP_4CTE(reverse)_3CLTR clones and also the control 5CLTR_SYNGP_Ψ _IRES_ 
EGFP_CLTR) in the presence and absence of Tat (Figure 4-7, panel B (right)). This 
indicated that Tat did not globally influence transcription of transfected DNA.  In contrast, 
the GFP expression was higher when Tat was provided in trans, demonstrating the Tat 
responsivity of the CLTR encoded in SYNGP_4CTE clones (Figure 4-7, panel B). In 
addition, the highest MFI was observed in the 
5CLTR_SYNGP_Ψ_IRES_EGFP_4CTE_3CLTR clone, which encodes 4 copies of the 
CTE in the correct orientation (Figure 4-7, panel B, lane 2). However, the 
5CLTR_SYNGP_Ψ_IRES_EGFP_4CTE(reverse)_3CLTR clone MFI was very similar 
compared to the control 5CLTR_SYNGP_Ψ_IRES_EGFP_3CLTR even in the presence of 
Tat (Figure 4-7, panel B, lane 3).  
 
The observation that the CMV promoter encoded in EvroGene TagRFP vector did not 
show Tat responsiveness (Figure 4-7, panel C) was expected because the stimulation of 
viral transcription is carried out by the interaction of Tat with the Trans-acting response 
element (TAR) located in the R region from HIV-1, which is absent in pEvroGene TagRFP 
(Roy et al. 1990). 
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Figure 4-7. Mean fluorescence intensity (48 h.p.t.) in transfected HEK-293T cells with SYNGP 
clones and DEST40_tat. The envelope was provided in trans with pCMV-VSV-G as usual. We 
transfected the following amount of DNA: [1µg of each SYNGP clone : 1µg of pCSGW: 100ng 
pCMV_VSV-G: 500ng DEST40_tat]. (A) Diagram of SYNGP clones (encoding CLTRs, the 
HIV-1 packaging signal, codon-optimized HIV-1 gag-pol genes, an IRES-GFP cassette and 4 
copies of the CTE), the pCMV_VSV-G and pEvrogene-RFP (transfection control) vectors. (B) 
Mean fluorescence intensity (MFI) in transfected HEK-293T cells; RFP fluorescence was used as 
transfection control. The error bars show the standard deviation for each titre (triplicates) (C) 
Diagram of Tat responsiveness in the CLTR encoded in 5CLTR_ Ψ 
SYNGP_IRES_GFP_3CLTR. 
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4.1.4 5CLTR_ Ψ_SYNGP_IRES-GFP_4CTE_3CLTR clone was not infectious 
in the absence of Tat and Rev. However, both proteins rescued viral 
infectivity 
 
After confirming the Tat responsiveness of the CLTR encoded in SYNGP_4CTE clones 
(Figure 4-7), we wanted to investigate if they were able to package a competent genome 
(CSGW) provided in trans and become infectious. In addition, we supplied Tat and Rev 
proteins during transfection to determine if they could rescue the viral infectivity (in the 
absence or presence of CSGW). The 4CTEs from SYNGP_4CTE clones would replace 
Rev function, so we were expecting to achieve Rev independent infectious particles. We 
co-transfected pCSGW, SYNGP_4CTE clones and pCMV_VSV-G (VSV envelope) 
together with Tat, Rev or both into HEK-293T cells to produce single cycle of replication 
particles as usual.  The supernatant was harvested at 48 hours post transfection and used to 
inoculate AA-2 cells to determine the viral titre (Figure 4-10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The addition of Tat, Rev or both in trans rescued infectivity in SYNGP_4CTE clones, but 
no infection was detected in the target cells in their absence even when CSGW was 
provided (Figure 4-10, panel A). The mean titre for SYNGP_4CTE clones was similar  
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Figure 4-8. Diagram of SYNGP_4CTE 
clones, DEST40_tat and DEST40_rev 
plasmids employed in this experiment. 
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compared to the control 5CLTR_SYNGP_Ψ_IRES_EGFP_3CLTR (which lacks 4CTEs in 
cis),  when Tat and Rev were supplied together in trans. Viral infectivity was recovered 
when Tat or Rev were provided in trans, generating infectious particles in a Tat/Rev 
independent manner (Figure 4-10, panel A). However, the 
5CLTR_SYNGP_Ψ_IRES_EGFP_3CLTR  and SYNGP_4CTE titres were ∼5-fold higher 
when only Tat was supplied compared when only Rev was supplied (Figure 4-10, panel A, 
orange and red columns). The 5CLTR_SYNGP_Ψ_IRES_EGFP_3CLTR  and 
SYNGP_4CTE clones titres were ∼5-fold higher compared when only Tat or only Rev 
were provided during transfection (Figure 4-10, panel A, grey columns). The 
5CLTR_SYNGP_Ψ_IRES_EGFP_3CLTR and SYNGP_4CTE clones had similar titres 
under each condition (Figure 4-10, panel A, lanes 3-5). However, CA expression levels in 
transfected HEK-293T cells were higher in SYNGP_4CTE clones compared to 
5CLTR_SYNGP_Ψ_IRES_EGFP_3CLTR transfection, but Gag expression was very 
similar in all cases under each condition (Figure 4-10, upper panel B). The amount of 
VLPs produced from 5CLTR_SYNGP_Ψ_IRES_EGFP_3CLTR and SYNGP_4CTE 
clones correlated to more capsid expression in transfected HEK-293T when only Tat or 
both proteins were added in trans (Figure 4-10, panel B, bottom lane). The CA P25 band 
was particularly prominent  in the purified VLPs (Figure 4-10 , panel B, bottom lane), the 
precise reason for this is unclear. 
 
No infection was observed when CSGW was not provided in trans, despite the addition of 
Tat and Rev proteins (Figure 4-9). However, the SYNGP_4CTE clones were able to 
package CSGW when provided in trans in the presence of Tat an Rev, but they failed to be 
infectious in their absence. Despite the addition of 4CTEs from SYNGP_4CTE clones did 
not rescue the viral infectivity in the absence of CSGW and the regulatory proteins, 
suggesting that Tat and Rev were still essential for these viruses. When both regulatory 
proteins were added in trans together with CSGW, the viral titre reached about 105.5 log 
i.u./ml for SYNGP_4CTE clones.  
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Figure 4-9. Infectivity assay to determine the viral titre in AA-2 cells of SYNGP_4CTEs (in 
the absence of CSGW) produced by transfection into HEK-293T cells. No GFP expression 
was observed when CSGW was supplied during transfection. The DNA transfected amounts 
were [1µg of each SYNGP clone : 100ng pCMV_VSV-G: 500ng DEST40_tat: 500ng 
DEST40_rev]. (A) Diagram of SYNGP_4CTE clones used in this experiment. (B) Mean titre 
of SYNGP_4CTE clones in AA-2 cells 48 h.p.i. (SYNGP as negative control). The CSGW 
vector was not provided in trans, and no infection was detected despite the addition of Tat 
and Rev together with the SYNGP_4CTE vectors. 
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Figure 4-10. GFP reporter expression of SYNGP clones in AA-2 cells and WB analysis 
for Gag and p24 (using mouse anti-p24 antibody). The SYNGP clones were transfected 
in HEK-293T cells [1µg of each SYNGP clone: 1µg of pCSGW: 100ng pCMV_VSV-G: 
500ng DEST40_tat: 500ng DEST40_rev]. (A) Mean viral titre of SYNGP clones in AA-
2 cells 48 h.p.i. The viral titre was determined by flow cytometry measuring GFP 
expression in PM1 cells and the error bars show the standard deviation for each titre 
(triplicates). (B) Western blot analysis for Gag/p24 expression in transfected HEK-293T 
cells 48 h.p.t. (D) VLPs collected and purified by sucrose cushion centrifugation from the 
supernatant of transfected HEK-293Ts (48 h.p.t.).  
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4.2 Discussion chapter 4 
 
The 5CLTR was more efficient at driving transcription than the 5MLTR, reaching higher 
levels of infection under all conditions (adding Tat, Rev or both) (Figure 4-4). This result 
suggested that the CLTR is still Tat dependent and fails to drive transcription efficiently in 
its absence. In order to determine the ability of the CLTR to drive transcription in a Tat 
independent manner we could remove the R region of the 5´end that encodes the TAR 
loop, and investigate  the viral RNAs produced within the transfected cells. However, this 
will generate an aberrant virus unable to carry out reverse transcription and subsequenlty 
be unable to complete the viral replication cycle (Berkhout et al. 2001; Kleiman et al. 
2002). This fact highlights the limitations of studying viral transcription in the absence of 
Tat protein, which could be also involved in another functions not related to viral 
transcription. 
 
The viral titre was severely affected when the 5´and 3´ends in CSGW_Flexi clones were 
modified CLTRs or MLTRs (Figure 4-4 and 4-5). The CLTR supported transcription when 
it was located in the 5´end, but other aspects, most likely reverse transcription were 
affected in the Flexi_3CLTR clone compared to Flexi_3LTR, Flexi_3MLTR and the 
controls (CSGW and CSGW_Flexi) when only Tat was added in trans (Figure 4-4, panel 
B, lane 6). Perhaps the CLTR requires more time to complete reverse transcription than the 
wild type HIV-1 LTR. In addtition, the titre was decreased ∼1 log when the CLTR or 
MLTR were located at the 3´end under each conditions (none, Tat, Rev or both) (Figure 4-
4, lane 6 and 7). These results suggested that non-transcriptional aspects of the LTR such 
as reverse transcription could be affected in Flexi_3CLTR, Flexi_3MLTR clones. Because 
the CSGW_Flexi_3´LTR clone did not shown this pattern and its titre was similar 
compared to CSGW and CSGW_Flexi controls (Figure 4-4, lanes 5-7). This suggests that 
the CLTR and MLTR constructs support reverse transcription less efficiently than the wild 
type HIV-1 LTR, but are still able to generate infectious viruses. The MLTR chimeric 
promoter was designed for the murine host, and we only developed this experiment in 
human cells, perhaps explaining why the MLTR is not as efficient as the HIV-1 LTR is 
driving transcription and reverse transcription. Introducing the CLTR and MLTR probably 
altered RNA secondary structures in the wild type LTR, which could have affected reverse 
transcription in 5CLTR_Flexi and 5MLTR_Flexi clones (Figure 4-4). Our evidence 
demonstrated that viral RNA are able to express Gag and p24 successfully in transfected 
HEK-293T and generating VLPs.  
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However, the VLPs could lack thr viral genome, so we could have performed RNA 
extractions from transfected cells to investigate the differences between RNA species for 
each CSGW_Flexi and SYNGP clones. Thus, we could have also investigated the RNA 
content within the VLPs to detect if the viral genome is able to be packaged into nascent 
particles or perhaps can not interact with the packaging signal. Several experiments were 
performed to investigate the RNA content in VLPs by qPCR, but none of the results were 
conclusive and are not included in this thesis. Moreover, other investigations have 
determined the essential role of the HIV-1 RNA folding, encoding highly variable regions 
but also high conserved structures with unknown functions (Wilkinson et al. 2008; 
Westerhout et al. 2005).  
 
Gag expression was similar for all conditions for CSGW_Flexi vector genomes when Tat 
or Rev were transfected in trans (Figure 4-4, panels A, B, C and D). However, we obtained 
similar levels of Gag for CSGW_Flexi clones when the regulatory proteins were not 
provided in trans (Figure 4-5, bottom panel D). The western blot analysis for Gag/CA 
expression demonstrated that the infectivity problems in CSGW_Flexi clones were not 
related to Gag protein expression or its processivity within the transfected HEK-293T cells 
(Figure 4-4). VLPs produced from CSGW_Flexi vector genomes and SYNGP vector were 
very similar under all conditions, even when Tat and Rev proteins were not provided in 
trans (Figure 4-4, panel D).  
 
However, the presence of the CLTR or MLTR in the 5’end should be able to drive viral 
transcription in CSGW_Flexi clones, as the enhancers in the CMV promoter are widely 
regarded to be relatively efficient at driving transcription. No evidence was observed to 
suggest issues with VLP formation for SYNGP_4CTE clones, but they could lack the viral 
genome or could be aberrant in some other way (Lu et al. 2011). Moreover, we detected 
some p25 intermediate protein in western blot analysis of VLPs from all SYNGP clones 
(Figure 4-10, panel B). We could have investigated if the generated VLPs had a proper 
morphology because is not possible to determine this feature by western blot analysis, so 
we could have prepared some purified VLPs for each CSGW_Flexi and SYNGP clones to 
submitt to electron mycroscopy and approach this hypothesis. Thus, to elucidate the likely 
problems with full-length RNA packaging/production we need to investigate the RNA 
production within transfected cells by RNA extraction and subsequently northern blot 
analysis.  
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Notably, when CSGW was provided in trans, Gag expression from SYNGP_4CTE clones 
was capable of supporting a functional single round of infection when Tat  or Rev were 
provided in trans together with CSGW vector (Figure 4-10).  This result suggests that 
transcription levels and viral RNA export were not sufficient to complete the first cycle of 
replication in SYNGP_4CTE clones in the absence of the regulatory proteins and CSGW 
vector (Figure 4-10, panel A, lanes 2-4). The SYNGP_4CTE clones in the context of a 
viral genome can be expressed at appropriate levels and package a competent genome.  
Indeed adding Rev alone did not increase the abundance of nascent VLPs (Figure 4-10, 
panel B) suggesting that the Rev dependecy of this system could be as much to do with the 
dependency of CSGW on Rev as a requirement for Rev to support the expression of Gag 
and subsequent VLP assembly.  Perhaps the modifications introduced by introducing the 
CLTR and MLTR into CSGW_Flexi clones are affecting the viral RNA secondary 
structure, which is required to interact with the Gag protein to package the viral genome 
into the nascent particles (Amarasinghe et al. 2001). Alternatively, the viral genome is 
generated within the transfected cell, but it could be unable to be packaged within the 
nascent viral particles (Mailler et al. 2016). 
 
The addition of 4CTEs into 5CLTR_SYNGP_Ψ_IRES_EGFP_3CLTR clone 
(SYNGP_4CTE) could have contributed to the viral RNA export to the cytoplasm, and 
their orientation seems relevant somehow (Figure 4-7, panel B, lane 2 and 3). In addition, 
the mean fluorescence intensity observed in transfected HEK-293T cells with 
5CLTR_SYNGP_Ψ_IRES_EGFP_3CLTR and SYNGP_4CTE clones was similar in 
SYNGP_4CTE clone in the absence of Tat compared to SYNGP_4CTE(reverse) clone 
with Tat in trans (Figure 4-7, panel B), suggesting that the absence of 4CTEs in cis could 
attenuate viral transcription somehow, perhaps because viral RNAs could remain inside the 
nucleus and not be exported to the cytoplasm (Cmarko et al. 2002).  However, no infection 
was detected from VLPs generated from SYNGP_4CTE clones in the absence of CSGW 
vector and the regulatory proteins (Figure 4-10, panel B), but the addition of CSGW, Tat 
and Rev rescued the viral infectivity of SYNGP_4CTE viruses (Figure 4-10).  These 
results suggest that maybe the 4CTEs are unable to interact with the viral RNAs and export 
them to the cytoplasm, and viral transcripts remain stuck inside the nucleus (Rizvi et al. 
1997). To investigate if the viral RNAs could remain in the nucleus we could have done 
RNA extractions from transfected cells with SYNGP clones (with 4CTEs) and compare 
the amounts of full-length genomes produced (northern blot) or include a fluorescent dye  
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in viral RNAs to detect the amount of RNA that remain in the nucleus compared to the 
cytoplasm in transfected cells. The SYNGP_4CTE clones still defective at some step 
following viral integration, despite the higher MFI detected in transfected HEK-293T cells 
shown in Figure 4-7, panel B. We could detect high levels of GFP expression after 
integration using SYNGP_4CTE clones, but they are defective afterwards because they are 
unable to generate infectious viruses. Our evidence demonstrated that Gag is efficiently 
expressed in SYNGP_4CTE clones, and capable producing VLPs, suggesting that viral 
transcription is not affected and the problems could be likely related to RNA 
stability/transport (Zhou et al. 2005). 
 
To really understand the major problem in SYNGP_4CTE clones we will need to 
investigate each step along the viral life cycle, such as viral RNA production or the 
packaging of the viral genome into the nascent particles, which will take much intensive 
research not possible in this PhD due to time constraints. The aim of this project was to 
achieve a Tat and Rev independent HIV-1. At this point we had two possibilites: determine 
the causes that impair viral replication within human cells in SYNGP_4CTE clones, or 
proceed with development of another single cycle of replication virus using CSGW vector 
as template instead of SYNGP. 
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5.1 Results 
 
5.1.1 CSGW containing 4 copies of the Constitutive Transport Element (CTE) 
is able to generate infectious particles in a Tat-Rev independent manner in 
human cells 
 
SYNGP_4CTE clones failed to generate infectious viral progeny in a Tat and Rev 
independent manner, and both proteins were always required for the viability of these 
viruses (Figure 4-10). There are several studies showing the ability of constitutive transport 
elements encoded in lentiviral vectors that increase the viral titre, contributing to the export 
and stability of the viral RNA (Nasioulas et al. 1994). These studies demonstrate that the 
absence of infectivity from SYNGP_4CTE could be related to viral RNA transport. We 
suspected that viral RNAs were not produced efficiently in the absence of Tat from 
SYNGP_4CTE clones, so we transferred the 4CTEs into CSGW to investigate whether 
they could generate infectious Rev independent particles as the parental vector SYNGP did 
before (Figure 5-1). The 4CTEs were cloned into CSGW using the natural restriction site 
SbfI at position 9030, immediately after the GFP gene and preceding the 3´ΔU3 LTR 
(Figure 5-1). 
 
 
 
 
 
 
 
 
 
We expected to rescue Rev function in human cells by adding the 4CTEs into CSGW. The 
Tat and Rev ´independence´ was achieved by CSGW_4CTE construct, (which encodes a 
Tat dependent LTR) (Figure 5-2) when HEK-293Ts were transfected using 
pCSGW_4CTE, pSYNGP and pCMV_VSV-G. Following this promising result, we 
wanted to determine whether the CSGW_4CTE clone was able to infect murine cells. In 
order to carry out this experiment we used murine macrophages RAW 264.7 as target cells, 
which will be infected with our pseudotyped CSGW_4CTE virus (Figure 5-3).  
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Figure 5-1. Diagram of CSGW and CSGW encoding 4 copies of the 
CTE from Mason-Pfzer monkey virus (CSGW_4CTE) 
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Unfortunately, the CSGW_4CTE clone was unable to generate the same level of infection 
in RAW cells compared to higly permissive human AA-2 cells, but some infected cells 
were detected (Figure 5-3). The CSGW_4CTE construct was transfected together with 
pSYNGP, pCMV_VSV-G, pDEST40_tat and pDEST40_rev in HEK-293T cells to 
produce viral particles as usual (Figure 5-4, panel A). Surprisingly, the CSGW_4CTE 
construct generated infectious viruses in a Tat and Rev independent manner (Figure 5-4, 
panel B). The CSGW_4CTE clone was also infectious when Tat, Rev or both together 
were supplied in trans (Figure 5-4, panel B).  The CSGW_4CTE titre in the absence of the 
HIV-1 regulatory proteins was similar compared to the titre when only Rev was added in 
trans (Figure 5-4, panel B, white and red columns). However, the mean titre from 
CSGW_4CTE was slightly reduced for each condition compared to the control CSGW 
(Figure 5-4, panel B, lane 1 and 2). The CSGW_4CTE titre did not increase when Rev was 
added in trans despite the presence of 4 copies of the CTE in cis (Figure 5-4, panel B). No 
differences were observed in Gag/CA expression in transfected HEK-293Ts, or in the 
VLPs collected from the supernatant between CSGW_4CTE and CSGW_4CTE_3LTR 
(Figure 5-4, bottom panel B). We wanted to generate a replication competent entity by 
replacing the ΔU3 region (located at the 3’end in CSGW_4CTE vector) for a wild type U3 
region. The 5’LTR needs to be functional after reverse transcription, and the wild type 
LTRs located at both ends of the vector genome CSGW_4CTE provide us a more realistic 
model to work with at the CL2 lab. This modification could also produce a higher viral 
titre during the first cycle of replication (Figure 5-2).  
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Figure 5-2. Diagram of CSGW_4CTE and CSGW_4CTE encoding a 
competent HIV-1 LTR (CSGW_4CTE_3LTR) 
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Figure 5-3. Murine RAW 264.7 cells infected with CSGW_4CTE viruses produced
in HEK-293Ts. Cells were incubated for 72 hours after the inoculation.
10x10x
 
The addition of a competent LTR at the 3’end of CSGW_4CTE did not increase viral titre 
under all conditions, resulting in a very similar titre compared to the CSGW_4CTE 
containing a 3´ΔU3 LTR (CSGW_4CTE)(Figure 5-4, panel C). The CSGW_4CTE_3LTR 
was also able to generate infectious viral particles in a Tat and Rev independent manner, 
similar to the CSGW_4CTE (Figure 5-4, panel C). The addition of the HIV-1 regulatory 
proteins (in trans) did not increase Gag or CA expression, and Gag intermediates were 
observed for all conditions in CSGW_4CTE and CSGW_4CTE_3LTR clones (Figure 5-4, 
panel B and C).  
 
 
 
 
 
 
 
 
 
 
 
These results demonstrated the ability of the CTE to rescue the infectivity in CSGW_4CTE 
and CSGW_4CTE_3LTR clones by replacing Rev function and supporting the viral RNA 
export and stability within human cells (Figure 5-4, panel B and C). We also demonstrated 
that pseudotyped HIV-1 particles generated using CSGW including 4 copies of the CTE in 
cis (CSGW_4CTE) contributed to the generation of a Tat and Rev independent viruses 
(Figure 5-4, panel B). These results were the first evidence that supported the development 
of an HIV-1 Tat and Rev independent clone, which seems to be achievable despite the 
previous negative results obtained in this thesis. However, these experiments were 
performed in human cells only (HEK-293T and AA-2), and more investigation needs to be 
done prior to attempting to reproduce the same results in murine cells. Importantly, the 
lack of the HIV-1 regulatory proteins severely attenuates the ability of CSGW_4CTE to 
replicate efficiently in their absence, and would have to be much fitter before we could 
attempt to reproduce the same result in murine cells. 
 
 
 
Figure 5-3. Murine RAW 264.7 cells infected with CSGW_4CTE viruses produced 
in HEK-293Ts. Cells were incubated for 72 hours after the inoculation. 
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Figure 5-4. Experiment to determine the ability of CSGW_4CTE and CSGW_4CTE_3LTR to 
generate infectious VLPs in human cells by transfection. We also determined the viral titre infecting 
human AA-2 afterwards. The amount of transfected DNA was 1µg of 
CSGW_4CTE/CSGW_4CTE_3LTR, 1µg of pSYNGP, 100ng of pCMV_VSV-G, 500ng of 
DEST40_tat and 500ng of DEST40_rev. (A) pCSGW clones including 4 copies of the CTE. HIV-1 
Codon-optimized gag-pol genes were provided by pSYNGP and the envelope by pCMV-VSV-G. (B) 
Mean titre of CSGW_4CTE clones in AA-2 cells. The error bars show the standard deviation for each 
titre (triplicates). DEST40_tat and DEST40_rev were added in trans (orange and red bars 
respectively); Western blot for CSGW_4CTE (using mouse anti-p24 antibody) from transfected 
HEK-293T and viral particle production (VLPs) collected and purified from the supernatant by 
sucrose cushion centrifugation 48 hours post transfection (bottom panel B). (C) Mean titre of 
CSGW_4CTE encoding a competent LTR at the 3´end (CSGW_4CTE_3LTR) in AA-2 cells; western 
blot for CSGW_4CTE_3LTR (using mouse anti-p24 antibody) from transfected HEK-293T and 
VLPs collected and purified from the supernatant by sucrose cushion centrifugation 48 hours post 
transfection (bottom panel C). Molecular weight is shown in kDa.  
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5.1.2 CSGW_4CTE clones encoding codon-optimized gag-pol HIV-1 genes in 
cis efficiently generated Gag, but VLPs produced were not infectious 
 
The successful generation of single cycle of replication HIV-1 particles through co-
transfecting  CSGW_4CTE (together with SYNGP and VSV-G in trans) suggested that the 
generation of independent HIV-1 Tat and Rev particles could be achieved with HIV-1 gag-
pol genes provided in cis. As we had already developed the CSGW_4CTE construct that 
lacks the HIV-1 gag-pol genes in cis, and we needed to provide in trans using SYNGP 
during transfection. We transferred the human codon-optimized gag-pol genes from 
SYNGP using NdeI and NotI sites encoded in CSGW_4CTE_3LTR (Figure 2-1) to 
generate the vector genome CSGW_GP_4CTE_3LTR, which encodes the gag-pol genes 
after the SFFV promoter  (Figure -5-5). 
 
 
 
 
 
 
Introducing HIV-1 gag and pol genes (4307 bp) into CSGW_4CTE considerably increased 
the size of the vector (exceeding 15kb), but there are studies showing that viral titre is not 
affected even when the proviral length is larger than 18 kb (Yacoub et al. 2007). Previous 
results demonstrated the ability of CSGW_4CTE to generate infectious particles in a Tat 
and Rev independent manner, so we expected to obtain infectious Tat and Rev independent 
particles again using the Flexi_GP_4CTE_3LTR construct (Figure 5-5). We created 
additional Flexi_GP clones encoding CLTRs and MLTRs at both ends of the genome using 
the same strategy that we used to generate the CSGW_Flexi clones (Figure 5-6, panel A). 
We co-transfected the Flexi_GP clones together with pCMV_VSV-G into human HEK-
293T cells to produce viral particles that were inoculated onto AA-2 cells. The codon-
optimized gag-pol genes will be provided by these clones (in cis). 
 
 
 
Figure 5-5. Diagram of CSGW_4CTE_3LTR encoding HIV-1 codon-optimized gag-pol 
genes (Flexi_GP_4CTE_3LTR) 
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Figure X. A) Diagram of the CSGW_Flexi_GP clones encoding the HIV-1 gag-pol codon-optimized
genes from pSYNGP, the CLTR/MLTR and 4 copies of the CTE. B) Average titre of Flexi_GP clones
in AA-2 cells. None of them were infectious despite the addition of Tat and Rev in trans during
transfection. C) Western Blot for Gag/CA in transfected HEK-293Ts and VLPs collected from the
supernatant.
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The CSGW_GP_4CTE_3LTR clone was unable to generate Tat and Rev independent 
particles, but Gag/CA expression was similar compared to CSGW_4CTE positive control 
(Figure 5-6, panel B and C). The 5CLTR_Flexi_GP_4CTE_3CLTR and 
5MLTR_Flexi_GP_4CTE_3MLTR clones were not infectious in the absence of regulatory 
proteins, and Gag/CA expression was similar compared to Flexi_GP_4CTE_3LTR and 
CSGW_4CTE control (Figure 5-6, panel B and C). Even the addition of Tat and Rev in 
trans did not rescue the infectivity for Flexi_GP_4CTE_3LTR, 
5CLTR_Flexi_4CTE_GP_3CLTR and 5MLTR_Flexi_4CTE_GP_3MLTR clones (Figure 
5-6, panel B). Western blots determined that Gag production (p55) was similar for all 
clones under all conditions, except for the 5MLTR_Flexi_4CTE_GP_3MLTR clone, 
which produced less pelletable CA protein compared to Flexi_GP_4CTE_3LTR and 
5CLTR_Flexi_4CTE_GP_3CLTR constructs (Figure 5-6, panel C). Gag intermediates 
were observed in Flexi_GP_4CTE_3LTR, 5CLTR_Flexi_4CTE_GP_3CLTR and 
5MLTR_Flexi_4CTE_GP_3MLTR transfected cells, but the 
5CLTR_Flexi_4CTE_GP_3CLTR and CSGW_4CTE produced more CA within 
transfected cells than the other constructs (Figure 5-6, panel C). Transferring the HIV-1 
codon-optimized gag-pol genes into CSGW_4CTE resulted in no detectable infectious 
progeny (Figure 5-6). We only provided a viral envelope in trans (using pCMV_VSV-G as 
usual), but the gag-pol genes were not supplied in trans for this experiment. However,  the 
CSGW_GP_4CTE_3LTR construct was not infectious despite the addition of Tat and Rev 
proteins in trans (Figure 5-6, panel B). 
 
The CSGW_4CTE construct generated infectious particles in the absence of Tat and Rev 
when HIV-1 gag-pol genes were provided in trans by SYNGP (Figure 5-4), but including 
the gag and pol genes in cis into CSGW_4CTE_3LTR clone (CSGW_GP_4CTE_3LTR) 
totally abolished viral replication (Figure 5-6). The CSGW_GP_4CTE_3LTR construct 
was able to generate viral particles, but they were not infectious despite the successful 
generation of Gag within transfected cells, and CA from the VLPs collected from the 
supernatant (Figure 5-6, panel C). The high CpG content in codon-optimized gag-pol 
genes from SYNGP compared to wt gag-pol genes (227 to 24 respectively) could have 
disrupted the viral RNA secondary structures essential for the viability of CSGW_4CTE 
construct, so we decided to re-design these genes to reduce the CpG content and 
investigate if we could rescue viral infectivity. However, we did not measure transfection 
levels directly in AA-2 cells from Flexi_GP_4CTE clones, but the GFP expression 
detected in transfected HEK-293Ts were  
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similar compared to CSGW_4CTE (control). Perhaps the AA-2 cells could generate 
infectious VLPs when transfected, so we could attempt this experiment and determine the 
differences between transfected HEK-293Ts and AA-2 for p55 and VLPs production in 
cell lysates and from the supernatant and maybe reveal new insights. 
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 Figure 5-6. Experiment to determine the ability of Flexi_GP_4CTE clones to generate infectious VLPs in human cells by transfection. These clones were not infectious in AA-2 cells even in the 
presence of HIV regulatory proteins Tat and Rev. The amount of transfected DNA was 1µg for each 
Flexi_GP_4CTE clone, 100ng of pCMV_VSV-G, 500ng of DEST40_tat and 500ng of 
DEST40_rev. (A) Diagram of the Flexi_GP_4CTE clones encoding the HIV-1 gag-pol codon-
optimized genes from pSYNGP, the HIV-1 LTR, CLTR or MLTR and 4 copies of the CTE. (B) 
Mean titre of Flexi_GP clones in AA-2 cells. None of them were infectious despite the addition of 
Tat and Rev in trans during transfection. (C) Western blot for Flexi_GP_4CTE clones (using mouse 
anti-p24 antibody) from transfected HEK-293T and viral particle production (VLPs) collected and 
purified from the supernatant by sucrose cushion centrifugation 48 hours post transfection (bottom 
panel C). Molecular weight is shown in kDa.  
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5.1.3 Codon-optimized HIV-1 gag-pol with reduced number of CpGs was 
unable to generate HIV-1 particles 
 
The huge difference in the CpG content in codon-optimized gag-pol genes from SYNGP 
compared to wild type gag-pol genes from CMV_NLGP (227 to 24 respectively) could be 
the major problem affecting the viability of our SYNGP_4CTE and Flexi_4CTE_GP 
clones. Higher CpG content is related to pathogenicity and replication attenuation in RNA 
viruses (Atkinson et al. 2014; Gaunt et al. 2016). In order to reduce the number of CpGs 
within the human codon-optimized HIV-1 gag-pol genes from SYNGP, we re-designed 
these genes to encode fewer CpGs. This modification severely reduced the CpG content 
from 227 to 24, preserving the same amino acid sequence and the slippery sequence at the 
end of gag (1222-1503 position starting from gag ATG), which is essential to produce the 
required ratio of the Gag and Gag-Pol polyproteins (Biswas et al. 2004). The HIV-1 
slippery sequence is a well conserved sequence involved in the ribosomal frameshift, 
essential for viral replication (Mathew et al. 2015). The amino acid sequence remains the 
same in the new genes called WV_gag-pol, (which was synthesized by Genewiz Company 
into pUC57- Amp vector). We cloned the WV_gag-pol genes into Flexi_GP_4CTE using 
NdeI and NotI to introduce them downstream of the SSFV promoter (Figure 5-7). 
 
 
 
 
Perhaps by reducing the CpG content from HIV-1 codon-optimised gag-pol genes to 
achieve the same number of CpG as NGLP gag-pol genes could restore the infectivity for 
CSGW_GP_4CTE_3LTR construct. 
We transfected the Flexi_WV-GP_4CTE construct together with pCMV_VSV-G into 
HEK-293T cells, but we also wanted to determine the ability of this construct to package a 
competent genome in trans, such as CSGW, so we included this vector in the experiment 
as well (Figure 5-8). In addition, we provided DEST40_tat to compare how the Flexi_WV- 
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Figure 5-7. Diagram of CSGW_4CTE encoding HIV-1 codon-optimized gag-pol genes with 
reduced CpG number (Flexi_WV-GP_4CTE) 
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GP_4CTE expressed Gag under different conditions. The number of transfected cells was 
lower using Flexi_WV-GP_4CTE construct compared to SYNGP control (Figure 5-8, 
panel B). The Gag expression from CSGW_4CTE encoding WV_gag-pol genes 
(CSGW_WV-GP_4CTE) was very poor compared to Gag produced in pSYNGP 
transfected HEK-293T cells (Figure 5-8, panel C). The addition of CSGW in trans did not 
affect Gag expression, but including Tat in trans together with CSGW resulted in a slight 
increase in p55-Gag expression, but no difference was observed in CA expression (Figure 
5-8, panel C). No VLPs were generated from CSGW_4CTE_WV_GP construct, and 
subsequently no infection was detected in AA-2 cells , despite the addition of Tat and 
CSGW in trans (Figure 5-8, panel D). We did not attempt to provide codon-optimized 
gag-pol genes from SYNGP (in trans) together with CSGW_4CTE_WV_GP. Despite the 
barely expression from WV_GP, perhaps we could rescue Gag expression co-transfecting 
SYNGP with CSGW_4CTE_WV_GP, but this would not solve the additional problems 
that we likely introduced by reducing the CG content. 
 
These results suggest that the modifications introduced in gag-pol genes severely affected 
Gag expression. Reducing the CG number in HIV-1 gag-pol genes did not solve the 
infectivity problem when these genes were located in cis into CSGW_4CTE 
(CSGW_GP_4CTE_3LTR), and maybe introduced additional issues that abolished VLPs 
production (Figure 5-8, panel C). 
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Figure 5-8. Experiment to determine the effect reduced CpG number in codon-optimized HIV-1 
gag and pol genes by using WV_gag-pol (22CpGs) instead SYNGP (227 CpGs). We transfected 
HEK-293T cells with 1µg of pCSGW, 1µg of pSYNGP/pFlexi_WV_GP_4CTE, 100ng of 
pCMV_VSV-G and 500ng of DEST40_tat. The produced VLPs were collected and purified by 
sucrose cushion centrifugation 48 h.p.t. and inoculated into AA-2 cells to determine the viral titre. 
(A) Table of CpG content from HIV-1 gag-pol genes, HIV-1 codon-optimized gag-pol genes and 
HIV-1 codon-optimized gag-pol genes with reduced CpG number. (B) GFP expression from 
transfected HEK-293T cells. The GFP expression was lower in Flexi_WV_GP_4CTE compared 
to SYNGP (control). Thus, the percentage of transfection was also reduced for 
Flexi_WV_GP_4CTE. (C) Western blot analysis of Flexi_WV_GP_4CTE clone (using mouse 
anti-p24 antibody) from transfected HEK-293T and viral particle production (VLPs) collected 
and purified from the supernatant by sucrose cushion centrifugation 48 hours post transfection 
(bottom panel C). Molecular weight is shown in kDa.  (D) Mean titre (48 h.p.i.) of VLPs 
collected from the supernatant 48 h.p.t. The Flexi_WV_GP_4CTE clone was not infectious 
despite the addition of Tat in trans during transfection.  
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5.2 Discussion chapter 5 
 
We succesfully generated infectious particles using the CSGW_4CTE construct (when 
pSYNGP and pCMV_VSV-G were provided in trans) in a Tat and Rev independent 
manner from HEK-293T cells (Figure 5-4). When we tried to infect murine macrophages 
(RAW) with these viruses, which were generated in human cells, we only observed a few 
infected cells 72 hours post-infection (Figure 5-3). We have used the VSV envelope 
instead HIV-1 envelope in all experiments due to its ability to enhance viral infectivity and 
also to avoid incoming issues (Aiken 1997). Firstly we need to develop an HIV-1 clone 
able to replicate in murine cells before we replace the VSV envelope in our experiments. 
Thus, there are reports suggesting that pseudotyped HIV-1 particles using VSV-G protein 
enhace viral infectivity (Bartz et al. 1997; Aiken 1997), so we can totally focus in viral 
replication at this point. This enhanced viral infectivity by VSV envelope usage could 
explain why we saw a lower number of murine cells infected with CSGW_4CTE vector in 
the absence of Tat and Rev (produced in human HEK-293T cells by transfection adding 
pSYNGP and pCMV_VSV-G in trans), suggesting that even replacing Rev function by 4 
copies of the CTE is not sufficient to rescue the infectivity within murine cells (Figure 5-
3). 
 
There are reports showing that increasing the length of lentiviral vectors could severely 
affect packaging and subsequently the viral titre (Kumar et al. 2001). However, the length 
of Flexi_GP_4CTE clones should not impair viral replication, and the viral RNA genome 
of Flexi_GP_4CTE clones should be able to be packaged as CSGW_4CTE does. 
Surprisingly, the addition of Tat and Rev proteins in trans did not rescue viral infectivity 
from CSGW_GP_4CTE_3LTR, 5CLTR_CSGW_GP_4CTE_3CLTR and 
5MLTR_CSGW_GP_4CTE_3MLTR, suggesting that the viral genome must be unable to 
interact with HIV-1 regulatory proteins due to an aberrant RNA folding, impairing vital 
interactions along the viral replication cycle, such as Gag with full length genomes, or 
highly conserved regions in viral RNA could be also affected by introducing the gag-pol 
genes into Flexi_GP_4CTE clones (Le et al. 1990: Watts et al. 2009). In addition, reducing 
the CG content from HIV-1 codon-optimized genes could have affected RNA stability or 
folding, generating novel RNA secondary structures that impair viral replication. We 
unintentionally introduced more unknowns by reducing the CPG content in the codon-
optimized gag-pol genes. 
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This hypothesis could explain why the addition of Rev protein did not rescue the viral 
infectivity in Flexi_GP-4CTE clones (Figure 5-6). HIV-1 Rev protein interacts with the 
Rev Response Element (RRE) located within the env gene of full-length viral genomes, 
which are exported to the cytoplasm to be packaged into the nascent particles (Ping et al. 
1997). The Flexi_GP-4CTE vector encodes the RRE outside the env gene near the 3’end 
(its natural position), but the ability of wild-type CSGW to produce infectious viruses 
when SYNGP/CVR1_NLGP and CMV_VSV-G are provided during transfection supports 
the idea that the position of the RRE is not essential for RNA transport or stability. Thus, 
the RRE from CSGW_4CTE clone is not located at the 3’end, and previous experiments 
demonstrated the ability of CSGW_4CTE to generate infectious viral particles in the 
absence of Tat and Rev (Figure 5-4). Perhaps the position of the RRE in Flexi_GP_4CTE 
clones is affecting viral RNA transport and stability somehow, but we do not have further 
evidence to prove this hypothesis. However, we could transfer the RRE into its correct 
position (at the end of 3’ transcripts) and repeat the same experiments to determine if this 
modification rescues viral infectivity. The viral RNA folding is essential for Rev-RRE 
interaction, likely non-existent in our Flexi_GP_4CTE clones, suggesting the likely 
generation of aberrant viral RNAs within the host cell (Sherpa et al. 2015). There is 
evidence suggesting that viral non-coding RNAs (ncRNAs) are relevant epigenetic 
modulators for viral transcription, which could be absent or aberrant in Flexi_GP_4CTE 
clones (Saayman et al. 2014). The higher number of CpGs present in gag-pol genes from 
SYNGP compared to wild typ HIV-1 gag-pol genes (226-23 respectively) could also 
impede the generation of non-infectious particles, inhibiting transcription by RNA 
methylation (Bednarik et al. 1990; Blazkova et al. 2009). There is evidence to support CG 
dinucleotide suppression enabling antiviral defence targeting non-self RNA, which could 
be affecting our CSGW_GP_4CTE constructs (Takata et al. 2017). In addition, the usage 
of VSV envelope to generate the Flexi_GP_4CTE viruses instead using HIV-1 envelope 
could also affect the generation of viral transcripts within the host cell, impairing viral 
replication (Ran et al. 2017). 
The potential of CSGW_4CTE construct represents the best achievement we obtained at 
this point, generating infectious particles in a Tat and Rev independent manner. The 
CSGW_4CTE is a great candidate to develop an HIV-1 clone able to replicate in mice, but 
we need to investigate how this clone overcomes the absence of the regulatory proteins. 
We could have performed RNA extractions from transfected HEK-293T with 
CSGW_4CTE clone to investigate the RNA expression levels compared to wild-type 
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CSGW and also in VLPs by qPCR assays. Moreover, we tried several qPCR assays to 
investigate this hypothesis but the presence of background in all samples including the 
negative control discarded these results and still not clear yet if the 4CTEs encoded in 
CSGW_4CTE is subtituting Rev efficiently as we suggest with our previous results in this 
chapter. 
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6.1 Results 
 
6.1.1 NHGΔtat mutants do not express Tat in TZM-bl cells 
 
The development of an HIV-1 Tat and Rev independent clone has been a challenging aim, 
as illustrated by the efforts defended in this thesis to achieve this independence. However, 
the CSGW_4CTE clone successfully generated infectious Tat and Rev independent HIV-1 
particles (Figure 5-4), but this infectivity disappeared when gag-pol genes were included in 
cis within the CSGW_4CTE vector (Figure 5-6). These data provided hints about the 
possibility of the generation of an HIV-1 Tat and Rev independent clone, but we still need 
a better system to investigate the viral features. We decided to transfer our results obtained 
from the CL2 lab (single cycle of replication viruses) into replication competent vectors 
available in our lab, which represent a more realistic model to study HIV-1. The CL3 
facilities in the CVR allowed us to work with replication competent viruses within a safe 
environment. We decided to use the NHG vector, an HIV-1 replication competent genome 
encoding GFP in place of nef, which will allow us to determine the viral titre or degree of 
infectivity in infected cultures (Figure 6-1). 
 
 
 
 
 
 
In order to introduce the CLTR and MLTR chimeric promoters into NHG it was necessary 
to generate additional restriction sites preceding the 3’LTR. The replication competent 
vector NHG vector contains both wild type HIV-1 LTRs at the 5’ and 3’ ends (Figure 6-1).  
We only need to modify the 3’LTR here, because after the first cycle of replication the U3 
region from the 3’LTR will be copied at the 5’LTR, replacing the previous 5’U3 region by 
the 3’U3 region due to reverse transcription mechanism (Figure 1-5). This feature avoids 
to modify both LTRs to introduce our chimeric promoters CLTR and MLTR, so we only 
modified the 3’LTR, which will be located at both ends of the genome after the first cycle 
of replication. In summary, we only modified the 3’ LTR in NHG because it will be 
transferred to the 5’end after reverse transcription in subsequent cycles of replication.  
 
 Figure 6-1. Diagram of NHG vector, encoding an HIV-1 replication competent genome. The 
pNHG encodes a GFP reporter instead nef. 
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Firstly, we introduced a polylinker encoding NotI and XhoI restriction sites at position 
9568 (immediately before the 3’LTR). To determine the viability of the CLTR and MLTR,  
we generated mutations in the tat gene to abrogate its function and test if these chimeric 
promoters were able to carry out transcription and reverse transcription along several 
cycles of infection. We performed two kinds of mutations in the first exon of tat because 
the second exon overlaps with env. (Figure 6-2, panel A). The tat-F mutation is a 
frameshift modification along the first exon, the start codon was removed as well and we 
also introduced several stop codons (Figure 6-2, panel B). The tat-D mutation is a deletion 
of 43 nucleotides to severely impede reversion events, which could restore Tat expression 
after several cycles of replication in the Tat-F constructs. The NHG vectors were called 
NHG_Δtat-F and NHG_Δtat-D (Figure 6-2, panel B). We decided to develop two mutants 
of Tat to increase the possibilities to achieve replication competent virus able to replicate in 
its absence. 
 
Figure X. A) Tat exon 1 location in pNHG. B) Mutations made in tat exon 1: tat-F is a frameshift mutation introducing several stop codons and
where the start codon was removed ; tat-D is a deletion of 43 nucleotides to impede recombination events that could restore tat expression.
ATGGAACAAGCCCCAGAAGACCAAGGGCCACAGAGGGAGCCATACAATGAATGGACACTAGAGCTTTTAGAGGAACTTAAGAGTGAAGCTGTTAGACATTTTCCTA
GGATATGGCTCCATAACTTAGGACAACATATCTATGAAACTTACGGGGATACTTGGGCAGGAGTGGAAGCCATAATAAGAATTCTGCAACAACTGCTGTTTATCCATT
TCAGAATTGGGTGTCGACATAGCAGAATAGGCGTTACTCGACAGAGGAGAGCAAGAAATGGAGCCAGTAGATCCTAGACTAGAGCCCTGGAAGCATCCAGGAAGTC
AGCCTAAAACTGCTTGTACCAATTGCTATTGTAAAAAGTGTTGCTTTCATTGCCAAGTTTGTTTCATAACAAAAGCCTTAGGCATCTCCTATGGCAGGAAGAAGCGGAG
ACAGCGACGAAGACCTCCTCAAGGCAGTCAGACTCATCAAGTTTCTCTATCAAAGCAGTAAGTAATACATGTAATGCAACCTATACAAATAGCAATAGTAGCATTAGT
AGTAGCAATAATAATAGCAATAGTTGTGTGGTCCATAGTAATCATAGAATATAGGAAAATATTAAGACAAAGAAAAATAGACAGGTTAATTGATAGACTAATAGAA
AGAGCAGAAGACAGTGGCAATGAGAGTGAAGGAGAAATATCAGCACTTGTGGAGATGGGGGTGGAGATGGGGCACCATGCTCCTTGGGATGTTGATGATCTGTAG
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Figure 6-2. ( ) Tat exon 1 location in pNHG. (B) Mutations made in tat exon 1: tat-F is a 
frameshift mutation introducing several stop codons and the start codon was also removed; tat-
D is a deletion of 43 nucleotides to impede recombination events that could restore tat 
expression. 
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Then, we generated NHG_Δtat-F and NHG_Δtat-D constructs encoding LTR, CLTR or 
MLTR at the 3’end. Finally, we created 6 different NHG_Δtat-F and NHG_Δtat-D viruses 
(Figure 6-3). 
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 Figure 6-3. Diagram of NHG_Δtat-F and NHG_Δtat-D clones encoding a 3’LTR (control), 
CLTR and MLTR. The tat-F mutation is a frameshift that introduced several stop codons along 
the first exon, and the start codon was also removed; tat-D is a deletion of 43 nucleotides to 
impede recombination events that could restore tat expression. 
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We performed TZM assays to determine the absence of functional Tat protein in 
NHG_Δtat clones. TZM-bl cells are a reporter cell line encoding an E. coli β-galactosidase 
gene under control of an HIV-1 LTR promoter (Tat dependent) to measure Tat expression 
after a single round of infection. TZM-bl cells also express HIV-1 CD4 receptor and co-
receptors (CXCR4 and CCR5). (Figure 6-4, panel A). In the absence of Tat, the LTR is 
unable to drive transcription and the β-galactosidase enzyme is not generated. However, 
HIV-1 Tat stimulates the HIV-1 LTR from the TZM-bl cells, leading to the generation of 
the β-galactosidase enzyme, which hydrolyzes the X-Gal (lactose analogue), creating blue 
precipitates that we can observe and quantify (Figure 6-4, panel B). 
 
Firstly we transfected the 6 NHG_Δtat clones from (Figure 6-3) into TZM-bl cells, and 
then prepared a fresh X-Gal solution to add onto the TZM-bl cells 48 hours post-
transfection to detect Tat activity. The NHG_3LTR, NHG_3CLTR and NHG_3MLTR 
clones developed blue precipitates upon viral infection, but none of NHG_Δtat clones 
(NHG_Δtat_3LTR, NHG_Δtat_3CLTR and NHG_Δtat_3MLTR) formed blue precipitates 
(Figure 6-4, panel B). These TZM assays demonstrated that tat expression was not 
detected following transfection of NHG_Δtat clones, confirming that our Δtat-F and Δtat-
D mutations efficiently abrogated Tat expression during the first cycle of replication. 
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Figure 6-4.  (A) Diagram of a standard TZM-bl assay. TZM-bl cells are a reporter cell line 
presenting an E. coli β-galactosidase gene under control of an HIV-1 LTR (Tat dependent) to 
measure Tat expression after a single round of infection. TZM-bl also express HIV-1 receptor and 
co-receptor (CD4 and CXCR4 respectively). Diagram adapted from Akrit Sodhi, Silvia 
Montaner & J. Silvio Gutkind, Nature Reviews Molecular Cell Biology 5, 9981012 (December 
2004). (B) Transfection of NHG constructs into TMZ-bl cells to detect Tat expression. The 
amount of transfected DNA was 1µg of each NHG construct and 500ng of DEST40-tat]. Some 
blue crystals can be observed, consistent with Tat activity.  
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6.1.2 Tat expressed in trans rescues NHG-tat mutants. The CLTR and MLTR  
support reverse transcription efficiently 
 
We previously demonstrated that NHG_Δtat mutants do not express Tat protein, so the 
next step was to generate these replication competent viruses within the CL3 facilities 
following the same procedure as we did with the SIN vectors in CL2 labs (Figure 6-5). We 
transfected the NHG_Δtat clones (Figure 6-3) into human HEK-293T cells, and collected 
the viruses from the supernatant 48 hours post transfection to inoculate them onto PM1 
human lymphoid cell line to determine the viral titre (Figure 6-6, panel A). In order to 
generate NHG_Δtat clones it was necessary to provide DEST40_tat in trans during 
transfection to stimulate transcription levels for the first cycle of replication.  
 
 
 
 
 
 
 
 
 
All NHG_Δtat viruses were infectious in PM1 cells when Tat was supplied in trans during 
transfection (Figure 6-6).  The NHG_3LTR virus had a similar titre to the parental NHG 
virus, demonstrating that the addition of the polylinker near the 3´LTR did not affect viral 
fitness (Figure 6-6, panel A, lanes 1 and 2). However, the NHG_3CLTR and 
NHG_3MLTR titre decreased ∼10-fold compared to NHGwt and NHG_3LTR viruses 
(Figure 6-6, panel A, lanes 3 and 4). None of the NHG_Δtat mutants were infectious when 
Tat was not provided in trans during transfection, but their infectivity was rescued when 
Tat was added for the first cycle of replication (Figure 6-6, panel A, lanes 5 to 10). 
However, the titre from NHG_Δtat clones was reduced ∼10-fold compared to NHGwt, 
NHG_3LTR, NHG_3CLTR and NHG_3MLTR viruses (Figure 6-6, panel A). 
 
We performed western blot analysis in the transfected cells to detect Gag/CA expression, 
and we observed that Gag expression was slighly higher in NHG clones encoding tat in cis  
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Figure X. A) Protocol to generate single cycle of replication viruses or replication competent HIV-1 particles in
HEK-293T cells. B) Plasmids required to generate SIN vectors.
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Figure 6-5. Standard experiment to generate replication competent HIV-1 particles in 
human HEK-293T cells. The virions were collected 48 hours post-transfection and 
inoculated onto PM1 or AA-2 cells (human lymphoid cell lines) to determine the viral 
titre. 
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(NHGwt, NHG_3LTR, NHG_3CLTR and NHG_3MLTR). We did not observe p55 or p24 
expression in transfected HEK-293T cellls with NHG_Δtat constructs due to low 
transcription levels in the absence of Tat (when DEST40_tat was not provided in trans 
during transfection). Thus, infectious particles were not generated by the NHG_Δtat 
constructs in the absence of exogenous Tat, which correlates with the absence of p55 and 
p24 in transfected cells (Figure 6-6, panel B, lanes 9, 11, 13 and 15). It is essential to 
provide Tat protein during the first cycle of replication to enhance viral transcription and 
produce enough p55 and p24 proteins to allow the formation of nascent particles in 
transfected HEK-293T cells.  
 
The NHG_Δtat clones produced p55/p24 successfully when Tat was added in trans during 
transfection (Figure 6-6, panel B). The amount of Gag protein produced was very similar 
for parental NHG, NHG_3LTR, NHG_3CLTR and NHG_3MLTR viruses compared to 
NHG_Δtat clones when Tat was added in trans (Figure 6-6, panel B, bottom panel). After 
producing NHG_Δtat clones in human HEK-293T cells, we collected and filtered the 
supernatant containing these viruses and used them to inoculate a human lymphoid cell 
line (AA-2 cells). We intended to perform viral passages in an attempt to increase the viral 
fitness of these NHG_Δtat viruses. However, prior to attempting this experiment we 
decided to validate that the infectious viruses were truly tat-deficient.  We inoculated the 
NHG_Δtat viruses onto TZM-bl cells to perform a TZM assay 48 hours post-infection 
(Figure 6-7, panel A). We observed blue precipitates in NHGwt, NHG_3LTR, 
NHG_3CLTR and NHG_3MLTR viruses. However, the NHG_Δtat_3LTR, 
NHG_Δtat_3CLTR and NHG_Δtat_3MLTR viruses did not produce blue precipitates 
(Figure 6-7, panel A). Crucially, all NHG_Δtat viruses were infectious (GFP expression) 
when Tat was provided in trans during transfection (Figure 6-7, panel B) indicating that 
the absence of blue precipitate was not merely due to an absence of infected cells. 
 
The NHG_Δtat clones supported efficient transcription and reverse transcription during the 
first cycle of replication when Tat was provided in trans. These replication competent 
viruses will allow us to investigate their ability to complete subsequent cycles of 
replication in a Tat-independent manner within a more representative enviroment. These 
viruses could, in principle, adapt to human AA-2 cells increasing replicative fitness 
through repeated viral passage, and we should be able to detect (by direct sequencing) the  
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modifications selected in NHG_Δtat clones that increase the viral fitness after multiple 
cycles of replication. We have sequenced all viruses employed in these experiments by 
sequencing. 
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Figure 6-6. Experiment to determine the ability of NHG_Δtat constructs to generate infectious 
particles in PM1 by transfection. HEK-293T cells were transfected with NHG_Δtat constructs 
and viral particles were collected and purified by sucrose cushion centrifugation 48 h.p.t. The 
amount of transfected DNA was 1µg for each NHG_Δtat construct and 500ng of DEST40_tat. 
(A) Mean titre of NHG clones encoding tat in cis (left), NHG_Δtat-F and NHG_Δtat-D clones in 
PM1 cells. Tat was provided in trans by DEST40-tat for the first cycle of replication. No 
infection was observed in NHG_Δtat constructs when DEST40-tat was not supplied in trans 
during transfection. The error bars show the standard deviation for each titre (triplicates). (B) 
Western blot analysis for p55 and p24 (using mouse anti-p24 antibody) of transfected HEK-293T 
cells and viral particle production from the supernatant 48 hours post transfection (upper panel). 
Viral particles produced were collected and purified by sucrose cushion centrifugation 48 h.p.t. 
(bottom panel). Molecular marker shown in kDa. 
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Figure 6-7. Experiment to determine Tat expression of NHG_Δtat constructs in TZM-
bl cells after the first cycle of replication. We inoculated the same amount of viruses 
using the mean titre of each virus from Figure 6-6 to obtain same levels of infections 
for all constructs NHG. (A) GFP expression from infected TZM cells (48 h.p.i.) with 
NHG clones encoding tat in cis (left column) and NHG_Δtat constructs (NHG_Δtat-F 
and NHG_Δtat-D). (B) TZM assay to detect Tat expression in our NHG_Δtat 
constructs 48 h.p.i. Blue precipitates were generated when Tat was present in the 
system.  
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6.1.3 NHG_Δtat clones were able to complete subsequent cycles of 
replication in a Tat-independent manner 
 
Once we determined that all NHG_Δtat viruses were infectious during the first cycle of 
replication we proceeded to perform viral passage experiments to increase the viral fitness. 
The levels of infection in a Tat free environment were expected to be low, but the 
NHG_Δtat viruses should be able to overcome this situation following several rounds of 
replication (Bordería et al. 2010), allowing the virus to evolve and adapt within human 
AA-2 cells prior attempting to infect murine cells. In summary, the resultant virus would 
be able to replicate efficiently in a Tat-independent manner predisposing such a virus to 
replicate within murine cells. The modifications introduced through viral passage could be 
transferred into our CSGW_Flexi and SYNGP_4CTE systems to finally acquire a Tat 
independent virus within a CL2 lab, which is an easier and also safer way to investigate the 
molecular basis of these adaptations. 
 
We passaged all the viruses shown in Figure 6-3. The NHG_3LTR, NHG_3CLTR and 
NHG_3MLTR viruses all displayed similar growth kinetics compared to the NHG wild 
type virus. These viruses killed all the cells in the culture within a week.  Specifically, the 
NHG_3MLTR only needed 3 days (Figure 6-9) whereas the NHG_Δtat-F_3LTR and 
NHG_Δtat-D_3LTR mutants needed 6 and 7 days respectively to reach same levels of 
infection as NHG_3LTR, NHG_3CLTR and NHG_3MLTR viruses. The NHG_Δtat-
F_3MLTR and the NHG_Δtat-D_3MLTR displayed similar growth curves (comparing 
both), but the NHG_Δtat-F_3CLTR and NHG_Δtat-D_3CLTR viruses propagated very 
slowly or not at all as the level of infection was stable (∼15% of cells infected/GFP 
positive) after 13 days (Figure 6-9). The next passage of all NHG_Δtat viruses determined 
that viral fitness had increased or perhaps achieved higher titre with growth kinetics 
resembling wild type growth curves (Figure 6-9). However, the NHG_Δtat-F_3CLTR and 
NHG_Δtat-D_3CLTR remained the same, and we did not observe any enhancement in the 
replicative fitness of these viruses. Unfortunately, the NHG_Δtat-F_3CLTR and 
NHG_Δtat-D_3CLTR passages were interrupted due to a protracted CL3 shutdown (red 
arrows), suspending the adaptation of these viruses for a considerable period of time. 
 
No differences were observed in the growth curves from NHG_tat-F_3LTR and NHG_tat-
D_3LTR viruses, suggesting that neither mutagenesis strategy affected viral replication.  
The incredibly rapid adaptation of NHG_Δtat-F_3LTR and NHG_Δtat-D_3LTR viruses to  
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the culture suggested a likely contamination event; same hypothesis could be applied to the 
NHG_Δtat-F_3MLTR and NHG_Δtat-D_3MLTR viruses. The NHG_Δtat-F_3CLTR and 
NHG_Δtat-D_3CLTR growth curves remained consistent along 13 days, confirming that 
viral adaptation is a slow process and the virus needs many cycles of replication before 
generate mutations to increase its fitness (Locher et al. 2003). Unfortunately, the viral titre 
from the NHG_Δtat viruses was so low as to be undetectable by flow cytometry. In 
addition, another shutdown was carried out for refurbishment within the CL3 facilities, and 
experiments were interrupted once again for approximately 6 months. Once the CL3 lab 
was available again, some viruses that were frozen prior the shutdown were inoculated 
onto fresh AA-2 cells, but they did not infect any cells. The frozen NHG_Δtat viruses 
could not be recovered and we speculate the titre was so low that freeze-thawing 
effectively eliminated infections virus from the culture. Thus, we decided to generate the 
NHG_Δtat-F_3CLTR and NHG_Δtat-D_3CLTR viruses once again. The new growth 
curves from NHG_Δtat-F_3CLTR and NHG_Δtat-D_3CLTR viruses had a very similar 
pattern as the previous experiments, where the percentage of infection remained similar for 
~8 days, but these samples were frozen due to CL3 fumigation/housekeeping duties by this 
time (Figure 6-8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To determine if the NHG_tat mutants had recovered functional Tat expression, we carried 
out a TZM-bl assay, which would also detect contamination events in NHG_tat mutants 
cultures. The rapid adaptation of NHG_Δtat-F_3LTR, NHG_Δtat-D_3LTR, NHG_Δtat-
F_3MLTR and NHG_Δtat-D_3MLTR viruses to human AA-2 cells culture was achieved  
 
Figure 6-8. NHG_Δtat-F_3CLTR and NHG_ Δtat-D_3CLTR viruses adaptation in 
human AA-2 cells. The growth curves of. Red arrows indicate shutdown period in the 
CL3 facilities and passages were interrupted. The right curve represents the growth of a 
fresh virus after the shutdown period that did not spread due to the interruption of the 
culture (frozen stock remove any infectivity from this virus). 
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by cross contamination of a wild type virus, which was determined by PCR analysis. 
Following this surprising results we decided to sequence tat 1 exon of infected cells from 
NHG_Δtat-F_3LTR, NHG_Δtat-D_3LTR, NHG_Δtat-F_3MLTR and NHG_Δtat-
D_3MLTR cultures, so we centrifuged each culture to collect the infected cells, and we 
extracted their genomic DNA and sequenced the first exon of tat (the site that we originally 
mutated). The sequencing results from NHG_Δtat-F_3LTR, NHG_Δtat-D_3LTR, 
NHG_Δtat-F_3MLTR and NHG_Δtat-D_3MLTR infected cells determined that tat exon 1 
was wild type (NHG tat) for all of them. We also performed TZM assays of all NHG_Δtat 
viruses, which confirmed the presence of functional Tat within the cultures (Figure 6-10). 
However, the NHG_Δtat-F_3CLTR and NHG_Δtat-D_3CLTR viruses were the only ones 
not contaminated.  
 
Despite the issues related to contamination events and extended and unpredictable 
shutdown periods in the CL3 lab, these results demonstrated that the CLTR was able to 
drive transcription and reverse transcription efficiently after subsequent rounds of infection 
in a Tat independent manner (Figure 6-9 and 6-10), resulting in the ‘best’ candidate to 
develop an HIV-1 Tat independent clone in human cells. Moreover, TZM assays did not 
detect Tat expression for NHG_Δtat-F_3CLTR and NHG_Δtat-D_3CLTR viruses after 11 
days post-infection, but they still infectious (figure 6-10). However, the NHG_Δtat-
F_3LTR and NHG_Δtat-F_3MLTR, NHG_Δtat-D_3LTR and NHG_Δtat-D_3MLTR 
viruses were expressing Tat 11 days post-infection (Figure 6-10) 
 
Conclusions derived from the NHG_Δtat-F_3LTR and NHG_Δtat-F_3MLTR, NHG_Δtat-
D_3LTR and NHG_Δtat-D_3MLTR viruses were not reliable due to contamination events, 
and more experiments need to be performed to investigate their potential. 
 
 
6 – Chapter 6 148 
0
10
20
30
40
50
60
70
80
0
10
20
30
40
50
60
70
80
0
10
20
30
40
50
60
70
80
NHG_3CLTR
NHG
In
fe
ct
io
n 
(%
 G
FP
)
NHG_3LTR
NHG_3MLTR
1 2 3 4
Days post-infection
1 2 3
1 2 3 4 1 2 3 4
0
10
20
30
40
50
60
70
80
0
10
20
30
40
50
60
70
80
0
10
20
30
40
50
60
70
80
0
10
20
30
40
50
60
70
80
0
10
20
30
40
50
60
70
80
0
10
20
30
40
50
60
70
80
1 2  3  4  5  6   
NHG_Δtat-F_3LTR
7   8  9 10 11 12
NHG_Δtat-D_3LTR
1 2    3   4     5    6    7   8    9  10 11  12
NHG_Δtat-F_3CLTR
1 2     3     4     5    6    7      8    9    10  11   12   13  
NHG_Δtat-D_3CLTR
1 2     3    4    5     6     7    8     9   10   11  12   13  
NHG_Δtat-F_3MLTR
1 2   3   4  5   6  7  8       9 10 11 12 13    14 15 16 17
NHG_Δtat-D_3MLTR
1 2   3  4  5  6   7  8       9 10 11 12 13  14 15 16 17
80
70
60
50
40
30
20
10
0
In
fe
ct
io
n 
(%
 G
FP
)
In
fe
ct
io
n 
(%
 G
FP
)
In
fe
ct
io
n 
(%
 G
FP
)
In
fe
ct
io
n 
(%
 G
FP
)
In
fe
ct
io
n 
(%
 G
FP
)
In
fe
ct
io
n 
(%
 G
FP
)
In
fe
ct
io
n 
(%
 G
FP
)
In
fe
ct
io
n 
(%
 G
FP
)
In
fe
ct
io
n 
(%
 G
FP
)
Days post-infection
Days post-infection Days post-infection
Days post-infection Days post-infection
Days post-infection Days post-infection
Days post-infection Days post-infection
1st
2nd
3rd
1st
3rd
1st
2nd 3rd 1st
2nd
3rd
2nd
 
 
 
Figure 6-9. HIV-1 adaptation in human AA-2 cells.  The NHG_Δtat-F and NHG_ Δtat-D 
viruses were passaged in 6 ml cultures of AA-2 until the viruses totally spread (most of cell 
expressing GFP and cytopathic effects). Then, we prepared a new culture with fresh AA-2 cells 
and inoculated the virus from the 1st passage (previously filtered with 0.45 µm 25mm diameter 
syringe filters). The inoculum for each virus into the new cultures was 500µl. To quantify GFP 
expression from the cultures we submitted to flow cytometry analysis the infected cells from 
each culture. Black arrows indicate the end of a passage, and red arrows a CL3 facility 
shutdown. 
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Figure 6-10. TZM-bl assays to detect Tat expression from NHG_Δtat-F and NHG_ Δtat-D viruses 
from AA-2 passages. We suspected that NHG_Δtat-F viruses will revert Tat function easily, but 
NHG_ Δtat-D viruses should be unable to express Tat. The TZM-bl cells were inoculated with 
NHG_3LTR, NHG_3CLTR, NHG_3MLTR and NHG_∆tat viruses 11 days post-infection and 
incubated for 72 hours prior the addition of X-gal. Some Tat expression was recovered (black 
arrows). NHG_3LTR, NHG_3CLTR, NHG_3MLTR virus inoculum was diluted 1:100 (control). The 
level of infection of NHG_Δtat-F and NHG_ Δtat-D viruses were too low to determine the viral titre 
by flow cytometry. 
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6.1.4 NHG-tat-rev-4CTE clones were able to complete subsequent cycles of 
replication in a Tat and Rev independent manner, but infectivity was lost 
along the passages 
 
Our previous results obtained from NHG_Δtat-F_3CLTR and NHG_Δtat-D_3CLTR 
passages demonstrated that they could still infectious after 11 days post-infection in a Tat 
independent manner (Figure 6-9). The TZM assays to detect Tat expression for NHG_Δtat-
F_3CLTR and NHG_Δtat-D_3CLTR viruses did not detect Tat expression, and these 
viruses were infectious after 11 days post-infection (Figure 6-7). These data support the 
concept that a Tat-independent virus encoding the CLTRs was possible, therefore we 
considered the NHG_Δtat-F_3MLTR and NHG_Δtat-D_3MLTR viruses as potential 
candidates to eventually replicate efficiently within a Tat independent environment. 
Further adaptation would be necessary prior to attempting to infect murine cells. In order 
to achieve a Tat and Rev independent HIV-1 clone able to infect murine cells it is 
necessary to remove Rev-dependency.  We attempted to select Rev-independent viruses by 
deleting rev exon 1 from NHG_Δtat viruses to generate NHG_Δtat_Δrev vectors that are 
unable to express HIV Tat and Rev proteins, so we could introduce 4 copies of the CTE 
and chimeric promoters CLTR and MLTR into NHG_Δtat_Δrev vectors to investigate the 
ability of this vector to replicate in the absence of the regulatory proteins. However, we 
could have introduced mutations in the HIV RRE to abolish Rev function or removing 
entirely the RRE from these constructs instead modifying the rev exon 1. However, the 
modifications in the RRE could alter the viral envelope structure (RRE is located within 
the env gene) and we decided to remove rev exon 1 that does not overlap with other genes. 
Same hypothesis was followed when we introduced mutations in the tat exon 1 in 
NHG_Δtat constructs, which did not altered other sequences along the genome. We could 
have modified the TAR element in NHG_Δtat clones, but altering the secondary structure 
of HIV LTR could severely impede the efficiency of viral replication. 
  
Therefore, we completely removed the first exon of rev, which does not overlap with any 
other viral genes (Δrev). The viral RNA stability and transport should have been severely 
attenuated, but our previous results carried out in the CL2 system using 4CTEs (encoded 
into CSGW vector genome) demonstrated that the 4CTEs were partially able to replace 
Rev function (Figure 5-4). We followed this strategy in our NHG_Δtat-D_Δrev viruses and 
transferred 4 copies of the CTE into them, generating 4 new viruses encoding Δtat-D and  
6 – Chapter 6 151 
 
Δrev mutations and also the chimeric CLTR and MLTR promoters at the 3’end (Figure 6-
11). The addition of 4CTEs should contribute to the adaptation of NHG_Δtat-Δrev_4CTE 
viruses along several cycles of replication in AA-2 cells within a Tat and Rev free 
environment.  Conceptually the modified LTRs were intended to eventually result in Tat 
independence and the CTEs to promote Rev-independence. 
 
The rev exon 2 was intact in NHG_Δtat-D-Δrev-4CTE viruses because it overlaps with the 
env gene. The NHG- Δtat-F mutants were excluded from this modification for their ability 
to easily revert to functional Tat expression (Figure 6-10). We transfected the NHG_Δtat-
D-Δrev_4CTE viruses (NHG_Δtat-D-Δrev_4CTE_3LTR, NHG_Δtat-D-
Δrev_4CTE_3CLTR and NHG_Δtat-D-Δrev_4CTE_3MLTR) into HEK-293T cells to 
generate replication competent HIV-1 particles, which were used to infect human AA-2  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
cells to perform viral passages. It was necessary to initially provide tat and rev genes in 
trans by co-transfection (using DEST40_tat and DEST40_rev respectively) to generate 
infectious NHG_Δtat-D-Δrev_4CTE viruses in the first cycle of replication. When these 
proteins were not provided together in trans, no infectious NHG_Δtat-D-Δrev_4CTE 
viruses were produced (Figure 6-5). 
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Figure X. A) Maps of the
replication competent The
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encoding a 43 nt deletion in tat
exon 1 (Δtat-D) and a deletion of
the first exon of rev (Δrev), 4CTEs
and chimeric LTRs. B) GFP
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Figure 6-11. NHG_Δtat-D-Δrev viruses encoding 4CTEs at the 3’ end. The LTR, CLTR and 
MLTR promoters are also located at the 3’end such as NHG_Δtat mutants. 
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We transfected the NHG_Δtat-D-Δrev_4CTE constructs into HEK-293T cells and 
collected the viruses 48 hours post-transfection. Prior to attemping the infection of fresh 
AA-2 cells we filtrated the supernatant from HEK-293T cells with 0.45 µm 25mm 
diameter syringe filters and then inoculated the viruses into AA-2 cells. We collected a 
sample of each culture every 24 hours post-infection, and changed the cell culture media to 
keep cells healthy. This protocol was repeated until the culture was entirely infected and 
therefore we collected and filtered the viruses from these cultures to inoculate them into 
fresh AA-2 cultures.  
 
The NHG_Δtat-D-Δrev-4CTE_3LTR virus was not infectious despite the addition of the 
regulatory proteins supplied in trans, but NHG_Δtat-D-Δrev-4CTE_3CLTR and 
NHG_Δtat-D-Δrev-4CTE_3MLTR were infectious 48 h.p.i. (Figure 6-12, panel B). The 
infectivity was consistent after 9 d.p.i., but no spreading was observed by this time. We 
reasoned that it was possible that the initial viral inoculum did not reach sufficient levels of 
infection to have adequate complexity from which to select fitter variants, which could 
have affected the spreading potential of NHG_Δtat-D-Δrev-4CTE_3CLTR and NHG_Δtat-
D-Δrev-4CTE_3MLTR viruses. We decided to generate these latter viruses in 10 cm 
dishes (in duplicate) by transfection of HEK-293T cells to generate a more diverse HIV-1 
population and increase the viral titre before performing spreading/passage experiments. 
By generating more viruses, we would increase the diversity, which could potentially 
facilitate the selection of fitter derivatives. The NHG_Δtat-D-Δrev-4CTE_3CLTR virus 
was concentrated ~20 times by benchtop centrifugation and inoculated onto AA-2 cells, 
producing a higher percentage of infected cells than the previous experiment (Figure 6-12, 
panel C). In addition, GFP positive cells were detected 9 d.p.i. with the NHG_Δtat-D-Δrev-
4CTE_3CLTR virus (Figure 6-13, panel A).  However, without further experimentation we 
are unable to conclude whether this represents initial Tat and Rev-dependent infection 
(from the inoculum) or resulted from limited spreading of the virus. Thus, the level of 
infection was too low to determine the viral titre or p24 expression from infected cells. 
 
It remains possible that the NHG_Δtat-D-Δrev-4CTE_3CLTR virus was able to 
inefficiently replicate in a Tat and Rev independent manner in human cells, but we 
observed a decay in GFP expression over time indicating the virus was either replication 
incompetent or severely attenuated (Figure 6-13, panel B).  
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Figure 6-12. (A) Maps of the 
replication competent constructs 
NHG_Δtat-D_Δrev_4CTE viruses 
encoding a 43 nt deletion in tat exon 
1 (Δtat-D) and a deletion of the first 
exon of rev (Δrev), 4CTEs near the 
3’end and chimeric LTRs (CLTRA 
or MLTR). (B) GFP expression of 
NHG-Δtat-D-Δrev_4CTE viruses in 
AA-2 cells 4 d.p.i. These viruses 
were generated in HEK-293T cells 
by transfection (1µg) and collected 
and purified by sucrose cushion 
centrifugation 48 h.p.t. Then, the 
resultant viruses were inoculated 
into AA-2 cells to start the passages 
(1ml for each virus). Panel C shows 
the NHG_Δtat-
D_Δrev_4CTE_3CLTR virus 
infection when concetrated 20 times 
by centrifugation before the 
inoculum into AA-2 cells. However, 
the level of infection of NHG_Δtat-
D_Δrev_4CTE viruses were too low 
to submit the AA-2 culture to flow 
cytometry analysis. 
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Figure 6-13. NHG_Δtat-D_Δrev_4CTE_3CLTR adaptation in AA-2 culture. (A) GFP 
expression in NHG_Δtat-D_Δrev_4CTE_3CLTR virus 12 d.p.i. Few cells were observed, 
but the level of infection was too low to submit the culture to flow cytometry analysis. 
(B) Growth curve of NHG_Δtat-D_Δrev_4CTE_3CLTR virus along 24 days in culture. 
GFP percentages are shown in the pannel at the right. The timepoint curve from figure B 
was perfomed by Victor Iliev, a graduate student working in our lab. This passage was 
finished after day 26 due to the lost of GFP expression from the culture. 
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6.2 Discussion chapter 6 
 
The NHG_Δtat-F and NHG_Δtat-D mutants were unable to generate sufficient 
transcription levels when Tat was not provided in trans during transfection, and we did not 
find differences in virion production (compared to NHGwt). The infectivity was reduced 
for all NHG_Δtat-F and NHG_Δtat-D clones (Figure 6-6). This result suggested that 
perhaps the viral RNAs were pooly synthesized (likely due to decreased LTR promoter 
activity in the absence of Tat-transactivation) in NHG_Δtat-F and NHG_Δtat-D mutants 
and demonstrated that the CLTR and MLTR chimeric promoters did not rescue Tat 
function during the first cycle of replication.  This was entirely expected as in the plasmid, 
the CLTR and MLTRs are only present at the 3’ end and cannot drive transcription in the 
first cycle of replication.  However, the ability of the CLTR and MLTR to drive 
transcription and reverse transcription efficiently (when Tat was provided in trans during 
transfection) was expected from previous results using the CSGW_Flexi system (Figure 6-
6, panel A). Moreover, the NHG_Δtat-F_3CLTR and NHG_Δtat-D_3CLTR clones 
replicated efficiently in the absence of Tat after 12 days post-infection, suggesting that the 
CLTR could be a good candidate to achieve Tat independence (Figure 6-13). 
 
The AA-2 cultures infected with NHG_Δtat-F viruses (frameshift) could easy revert and 
generate the tat exon 1 wild type sequence. However, the NHG_Δtat-D (deletion) should 
not revert as the frameshift mutation (the 43 nucleotides deletion should impair tat 
expression for several cycles of replication). The initial The initial NHG_Δtat-F and 
NHG_Δtat-D viruses employed to perform the passages were sequenced before attempting 
any experiment, but our results obtained from the TZM assays detected Tat expression in 
NHG_Δtat-D_3LTR, NHG_Δtat-D_3CLTR and NHG_Δtat-D_3MLTR cultures, which 
should not express Tat after the 43nt deletion we made (Figure 6-2). These findings suggest 
that the Tat expression could have originated from cross-contamination from other cultures 
during passage. However, the NHG_Δtat-F viruses recovered Tat expression after few 
rounds of replication and sequencing results confirmed this hypothesis. The frameshift 
mutation was easy to overcome for the virus, but this should not occur for the deletion 
mutation from NHG_ Δtat-D clones. 
 
Moreover, several viral passages attempts performed afterwards to avoid cross-
contamination events, but unfortunately these passages yielded very similar results,  
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suggesting that the plasmids employed to generate the NHG_Δtat-F and NHG_Δtat-D 
viruses could be the origin of this contamination even although we did not detect any Tat 
expression when they were transfected into TZM cells (Figure 6-4). It is remarkable that 
the NHG_Δtat-F_3CLTR and NHG_Δtat-D_3CLTR viruses were the only ones where the 
contamination events were not observed, suggesting that the results obtained from these 
passages could still be reliable (Figure 6-9). The NHG_Δtat-F_3CLTR and NHG_Δtat-
D_3CLTR clones caused similar levels of infection after several days, suggesting that 
perhaps the adaptation could be achieved with more time (Van Opijnen et al. 2007). The 
protracted and unpredictable shutdown periods within the CL3 facilities severely affected 
the consistency and potential of these viruses, and experiments were cancelled for long 
periods of time. However, we could resolve this problem by repeating the passages during 
longer periods of time with no interruptions in the near future and determine if NHG_Δtat-
F_3LTR, NHG_Δtat-F_3MLTR, NHG_Δtat-D_3LTR and NHG_Δtat-D_3MLTR viruses 
were able to replicate in a Tat free environment. 
 
The deletion of the first exon of rev (Δrev) and the addition of 4CTEs into NHG_Δtat-F 
and NHG_Δtat-D viruses was not as successful as we had hoped from the results obtained 
using CSGW_4CTE vector genome in the CL2 laboratory (Figure 5-4). The NHG_Δtat-D-
Δrev-4CTE clones (Figure 6-12, panel A) were infectious at early steps of infection, but 
unfortunately none of them could progress and spread within the AA-2 cultures. The 
NHG_Δtat-D-Δrev-4CTE_3MLTR was infectious for few days only, suggesting that the 
MLTR failed to support efficient replication following the first round of infection.  This 
could be due to a failure to drive transcription, reverse transcription, maintain RNA 
stability or other problems due to the absence of Tat and Rev. However, the NHG_Δtat-D-
Δrev-4CTE_3CLTR virus was infectious after 9 d.p.i., but did not progress as we expected 
(Figure 6-13, panel B). Unfortunately, we did not have time to perform cell free passages 
and determine whether this virus propagated at all. 
 
The initial levels of infection observed from NHG_Δtat-D-Δrev-4CTE_3CLTR virus 
suggested that it may be possible to develop an HIV-1 virus that is able to replicate in a Tat 
and Rev independent manner in human cells, but there could be several problems likely 
related to viral transcription and RNA stability that we could not determine. The CLTR 
seemed to partially overcome Tat function, but the issues related to CL3 refurbishment 
impaired the progress of the passages and further experiments need to be performed to 
demonstrate the CLTR ability to replace Tat function. However, the 4CTEs seemed to not  
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contribute to the RNA stability and transport in NHG_Δtat-D-Δrev-4CTE_3LTR, 
NHG_Δtat-D-Δrev-4CTE_3CLTR and NHG_Δtat-D-Δrev-4CTE_3MLTR viruses as we 
observed in CSGW_4CTE vector genomes (Figure 5-4). The mechanistic basis of these 
problems are yet to be determined, but future investigation of RNA production and viral 
transcription could determine what is affecting the potential of our NHG_Δtat-D-
Δrev_4CTE viruses to adapt and evolve within the culture. We could check this hypothesis 
developing reverse transcription assays to investigate the reverse transcription levels in 
NHG_Δtat-D-Δrev_4CTE viruses to determine the RNA species within transfected (HEK-
293T) and infected cells (AA-2). We could extract the viral RNA from infected AA-2 cells 
during the passages or adding a reverse transcriptase inhibitor to determine if the virus is 
spreading in culture or not. The RNA extractions could be also performed for viral 
particles produced during the first cycle of replication in HEK-293T cells to detect if 
NHG_Δtat-D-Δrev_4CTE viruses are able to package the viral RNA successfully or 
whether packaging is affected somehow. Moreover, to investigate if the viral RNAs export 
and stability is affected in NHG_Δtat-D-Δrev_4CTE viruses we could have performed 
northern blot analysis of viral RNAs extracted from transfected cells and compare the 
amounts of full-length genomes produced in all NHG_Δtat-D-Δrev_4CTE viruses. Thus, 
we could have included a fluorescent dye in viral RNAs to detect the amount of RNA that 
remain in the nucleus compared to the cytoplasm in transfected cells. 
 
Thus, the absence of nef gene in NHG constructs could be also affecting viral replication. 
Nef protein has well-characterized effects on host membrane trafficking and receptor 
downregulation, increasing the intrinsic infectivity of HIV-1 virions in a host-cell-
dependent manner. However, the addition of nef into NHG constructs will increase the 
size of the genome and we could introduce additional RNA secondary structures that 
could disrupt viral RNA packaging. The GFP reporter gene is replacing nef in all NHG 
constructs, therefore we need to preserve this gene to measure viral infectivity and in 
vitro evolution during the passages. We could include nef gene in NHG constructs to 
enhance viral infection in human or murine cells to facilitate the in vitro adaptation 
(passages) of our NHG_Δtat-D-Δrev-4CTE constructs. Published reports demonstrate that 
the negative effects of Nef expression are not present when Nef is expressed in T cells 
from transgenic mice, which moderate positive T cell activation process (Rhee et al. 1994). 
 
Unfortunately, the NHG_Δtat-D-Δrev-4CTE_3CLTR virus was not sufficient to generate 
Tat and Rev independent progeny, but the findings from this thesis suggest that this  
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ambitious aim could be achievable. Moreover, we could investigate the Tat and Rev 
independence using CL3 clones independently: investigate Tat independence in Δtat 
mutants encoding a CLTR (NHG_Δtat-D-_3CLTR) and investigating Rev independence 
using Δrev mutants encoding 4CTEs (NHG_Δtat-D-Δrev-4CTE_3CLTR). The HIV-1 
regulatory genes (tat and rev) are essential for viral survival, and overcoming both the 
function of both genes together could be impossible unless we understand better how we 
can overcome their relevant function with our CL3 viruses. Perhaps the aim of this thesis 
was too ambitious to be achieved in the period of time that we had. However, the findings 
obtained from this thesis suggest that we could focus in transcriptomics and RNA 
expression from NHG_Δtat-D-Δrev-4CTE_3CLTR and NHG_tat-D viruses, which could 
reveal new insights and maybe identify the factors that impair viral replication. In 
conclusion, supporting more intense research to investigate why the NHG_Δtat-D-Δrev-
4CTE_3CLTR failed to spread in human cells could overcome the issues that impair 
NHG_Δtat-D-Δrev-4CTE_3CLTR replication. 
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7.1 Final reflections 
 
7.1.1 Summary 
 
The primary aim of this project was to develop an HIV-1 clone able to replicate in mice, 
with the future aim of the generating an HIV-1 clone to assist in antiviral drug 
development. The potential of CLTR and MLTR promoters to generate infectious 
pseudotyped HIV-1 particles in human cells was successful, but attempts to reproduce this 
result in murine cells failed and opened up many questions that need to be investigated.  
 
The absence of Rev protein in our CSGW_Flexi and SYNGP constructs could be affecting 
full length viral RNA transport towards the cytoplasm, which could remain within the 
nucleus. The RNA stability of full-length viral and single spliced RNAs in the absence of 
Rev could contribute to their degradation (Blissenbach et al. 2010). Perhaps the 
modifications introduced by introducing the CLTR and MLTR into CSGW_Flexi clones 
are affecting the viral RNA secondary structure, which is required to interact with the Gag 
protein to package the viral genome into the nascent particles (Amarasinghe et al. 2001). 
Alternatively, the viral genome is efficienlty generated within the transfected cell, but it 
could be unable to be packaged within the nascent viral particles (Mailler et al. 2016). The 
5CLTR_SYNGP_Ψ_IRES_EGFP_3CLTR construct generated VLPs in human cells but 
they were not infectious. The RNA secondary structures in the 
5CLTR_SYNGP_Ψ_IRES_EGFP_3CLTR construct introduced by the addition of the 
CLTRs and other elements could be affecting the RNA stability and affecting the 
packaging of the viral genome into the nascent particles (Watts et al. 2009; Sükösd et al. 
2015). Thus, the SYNGP_4CTE clones were defective and unable to generate infectious 
viruses despite the higher MFI detected in transfected HEK-293T cells shown in Figure 4-
7, panel B. No evidence was observed to suggest issues with VLP formation for 
SYNGP_4CTE clones, but they could lack the viral genome or could be aberrant in some 
other way (Lu et al. 2011). Moreover, we detected some p25 intermediate protein in 
western blot analysis of VLPs from all SYNGP_4CTE clones (Figure 4-10, panel B). In 
addition, reducing the CpG content from HIV-1 codon-optimized genes (from SYNGP 
vector) could have affected RNA stability or folding, generating novel RNA secondary 
structures that impair viral replication.  
 
The length of Flexi_GP_4CTE clones should not impair viral replication, and the viral 
RNA genome of Flexi_GP_4CTE clones should be able to be packaged as CSGW_4CTE 
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does. Surprisingly, the addition of Tat and Rev proteins in trans did not rescue viral 
infectivity from CSGW_GP_4CTE_3LTR, 5CLTR_CSGW_GP_4CTE_3CLTR and 
5MLTR_CSGW_GP_4CTE_3MLTR, suggesting that the viral genome must be unable to 
interact with HIV-1 regulatory proteins due to an aberrant RNA folding, impairing vital 
interactions along the viral replication cycle, such as Gag with full length genomes, or 
highly conserved regions in viral RNA could be also affected by introducing the gag-pol 
genes into Flexi_GP_4CTE clones (Le et al. 1990: Watts et al. 2009). However, we 
succesfully generated infectious particles using the CSGW_4CTE construct (when 
pSYNGP and pCMV_VSV-G were provided in trans) in a Tat and Rev independent 
manner from HEK-293T cells (Figure 5-4). When we tried to infect murine macrophages 
(RAW) with these viruses, which were generated in human cells, we only observed a few 
infected cells 72 hours post-infection (Figure 5-3). These data suggest that replacing Rev 
function by 4 copies of the CTE is not sufficient to rescue the infectivity within murine 
cells (Figure 5-3). The Flexi_GP_4CTE vector encodes the RRE outside the env gene near 
the 3’end (its natural position), but the ability of wild-type CSGW to produce infectious 
viruses when SYNGP/CVR1_NLGP and CMV_VSV-G are provided during transfection 
supports the idea that the position of the RRE is not essential for RNA transport or 
stability.  
 
Finally, the infectivity was reduced for all NHG_Δtat-F and NHG_Δtat-D clones compared 
to wild-type NHG (Figure 6-6). These data suggested that perhaps the viral RNAs were 
pooly synthesized (likely due to decreased LTR promoter activity in the absence of Tat-
transactivation) in NHG_Δtat-F and NHG_Δtat-D mutants and demonstrated that the 
CLTR and MLTR chimeric promoters did not rescue Tat function during the first cycle of 
replication. Moreover, the NHG_Δtat-F_3CLTR and NHG_Δtat-D_3CLTR clones 
replicated efficiently in the absence of Tat after 12 days post-infection, suggesting that the 
CLTR could be a good candidate to achieve Tat independence (Figure 6-13). The 
NHG_Δtat-F_3CLTR and NHG_Δtat-D_3CLTR clones caused similar levels of infection 
after several days, suggesting that perhaps the adaptation could be achieved with more 
time (Berkhout et al. 2007). The deletion of the first exon of rev (Δrev) and the addition of 
4CTEs into NHG_Δtat-F and NHG_Δtat-D viruses was not as successful as we had hoped 
from the results obtained using CSGW_4CTE vector genome in the CL2 laboratory 
(Figure 5-4). The NHG_Δtat-D-Δrev-4CTE clones (Figure 6-12, panel A) were infectious 
at early steps of infection, but unfortunately none of them could progress and spread within  
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the AA-2 cultures. The NHG_Δtat-D-Δrev-4CTE_3MLTR was infectious for few days 
only, suggesting that the MLTR failed to support efficient replication following the first 
round of infection. This could be due to a failure to drive transcription, reverse 
transcription, maintain RNA stability or other problems due to the absence of Tat and Rev. 
The mechanistic basis of these problems are yet to be determined, but future investigation 
of RNA production and viral transcription could determine what is affecting the potential 
of our NHG_Δtat-D-Δrev_4CTE viruses to adapt and evolve within the culture.  
 
Unfortunately, the NHG_Δtat-D-Δrev-4CTE_3CLTR virus was not sufficient to generate 
Tat and Rev independent progeny, but the findings from this thesis suggest that this 
ambitious aim could be achievable and perhaps the aim of this thesis was too ambitious to 
be achieved in the period of time that we had. Unfortunately, the NHG_Δtat-D-Δrev-
4CTE_3CLTR virus was not sufficient to generate Tat and Rev independent progeny and 
failed after several days of culture (and perhaps only generated one round of infectious 
particles from transient transfection when Tat was added in trans). The findings from this 
thesis suggest that Tat and Rev independent virus could be achievable and perhaps, with 
modifications, the NHG_Δtat-D-Δrev-4CTE_3CLTR clone could become a future 
candidate for HIV research.  
 
 
7.1.2 Potential for future research 
 
Moving forward, we could investigate the Tat and Rev independence using the CL3 clones 
independently: investigate Tat independence in tat mutants encoding a CLTR (NHG_Δtat-
D-_3CLTR) and investigating rev independence using Rev mutants encoding 4CTEs 
(NHG_Δtat-D-Δrev-4CTE_3CLTR). The HIV-1 regulatory genes (tat and rev) are 
essential for viral survival, and overcoming both gene functions together could be a big 
genetic barrier to overcome simultaneously. Unless we understand how we can overcome 
their relevant function within our CL3 viruses. Perhaps the aim of this thesis was too 
ambitious to be achieved by the period of time that we had and also for the challenging aim 
of the proposal. For example, several avenues were not examined due to time constraints.  
Although HIV-1 cannot ‘utilise’ murine cyclin T1 (Tat) or mCRM1(Rev) it is likely that 
HIV-1 could adapt to the murine orthologue if pressured to do so. With more time, I would 
have knocked out these factors in AA2 cells using CRISPR CAS9 technology and 
reconstituted their function with a (CRISPR resistant) murine orthologue.  Perhaps HIV-1  
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could adapt to utilise these individual murine orthologues an this could be a platform to 
investigate futher blocks to HIV-1 replication in murine cells. 
 
The potential for future research could approach investigations to determine the essential 
role of the HIV-1 RNA folding, encoding highly variable regions but also high conserved 
structures with unknown functions. Secondary structure studies have determined that the 
HIV-1 packaging signal contains several RNA loops (SL1 to SL4) involved in packaging 
the viral genome into the particles by Gag interactions that could be altered in the 
5CLTR_Ψ _SYNGP_IRES-GFP_3CLTR clone (Greatorex et al. 2002). The codon-
optimization of gag-pol genes contributes to the generation of more RNA species within 
human cells, but maybe the modifications made to reach this aim introduced novel RNA 
loops into the viral genome that could impair their packaging into the nascent particles. 
The compactly folded tertiary structure of viral RNA is essential for the viability of the 
virus at distinct steps along the replication cycle, such as reverse transcription, viral 
transcription or packaging (Berkhout et al. 2000). The RNA secondary structures are 
essential for the packaging of the viral genome within the viral particles. We 
unintentionally introduced more unknowns by reducing the CpG content in the codon-
optimized gag-pol genes that affected viral replication. 
 
This aspect suggests that the absence of infectivity could be also related to the disruption in 
the RNA folding in the viral genome introduced by codon optimization of gag-pol genes, 
or the higher number of CpGs in SYNGP compared to NLGP (226 to 23 respectively), 
which could impair viral replication kinetics (Atkinson et al. 2014; Gaunt et al 2016). We 
could have performed reverse transcription assays to quantify the reverse transcription 
levels in our CSGW_Flexi and SYNGP clones and investigate the RNA species within 
transfected cells to determine viral transcription more accurately. Thus, we could have 
investigated if the generated VLPs had a proper morphology because is not possible to 
determine this feature by western blot analysis, so we could have prepared some purified 
VLPs for each CSGW_Flexi and SYNGP clones to submitt to electron mycroscopy and 
approach this hypothesis. To elucidate the likely problems with full-length RNA 
packaging/production we could investigate the RNA production within transfected cells by 
RNA extraction and subsequently northern blot analysis.  
 
Our hypothesis will focus on viral RNA production, stability and transport within 
transfected cells to determine the ability of the constructs develop in this thesis to identify  
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the problems of infectivity or packaging. We could investigate whether the viral RNAs 
remain stucked in the nucleus performing RNA extractions from transfected cells with 
SYNGP_4CTE clones (with 4CTEs in cis) and compare the amounts of full-length 
genomes produced (northern blot) or include a fluorescent dye in viral RNAs to detect the 
amount of RNA that remain in the nucleus compared to the cytoplasm in transfected cells. 
The VLPs generated from SYNGP_4CTE clones could lack the viral genome, so we could 
have performed RNA extractions from transfected cells to investigate the differences 
between RNA species for each CSGW_Flexi and SYNGP clones. Thus, we could have 
also investigated the RNA content within the VLPs to detect if the viral genome is able to 
be packaged into nascent particles or perhaps can not interact with the packaging signal. 
Several experiments were performed to investigate the RNA content in VLPs by qPCR. 
 
We could have performed RNA extractions from transfected HEK-293T with 
CSGW_4CTE clone to investigate the RNA expression levels compared to wild-type 
CSGW and also in VLPs by qPCR assays. Moreover, we tried several qPCR assays to 
investigate this hypothesis but the presence of background in all samples including the 
negative control discarded these results and still not clear yet if the 4CTEs encoded in 
CSGW_4CTE construct is subtituting Rev efficiently as we suggest with our results. 
However, the potential of CSGW_4CTE construct represents the best achievement we 
obtained at this point, generating infectious particles in a Tat and Rev independent manner. 
The CSGW_4CTE is a great candidate to develop an HIV-1 clone able to replicate in mice, 
but we need to investigate how this clone overcomes the absence of the regulatory 
proteins. We should be able to reproduce the results of CSGW_4CTE clone generating 
infectious particles in the absence of Tat and Rev in murine cells, but urther investigations 
need to be done to determine the features of this construct in human cells. The RRE from 
CSGW_4CTE clone is not located at the 3’end, but previous experiments demonstrated the 
ability of CSGW_4CTE to generate infectious viral particles in the absence of Tat and Rev 
(Figure 5-4). However, we could transfer the RRE into its correct position (at the end of 3’ 
transcripts) in CSGW_4CTE and repeat the same experiments to determine if this 
modification enhances viral infectivity or maybe contributes to the RNA transport in a 
Rev-independent manner. 
 
The reverse transcription assays could be also developed to investigate the reverse 
transcription levels in NHG_Δtat-D-Δrev_4CTE viruses to determine the RNA species 
within transfected (HEK-293T) and infected cells (AA-2). We could extract the viral RNA  
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from infected AA-2 cells during the passages or adding a reverse transcriptase inhibitor to 
determine if the virus is spreading in culture or not. The RNA extractions could be also 
performed for viral particles produced during the first cycle of replication in HEK-293T 
cells to detect if NHG_Δtat-D-Δrev_4CTE viruses are able to package the viral RNA 
successfully or whether packaging is affected somehow. Moreover, to investigate if the 
viral RNAs export and stability is affected in NHG_Δtat-D-Δrev_4CTE viruses we could 
have performed northern blot analysis of viral RNAs extracted from transfected cells and 
compare the amounts of full-length genomes produced in all NHG_Δtat-D-Δrev_4CTE 
viruses. Thus, we could have included a fluorescent dye in viral RNAs to detect the 
amount of RNA that remain in the nucleus compared to the cytoplasm in transfected cells. 
 
Nonetheless, although Tat-responsivity was maintained, CLTR and MLTR containing 
viruses were viable (partially substituting for Tat function) and the MPMV CTEs improved 
the single cycle HIV-1 systems, our findings suggest that   assisted evolution could one 
day  pave the way for  an HIV-1 virus that replicates in murine cells.  However, the 
success about HIV-1 curative therapies involves the usage of animal models, but their 
current limitations severely impede the potential of vaccine development to cure HIV 
infection. Perhaps we could transfer the discoveries from the ‘cured’ patient into animal 
models to investigate and reveal new insights about a cure that we could export to humans. 
The current antiretroviral treatments fail to erradicate HIV infection in patients despite the 
combination of different drugs targeting several proteins of the virus. We could solve these 
limitations at long-term if we investigate the CSGW_4CTE construct ability to produce 
infectious particles in the absence of HIV regulatory proteins. We could transfer the 
features from this construct to a replication competent vector such us the  NHG_Δtat-D-
Δrev_4CTE_3CLTR construct to adapt this virus to human cultures before attemping 
murine cells. By developing a HIV-1 clone able to replicate in murine cells in the absence 
of Tat and Rev proteins will generate a huge contribution of the usage of this virus in 
animal models that won’t need to be ‘humanized’ (humanized mice) and adapted to HIV-1 
infection (current macaque animal models). Thus, extrapolating results obtained in current 
animal models to human disease is often not straightforward, and HIV-1 is highly specific 
for humans and faces multiple barriers to replication in most other animals. The 
development of strains that more accurately reflect the features of the virus responsible for 
the AIDS pandemic would overcome many of the remaining limitations of current models, 
and it is posible that no animal model will ever fully capture all of the features of human 
HIV-1 infection (Hatziioannou et al. 2012). 
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Developing an adapted HIV-1 clone for mice will be a great achievement to investigate 
curative therapies to erradicate HIV-1 from infected patients. However, there is still a long 
way to go and much that needs to be performed to achieve this aim. 
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